id	sid	tid	token	lemma	pos
dpc-3629	1	1	dermatology	dermatology	NOUN
dpc-3629	1	2	:	:	PUNCT
dpc-3629	1	3	practical	practical	ADJ
dpc-3629	1	4	and	and	CCONJ
dpc-3629	1	5	conceptual	conceptual	ADJ
dpc-3629	1	6	original	original	ADJ
dpc-3629	1	7	article	article	NOUN
dpc-3629	1	8	|	|	ADV
dpc-3629	1	9	dermatol	dermatol	ADJ
dpc-3629	1	10	pract	pract	NOUN
dpc-3629	1	11	concept	concept	NOUN
dpc-3629	1	12	.	.	PUNCT
dpc-3629	2	1	2024;14(1):e2024034	2024;14(1):e2024034	NUM
dpc-3629	2	2	1	1	NUM
dpc-3629	2	3	efficacy	efficacy	NOUN
dpc-3629	2	4	of	of	ADP
dpc-3629	2	5	topical	topical	ADJ
dpc-3629	2	6	dapsone	dapsone	NOUN
dpc-3629	2	7	5	5	NUM
dpc-3629	2	8	%	%	NOUN
dpc-3629	2	9	gel	gel	NOUN
dpc-3629	2	10	for	for	ADP
dpc-3629	2	11	the	the	DET
dpc-3629	2	12	treatment	treatment	NOUN
dpc-3629	2	13	of	of	ADP
dpc-3629	2	14	erythematotelangiectatic	erythematotelangiectatic	ADJ
dpc-3629	2	15	rosacea	rosacea	NOUN
dpc-3629	2	16	:	:	PUNCT
dpc-3629	2	17	new	new	ADJ
dpc-3629	2	18	treatment	treatment	NOUN
dpc-3629	2	19	option	option	NOUN
dpc-3629	2	20	with	with	ADP
dpc-3629	2	21	old	old	ADJ
dpc-3629	2	22	drug	drug	NOUN
dpc-3629	2	23	şule	şule	NOUN
dpc-3629	2	24	gökşin1	gökşin1	NOUN
dpc-3629	2	25	,	,	PUNCT
dpc-3629	2	26	işıl	işıl	ADJ
dpc-3629	2	27	göğem	göğem	PROPN
dpc-3629	2	28	i̇mren2	i̇mren2	PROPN
dpc-3629	2	29	,	,	PUNCT
dpc-3629	2	30	nida	nida	PROPN
dpc-3629	2	31	kaçar1	kaçar1	PROPN
dpc-3629	2	32	1	1	NUM
dpc-3629	2	33	pamukkale	pamukkale	PROPN
dpc-3629	2	34	university	university	PROPN
dpc-3629	2	35	medical	medical	ADJ
dpc-3629	2	36	faculty	faculty	NOUN
dpc-3629	2	37	,	,	PUNCT
dpc-3629	2	38	dermatology	dermatology	NOUN
dpc-3629	2	39	department	department	NOUN
dpc-3629	2	40	,	,	PUNCT
dpc-3629	2	41	denizli	denizli	PROPN
dpc-3629	2	42	,	,	PUNCT
dpc-3629	2	43	turkey	turkey	PROPN
dpc-3629	2	44	2	2	NUM
dpc-3629	2	45	denizli	denizli	PROPN
dpc-3629	2	46	state	state	NOUN
dpc-3629	2	47	hospital	hospital	NOUN
dpc-3629	2	48	,	,	PUNCT
dpc-3629	2	49	dermatology	dermatology	NOUN
dpc-3629	2	50	department	department	NOUN
dpc-3629	2	51	,	,	PUNCT
dpc-3629	2	52	denizli	denizli	PROPN
dpc-3629	2	53	,	,	PUNCT
dpc-3629	2	54	turkey	turkey	NOUN
dpc-3629	2	55	key	key	ADJ
dpc-3629	2	56	words	word	NOUN
dpc-3629	2	57	:	:	PUNCT
dpc-3629	2	58	dapsone	dapsone	NOUN
dpc-3629	2	59	gel	gel	NOUN
dpc-3629	2	60	,	,	PUNCT
dpc-3629	2	61	treatment	treatment	NOUN
dpc-3629	2	62	,	,	PUNCT
dpc-3629	2	63	adverse	adverse	ADJ
dpc-3629	2	64	events	event	NOUN
dpc-3629	2	65	,	,	PUNCT
dpc-3629	2	66	erythematotelangiectatic	erythematotelangiectatic	ADJ
dpc-3629	2	67	rosacea	rosacea	NOUN
dpc-3629	2	68	.	.	PUNCT
dpc-3629	3	1	citation	citation	NOUN
dpc-3629	3	2	:	:	PUNCT
dpc-3629	3	3	gökşin	gökşin	NOUN
dpc-3629	3	4	ş	ş	NOUN
dpc-3629	3	5	,	,	PUNCT
dpc-3629	3	6	göğem	göğem	NOUN
dpc-3629	3	7	i̇mre	i̇mre	PROPN
dpc-3629	3	8	i	i	PROPN
dpc-3629	3	9	,	,	PUNCT
dpc-3629	3	10	kaçar	kaçar	PROPN
dpc-3629	3	11	n.	n.	PROPN
dpc-3629	3	12	efficacy	efficacy	PROPN
dpc-3629	3	13	of	of	ADP
dpc-3629	3	14	topical	topical	ADJ
dpc-3629	3	15	dapsone	dapsone	NOUN
dpc-3629	3	16	5	5	NUM
dpc-3629	3	17	%	%	NOUN
dpc-3629	3	18	gel	gel	NOUN
dpc-3629	3	19	for	for	ADP
dpc-3629	3	20	the	the	DET
dpc-3629	3	21	treatment	treatment	NOUN
dpc-3629	3	22	of	of	ADP
dpc-3629	3	23	erythematotelangiectatic	erythematotelangiectatic	ADJ
dpc-3629	3	24	rosacea	rosacea	NOUN
dpc-3629	3	25	:	:	PUNCT
dpc-3629	3	26	 	 	SPACE
dpc-3629	3	27	new	new	ADJ
dpc-3629	3	28	treatment	treatment	NOUN
dpc-3629	3	29	option	option	NOUN
dpc-3629	3	30	with	with	ADP
dpc-3629	3	31	old	old	ADJ
dpc-3629	3	32	drug	drug	NOUN
dpc-3629	3	33	.	.	PUNCT
dpc-3629	4	1	dermatol	dermatol	NOUN
dpc-3629	4	2	pract	pract	PROPN
dpc-3629	4	3	concept	concept	NOUN
dpc-3629	4	4	.	.	PUNCT
dpc-3629	5	1	2024;14(1):e2024034	2024;14(1):e2024034	X
dpc-3629	5	2	.	.	PUNCT
dpc-3629	5	3	doi	doi	NOUN
dpc-3629	5	4	:	:	PUNCT
dpc-3629	5	5	https://doi.org/10.5826	https://doi.org/10.5826	ADV
dpc-3629	5	6	/dpc.1401a34	/dpc.1401a34	PUNCT
dpc-3629	5	7	accepted	accept	VERB
dpc-3629	5	8	:	:	PUNCT
dpc-3629	5	9	july	july	PROPN
dpc-3629	5	10	26	26	NUM
dpc-3629	5	11	,	,	PUNCT
dpc-3629	5	12	2023	2023	NUM
dpc-3629	5	13	;	;	PUNCT
dpc-3629	5	14	published	publish	VERB
dpc-3629	5	15	:	:	PUNCT
dpc-3629	5	16	january	january	PROPN
dpc-3629	5	17	2024	2024	NUM
dpc-3629	6	1	copyright	copyright	NOUN
dpc-3629	6	2	:	:	PUNCT
dpc-3629	6	3	©	©	PROPN
dpc-3629	6	4	2024	2024	NUM
dpc-3629	6	5	gökşin	gökşin	NOUN
dpc-3629	6	6	et	et	PROPN
dpc-3629	6	7	al	al	PROPN
dpc-3629	6	8	.	.	PUNCT
dpc-3629	7	1	this	this	PRON
dpc-3629	7	2	is	be	AUX
dpc-3629	7	3	an	an	DET
dpc-3629	7	4	open	open	ADJ
dpc-3629	7	5	-	-	PUNCT
dpc-3629	7	6	access	access	NOUN
dpc-3629	7	7	article	article	NOUN
dpc-3629	7	8	distributed	distribute	VERB
dpc-3629	7	9	under	under	ADP
dpc-3629	7	10	the	the	DET
dpc-3629	7	11	terms	term	NOUN
dpc-3629	7	12	of	of	ADP
dpc-3629	7	13	the	the	DET
dpc-3629	7	14	creative	creative	ADJ
dpc-3629	7	15	commons	common	NOUN
dpc-3629	7	16	attributionnoncommercial	attributionnoncommercial	ADJ
dpc-3629	7	17	license	license	NOUN
dpc-3629	7	18	(	(	PUNCT
dpc-3629	7	19	by	by	ADP
dpc-3629	7	20	-	-	PUNCT
dpc-3629	7	21	nc-4.0	nc-4.0	NOUN
dpc-3629	7	22	)	)	PUNCT
dpc-3629	7	23	,	,	PUNCT
dpc-3629	7	24	https://creativecommons.org/licenses/by-nc/4.0/	https://creativecommons.org/licenses/by-nc/4.0/	PROPN
dpc-3629	7	25	,	,	PUNCT
dpc-3629	7	26	which	which	PRON
dpc-3629	7	27	permits	permit	VERB
dpc-3629	7	28	unrestricted	unrestricted	ADJ
dpc-3629	7	29	noncommercial	noncommercial	ADJ
dpc-3629	7	30	use	use	NOUN
dpc-3629	7	31	,	,	PUNCT
dpc-3629	7	32	distribution	distribution	NOUN
dpc-3629	7	33	,	,	PUNCT
dpc-3629	7	34	and	and	CCONJ
dpc-3629	7	35	reproduction	reproduction	NOUN
dpc-3629	7	36	in	in	ADP
dpc-3629	7	37	any	any	DET
dpc-3629	7	38	medium	medium	NOUN
dpc-3629	7	39	,	,	PUNCT
dpc-3629	7	40	provided	provide	VERB
dpc-3629	7	41	the	the	DET
dpc-3629	7	42	original	original	ADJ
dpc-3629	7	43	authors	author	NOUN
dpc-3629	7	44	and	and	CCONJ
dpc-3629	7	45	source	source	NOUN
dpc-3629	7	46	are	be	AUX
dpc-3629	7	47	credited	credit	VERB
dpc-3629	7	48	.	.	PUNCT
dpc-3629	8	1	funding	funding	NOUN
dpc-3629	8	2	:	:	PUNCT
dpc-3629	8	3	none	none	NOUN
dpc-3629	8	4	.	.	PUNCT
dpc-3629	9	1	competing	compete	VERB
dpc-3629	9	2	interests	interest	NOUN
dpc-3629	9	3	:	:	PUNCT
dpc-3629	9	4	none	none	NOUN
dpc-3629	9	5	.	.	PUNCT
dpc-3629	10	1	authorship	authorship	NOUN
dpc-3629	10	2	:	:	PUNCT
dpc-3629	10	3	şule	şule	ADJ
dpc-3629	10	4	gökşin	gökşin	NOUN
dpc-3629	10	5	;	;	PUNCT
dpc-3629	10	6	design	design	NOUN
dpc-3629	10	7	,	,	PUNCT
dpc-3629	10	8	concept	concept	NOUN
dpc-3629	10	9	,	,	PUNCT
dpc-3629	10	10	literature	literature	NOUN
dpc-3629	10	11	search	search	NOUN
dpc-3629	10	12	,	,	PUNCT
dpc-3629	10	13	analysis	analysis	NOUN
dpc-3629	10	14	and	and	CCONJ
dpc-3629	10	15	interpretation	interpretation	NOUN
dpc-3629	10	16	,	,	PUNCT
dpc-3629	10	17	writing	writing	NOUN
dpc-3629	10	18	,	,	PUNCT
dpc-3629	10	19	critical	critical	ADJ
dpc-3629	10	20	review	review	NOUN
dpc-3629	10	21	,	,	PUNCT
dpc-3629	10	22	işıl	işıl	ADJ
dpc-3629	10	23	i̇mren	i̇mren	NOUN
dpc-3629	10	24	göğem	göğem	PROPN
dpc-3629	10	25	;	;	PUNCT
dpc-3629	10	26	design	design	NOUN
dpc-3629	10	27	,	,	PUNCT
dpc-3629	10	28	concept	concept	NOUN
dpc-3629	10	29	,	,	PUNCT
dpc-3629	10	30	data	datum	NOUN
dpc-3629	10	31	collection	collection	NOUN
dpc-3629	10	32	and	and	CCONJ
dpc-3629	10	33	processing	processing	NOUN
dpc-3629	10	34	,	,	PUNCT
dpc-3629	10	35	literature	literature	NOUN
dpc-3629	10	36	search	search	NOUN
dpc-3629	10	37	,	,	PUNCT
dpc-3629	10	38	statistical	statistical	ADJ
dpc-3629	10	39	analysis	analysis	NOUN
dpc-3629	10	40	,	,	PUNCT
dpc-3629	10	41	nida	nida	PROPN
dpc-3629	10	42	kaçar	kaçar	PROPN
dpc-3629	10	43	;	;	PUNCT
dpc-3629	10	44	supervision	supervision	NOUN
dpc-3629	10	45	.	.	PUNCT
dpc-3629	11	1	corresponding	correspond	VERB
dpc-3629	11	2	author	author	NOUN
dpc-3629	11	3	:	:	PUNCT
dpc-3629	11	4	şule	şule	ADJ
dpc-3629	11	5	gökşin	gökşin	NOUN
dpc-3629	11	6	,	,	PUNCT
dpc-3629	11	7	çamlaraltı	çamlaraltı	NOUN
dpc-3629	11	8	mahallesi	mahallesi	NOUN
dpc-3629	11	9	,	,	PUNCT
dpc-3629	11	10	doğan	doğan	ADJ
dpc-3629	11	11	demircioğlu	demircioğlu	PROPN
dpc-3629	11	12	caddesi	caddesi	PROPN
dpc-3629	11	13	,	,	PUNCT
dpc-3629	11	14	no:71	no:71	PROPN
dpc-3629	11	15	aytuğ	aytuğ	VERB
dpc-3629	11	16	apt	apt	ADJ
dpc-3629	11	17	.	.	PUNCT
dpc-3629	11	18	daire:5	daire:5	NOUN
dpc-3629	11	19	,	,	PUNCT
dpc-3629	11	20	pk:20160	pk:20160	PROPN
dpc-3629	11	21	,	,	PUNCT
dpc-3629	11	22	kınıklı	kınıklı	NOUN
dpc-3629	11	23	–	–	PUNCT
dpc-3629	11	24	denizli	denizli	NOUN
dpc-3629	11	25	/	/	SYM
dpc-3629	11	26	turkey	turkey	PROPN
dpc-3629	11	27	.	.	PUNCT
dpc-3629	12	1	tel	tel	PROPN
dpc-3629	12	2	.	.	PROPN
dpc-3629	12	3	mobil	mobil	PROPN
dpc-3629	12	4	:	:	PUNCT
dpc-3629	12	5	+90.532.2520634	+90.532.2520634	X
dpc-3629	12	6	fax	fax	NOUN
dpc-3629	12	7	:	:	PUNCT
dpc-3629	12	8	+90.258.2966001	+90.258.2966001	NUM
dpc-3629	12	9	.	.	PUNCT
dpc-3629	13	1	e	e	X
dpc-3629	13	2	-	-	NOUN
dpc-3629	13	3	mail	mail	NOUN
dpc-3629	13	4	:	:	PUNCT
dpc-3629	13	5	sule.goksin@hotmail.com	sule.goksin@hotmail.com	X
dpc-3629	13	6	introduction	introduction	NOUN
dpc-3629	13	7	:	:	PUNCT
dpc-3629	13	8	many	many	ADJ
dpc-3629	13	9	topical	topical	ADJ
dpc-3629	13	10	drugs	drug	NOUN
dpc-3629	13	11	are	be	AUX
dpc-3629	13	12	used	use	VERB
dpc-3629	13	13	in	in	ADP
dpc-3629	13	14	the	the	DET
dpc-3629	13	15	treatment	treatment	NOUN
dpc-3629	13	16	of	of	ADP
dpc-3629	13	17	erythematotelangiectatic	erythematotelangiectatic	ADJ
dpc-3629	13	18	rosacea	rosacea	PROPN
dpc-3629	13	19	(	(	PUNCT
dpc-3629	13	20	etr	etr	PROPN
dpc-3629	13	21	)	)	PUNCT
dpc-3629	13	22	.	.	PUNCT
dpc-3629	14	1	however	however	ADV
dpc-3629	14	2	,	,	PUNCT
dpc-3629	14	3	dapsone	dapsone	PROPN
dpc-3629	14	4	5	5	NUM
dpc-3629	14	5	%	%	NOUN
dpc-3629	14	6	gel	gel	NOUN
dpc-3629	14	7	has	have	AUX
dpc-3629	14	8	never	never	ADV
dpc-3629	14	9	been	be	AUX
dpc-3629	14	10	used	use	VERB
dpc-3629	14	11	in	in	ADP
dpc-3629	14	12	etr	etr	PROPN
dpc-3629	14	13	to	to	ADP
dpc-3629	14	14	date	date	NOUN
dpc-3629	14	15	.	.	PUNCT
dpc-3629	15	1	objectives	objective	NOUN
dpc-3629	15	2	:	:	PUNCT
dpc-3629	15	3	to	to	PART
dpc-3629	15	4	evaluate	evaluate	VERB
dpc-3629	15	5	the	the	DET
dpc-3629	15	6	efficacy	efficacy	NOUN
dpc-3629	15	7	of	of	ADP
dpc-3629	15	8	dapsone	dapsone	PROPN
dpc-3629	15	9	5	5	NUM
dpc-3629	15	10	%	%	NOUN
dpc-3629	15	11	gel	gel	NOUN
dpc-3629	15	12	as	as	ADP
dpc-3629	15	13	a	a	DET
dpc-3629	15	14	new	new	ADJ
dpc-3629	15	15	treatment	treatment	NOUN
dpc-3629	15	16	option	option	NOUN
dpc-3629	15	17	for	for	ADP
dpc-3629	15	18	etr	etr	PROPN
dpc-3629	15	19	.	.	PUNCT
dpc-3629	16	1	methods	method	NOUN
dpc-3629	16	2	:	:	PUNCT
dpc-3629	16	3	thirty	thirty	NUM
dpc-3629	16	4	-	-	PUNCT
dpc-3629	16	5	five	five	NUM
dpc-3629	16	6	patients	patient	NOUN
dpc-3629	16	7	with	with	ADP
dpc-3629	16	8	etr	etr	PROPN
dpc-3629	16	9	were	be	AUX
dpc-3629	16	10	included	include	VERB
dpc-3629	16	11	in	in	ADP
dpc-3629	16	12	the	the	DET
dpc-3629	16	13	study	study	NOUN
dpc-3629	16	14	.	.	PUNCT
dpc-3629	17	1	diagnosis	diagnosis	NOUN
dpc-3629	17	2	was	be	AUX
dpc-3629	17	3	made	make	VERB
dpc-3629	17	4	with	with	ADP
dpc-3629	17	5	national	national	PROPN
dpc-3629	17	6	rosacea	rosacea	PROPN
dpc-3629	17	7	society	society	NOUN
dpc-3629	17	8	criteria	criteria	PROPN
dpc-3629	17	9	.	.	PUNCT
dpc-3629	18	1	dapsone	dapsone	NOUN
dpc-3629	18	2	5	5	NUM
dpc-3629	18	3	%	%	NOUN
dpc-3629	18	4	gel	gel	NOUN
dpc-3629	18	5	was	be	AUX
dpc-3629	18	6	used	use	VERB
dpc-3629	18	7	topically	topically	ADV
dpc-3629	18	8	twice	twice	DET
dpc-3629	18	9	a	a	DET
dpc-3629	18	10	day	day	NOUN
dpc-3629	18	11	for	for	ADP
dpc-3629	18	12	12	12	NUM
dpc-3629	18	13	weeks	week	NOUN
dpc-3629	18	14	.	.	PUNCT
dpc-3629	19	1	investigator	investigator	NOUN
dpc-3629	19	2	global	global	ADJ
dpc-3629	19	3	assessment	assessment	NOUN
dpc-3629	19	4	(	(	PUNCT
dpc-3629	19	5	iga	iga	PROPN
dpc-3629	19	6	)	)	PUNCT
dpc-3629	19	7	4	4	NUM
dpc-3629	19	8	-	-	PUNCT
dpc-3629	19	9	point	point	NOUN
dpc-3629	19	10	scale	scale	NOUN
dpc-3629	19	11	(	(	PUNCT
dpc-3629	19	12	0	0	NUM
dpc-3629	19	13	→	→	SYM
dpc-3629	19	14	clean	clean	ADJ
dpc-3629	19	15	,	,	PUNCT
dpc-3629	19	16	1	1	NUM
dpc-3629	19	17	→	→	SYM
dpc-3629	19	18	mild	mild	ADJ
dpc-3629	19	19	,	,	PUNCT
dpc-3629	19	20	2	2	NUM
dpc-3629	19	21	→	→	SYM
dpc-3629	19	22	moderate	moderate	ADJ
dpc-3629	19	23	,	,	PUNCT
dpc-3629	19	24	3	3	NUM
dpc-3629	19	25	→	→	SYM
dpc-3629	19	26	severe	severe	ADJ
dpc-3629	19	27	,	,	PUNCT
dpc-3629	19	28	4	4	NUM
dpc-3629	19	29	→	→	SYM
dpc-3629	19	30	very	very	ADV
dpc-3629	19	31	severe	severe	ADJ
dpc-3629	19	32	)	)	PUNCT
dpc-3629	19	33	,	,	PUNCT
dpc-3629	19	34	visual	visual	ADJ
dpc-3629	19	35	analogue	analogue	NOUN
dpc-3629	19	36	scale	scale	NOUN
dpc-3629	19	37	(	(	PUNCT
dpc-3629	19	38	vas	vas	NOUN
dpc-3629	19	39	)	)	PUNCT
dpc-3629	19	40	and	and	CCONJ
dpc-3629	19	41	dermatology	dermatology	NOUN
dpc-3629	19	42	life	life	NOUN
dpc-3629	19	43	quality	quality	NOUN
dpc-3629	19	44	index	index	NOUN
dpc-3629	19	45	(	(	PUNCT
dpc-3629	19	46	dlqi	dlqi	PROPN
dpc-3629	19	47	)	)	PUNCT
dpc-3629	19	48	were	be	AUX
dpc-3629	19	49	used	use	VERB
dpc-3629	19	50	for	for	ADP
dpc-3629	19	51	evaluation	evaluation	NOUN
dpc-3629	19	52	(	(	PUNCT
dpc-3629	19	53	at	at	ADP
dpc-3629	19	54	baseline	baseline	NOUN
dpc-3629	19	55	,	,	PUNCT
dpc-3629	19	56	2nd	2nd	ADJ
dpc-3629	19	57	,	,	PUNCT
dpc-3629	19	58	6th	6th	ADJ
dpc-3629	19	59	,	,	PUNCT
dpc-3629	19	60	and	and	CCONJ
dpc-3629	19	61	12th	12th	ADJ
dpc-3629	19	62	weeks	week	NOUN
dpc-3629	19	63	)	)	PUNCT
dpc-3629	19	64	.	.	PUNCT
dpc-3629	20	1	results	result	NOUN
dpc-3629	20	2	:	:	PUNCT
dpc-3629	20	3	iga	iga	PROPN
dpc-3629	20	4	scores	score	NOUN
dpc-3629	20	5	among	among	ADP
dpc-3629	20	6	baseline	baseline	PROPN
dpc-3629	20	7	(	(	PUNCT
dpc-3629	20	8	2	2	NUM
dpc-3629	20	9	→	→	SYM
dpc-3629	20	10	62.9	62.9	NUM
dpc-3629	20	11	%	%	NOUN
dpc-3629	20	12	,	,	PUNCT
dpc-3629	20	13	3	3	NUM
dpc-3629	20	14	→	→	SYM
dpc-3629	20	15	34.3	34.3	NUM
dpc-3629	20	16	%	%	NOUN
dpc-3629	20	17	,	,	PUNCT
dpc-3629	20	18	4	4	NUM
dpc-3629	20	19	→	→	SYM
dpc-3629	20	20	2.9	2.9	NUM
dpc-3629	20	21	%	%	NOUN
dpc-3629	20	22	)	)	PUNCT
dpc-3629	20	23	and	and	CCONJ
dpc-3629	20	24	2nd	2nd	ADJ
dpc-3629	20	25	(	(	PUNCT
dpc-3629	20	26	1	1	NUM
dpc-3629	20	27	→	→	SYM
dpc-3629	20	28	14.3	14.3	NUM
dpc-3629	20	29	%	%	NOUN
dpc-3629	20	30	,	,	PUNCT
dpc-3629	20	31	2	2	NUM
dpc-3629	20	32	→	→	SYM
dpc-3629	20	33	77	77	NUM
dpc-3629	20	34	,	,	PUNCT
dpc-3629	20	35	1	1	NUM
dpc-3629	20	36	%	%	NOUN
dpc-3629	20	37	,	,	PUNCT
dpc-3629	20	38	3	3	NUM
dpc-3629	20	39	→	→	SYM
dpc-3629	20	40	8.6	8.6	NUM
dpc-3629	20	41	%	%	NOUN
dpc-3629	20	42	)	)	PUNCT
dpc-3629	20	43	,	,	PUNCT
dpc-3629	20	44	6th	6th	NOUN
dpc-3629	20	45	(	(	PUNCT
dpc-3629	20	46	1	1	NUM
dpc-3629	20	47	→	→	SYM
dpc-3629	20	48	45	45	NUM
dpc-3629	20	49	,	,	PUNCT
dpc-3629	20	50	7	7	NUM
dpc-3629	20	51	%	%	NOUN
dpc-3629	20	52	,	,	PUNCT
dpc-3629	20	53	2	2	NUM
dpc-3629	20	54	→	→	SYM
dpc-3629	20	55	54.3	54.3	NUM
dpc-3629	20	56	%	%	NOUN
dpc-3629	20	57	)	)	PUNCT
dpc-3629	20	58	and	and	CCONJ
dpc-3629	20	59	12th	12th	ADJ
dpc-3629	20	60	weeks	week	NOUN
dpc-3629	20	61	(	(	PUNCT
dpc-3629	20	62	1	1	NUM
dpc-3629	20	63	→	→	SYM
dpc-3629	20	64	62.9	62.9	NUM
dpc-3629	20	65	%	%	NOUN
dpc-3629	20	66	,	,	PUNCT
dpc-3629	20	67	2	2	NUM
dpc-3629	20	68	→	→	SYM
dpc-3629	20	69	37.1	37.1	NUM
dpc-3629	20	70	%	%	NOUN
dpc-3629	20	71	)	)	PUNCT
dpc-3629	20	72	were	be	AUX
dpc-3629	20	73	found	find	VERB
dpc-3629	20	74	to	to	PART
dpc-3629	20	75	be	be	AUX
dpc-3629	20	76	statistically	statistically	ADV
dpc-3629	20	77	significant	significant	ADJ
dpc-3629	20	78	(	(	PUNCT
dpc-3629	20	79	p	p	X
dpc-3629	20	80	<	<	X
dpc-3629	20	81	0.001	0.001	NUM
dpc-3629	20	82	)	)	PUNCT
dpc-3629	20	83	.	.	PUNCT
dpc-3629	21	1	median	median	PROPN
dpc-3629	21	2	vas	vas	PROPN
dpc-3629	21	3	scores	score	NOUN
dpc-3629	21	4	among	among	ADP
dpc-3629	21	5	baseline	baseline	PROPN
dpc-3629	21	6	(	(	PUNCT
dpc-3629	21	7	median	median	NOUN
dpc-3629	21	8	=	=	NOUN
dpc-3629	21	9	7	7	NUM
dpc-3629	21	10	[	[	SYM
dpc-3629	21	11	5	5	NUM
dpc-3629	21	12	-	-	SYM
dpc-3629	21	13	9	9	NUM
dpc-3629	21	14	]	]	PUNCT
dpc-3629	21	15	)	)	PUNCT
dpc-3629	21	16	and	and	CCONJ
dpc-3629	21	17	2nd	2nd	ADJ
dpc-3629	21	18	(	(	PUNCT
dpc-3629	21	19	median=5	median=5	PROPN
dpc-3629	22	1	[	[	X
dpc-3629	22	2	3	3	NUM
dpc-3629	22	3	-	-	SYM
dpc-3629	22	4	8	8	NUM
dpc-3629	22	5	]	]	NUM
dpc-3629	22	6	)	)	PUNCT
dpc-3629	22	7	,	,	PUNCT
dpc-3629	22	8	6th	6th	NOUN
dpc-3629	22	9	(	(	PUNCT
dpc-3629	22	10	median=5	median=5	PROPN
dpc-3629	23	1	[	[	X
dpc-3629	23	2	3	3	NUM
dpc-3629	23	3	-	-	SYM
dpc-3629	23	4	6	6	NUM
dpc-3629	23	5	]	]	PUNCT
dpc-3629	23	6	)	)	PUNCT
dpc-3629	23	7	and	and	CCONJ
dpc-3629	23	8	12th	12th	ADJ
dpc-3629	23	9	weeks	week	NOUN
dpc-3629	23	10	(	(	PUNCT
dpc-3629	23	11	median	median	NOUN
dpc-3629	23	12	=	=	SYM
dpc-3629	23	13	4	4	NUM
dpc-3629	23	14	[	[	SYM
dpc-3629	23	15	2	2	NUM
dpc-3629	23	16	-	-	SYM
dpc-3629	23	17	6	6	NUM
dpc-3629	23	18	]	]	PUNCT
dpc-3629	23	19	)	)	PUNCT
dpc-3629	23	20	were	be	AUX
dpc-3629	23	21	statistically	statistically	ADV
dpc-3629	23	22	significant	significant	ADJ
dpc-3629	23	23	(	(	PUNCT
dpc-3629	23	24	p	p	X
dpc-3629	23	25	<	<	X
dpc-3629	23	26	0.001	0.001	NUM
dpc-3629	23	27	)	)	PUNCT
dpc-3629	23	28	.	.	PUNCT
dpc-3629	24	1	median	median	PROPN
dpc-3629	24	2	dlqi	dlqi	PROPN
dpc-3629	24	3	scores	score	NOUN
dpc-3629	24	4	among	among	ADP
dpc-3629	24	5	baseline	baseline	PROPN
dpc-3629	24	6	(	(	PUNCT
dpc-3629	24	7	median	median	NOUN
dpc-3629	24	8	=	=	SYM
dpc-3629	24	9	8	8	NUM
dpc-3629	24	10	[	[	SYM
dpc-3629	24	11	6	6	NUM
dpc-3629	24	12	-	-	SYM
dpc-3629	24	13	14	14	NUM
dpc-3629	24	14	]	]	PUNCT
dpc-3629	24	15	)	)	PUNCT
dpc-3629	24	16	and	and	CCONJ
dpc-3629	24	17	2nd	2nd	ADJ
dpc-3629	24	18	(	(	PUNCT
dpc-3629	24	19	median	median	NOUN
dpc-3629	24	20	 	 	SPACE
dpc-3629	24	21	=	=	SYM
dpc-3629	24	22	5	5	NUM
dpc-3629	25	1	[	[	SYM
dpc-3629	25	2	3	3	NUM
dpc-3629	25	3	-	-	SYM
dpc-3629	25	4	11	11	NUM
dpc-3629	25	5	]	]	NUM
dpc-3629	25	6	)	)	PUNCT
dpc-3629	25	7	,	,	PUNCT
dpc-3629	25	8	6th	6th	NOUN
dpc-3629	25	9	(	(	PUNCT
dpc-3629	25	10	median	median	NOUN
dpc-3629	25	11	=	=	SYM
dpc-3629	25	12	5	5	NUM
dpc-3629	25	13	[	[	SYM
dpc-3629	25	14	3	3	NUM
dpc-3629	25	15	-	-	SYM
dpc-3629	25	16	11	11	NUM
dpc-3629	25	17	]	]	PUNCT
dpc-3629	25	18	)	)	PUNCT
dpc-3629	25	19	and	and	CCONJ
dpc-3629	25	20	12th	12th	ADJ
dpc-3629	25	21	weeks	week	NOUN
dpc-3629	25	22	(	(	PUNCT
dpc-3629	25	23	median	median	NOUN
dpc-3629	25	24	=	=	SYM
dpc-3629	25	25	4	4	NUM
dpc-3629	26	1	[	[	SYM
dpc-3629	26	2	2	2	NUM
dpc-3629	26	3	-	-	SYM
dpc-3629	26	4	9	9	NUM
dpc-3629	26	5	]	]	PUNCT
dpc-3629	26	6	)	)	PUNCT
dpc-3629	26	7	were	be	AUX
dpc-3629	26	8	statistically	statistically	ADV
dpc-3629	26	9	significant	significant	ADJ
dpc-3629	26	10	(	(	PUNCT
dpc-3629	26	11	p<0.001	p<0.001	PROPN
dpc-3629	26	12	)	)	PUNCT
dpc-3629	26	13	.	.	PUNCT
dpc-3629	27	1	concurrent	concurrent	ADJ
dpc-3629	27	2	systemic	systemic	ADJ
dpc-3629	27	3	disease	disease	NOUN
dpc-3629	27	4	was	be	AUX
dpc-3629	27	5	a	a	DET
dpc-3629	27	6	risk	risk	NOUN
dpc-3629	27	7	factor	factor	NOUN
dpc-3629	27	8	for	for	ADP
dpc-3629	27	9	poor	poor	ADJ
dpc-3629	27	10	treatment	treatment	NOUN
dpc-3629	27	11	response	response	NOUN
dpc-3629	27	12	(	(	PUNCT
dpc-3629	27	13	p	p	X
dpc-3629	27	14	=	=	NOUN
dpc-3629	27	15	0.034	0.034	NUM
dpc-3629	27	16	)	)	PUNCT
dpc-3629	27	17	.	.	PUNCT
dpc-3629	28	1	mild	mild	ADJ
dpc-3629	28	2	irritation	irritation	NOUN
dpc-3629	28	3	was	be	AUX
dpc-3629	28	4	observed	observe	VERB
dpc-3629	28	5	in	in	ADP
dpc-3629	28	6	3	3	NUM
dpc-3629	28	7	patients	patient	NOUN
dpc-3629	28	8	(	(	PUNCT
dpc-3629	28	9	8.5	8.5	NUM
dpc-3629	28	10	%	%	NOUN
dpc-3629	28	11	)	)	PUNCT
dpc-3629	28	12	during	during	ADP
dpc-3629	28	13	treatment	treatment	NOUN
dpc-3629	28	14	.	.	PUNCT
dpc-3629	29	1	conclusions	conclusion	NOUN
dpc-3629	29	2	:	:	PUNCT
dpc-3629	29	3	dapsone	dapsone	NOUN
dpc-3629	29	4	5	5	NUM
dpc-3629	29	5	%	%	NOUN
dpc-3629	29	6	gel	gel	NOUN
dpc-3629	29	7	was	be	AUX
dpc-3629	29	8	effective	effective	ADJ
dpc-3629	29	9	and	and	CCONJ
dpc-3629	29	10	well	well	ADV
dpc-3629	29	11	tolerated	tolerate	VERB
dpc-3629	29	12	in	in	ADP
dpc-3629	29	13	etr	etr	PROPN
dpc-3629	29	14	treatment	treatment	NOUN
dpc-3629	29	15	.	.	PUNCT
dpc-3629	30	1	abstract	abstract	ADJ
dpc-3629	30	2	2	2	NUM
dpc-3629	30	3	original	original	ADJ
dpc-3629	30	4	article	article	NOUN
dpc-3629	30	5	|	|	ADV
dpc-3629	30	6	dermatol	dermatol	ADJ
dpc-3629	30	7	pract	pract	NOUN
dpc-3629	30	8	concept	concept	NOUN
dpc-3629	30	9	.	.	PUNCT
dpc-3629	31	1	2024;14(1):e2024034	2024;14(1):e2024034	NUM
dpc-3629	31	2	introduction	introduction	NOUN
dpc-3629	31	3	rosacea	rosacea	NOUN
dpc-3629	31	4	is	be	AUX
dpc-3629	31	5	a	a	DET
dpc-3629	31	6	chronic	chronic	NOUN
dpc-3629	31	7	,	,	PUNCT
dpc-3629	31	8	recurrent	recurrent	ADJ
dpc-3629	31	9	,	,	PUNCT
dpc-3629	31	10	inflammatory	inflammatory	ADJ
dpc-3629	31	11	skin	skin	NOUN
dpc-3629	31	12	disease	disease	NOUN
dpc-3629	31	13	localized	localize	VERB
dpc-3629	31	14	in	in	ADP
dpc-3629	31	15	the	the	DET
dpc-3629	31	16	centrofacial	centrofacial	ADJ
dpc-3629	31	17	region	region	NOUN
dpc-3629	31	18	,	,	PUNCT
dpc-3629	31	19	characterized	characterize	VERB
dpc-3629	31	20	by	by	ADP
dpc-3629	31	21	transient	transient	NOUN
dpc-3629	31	22	flushing	flush	VERB
dpc-3629	31	23	,	,	PUNCT
dpc-3629	31	24	persistent	persistent	ADJ
dpc-3629	31	25	erythema	erythema	NOUN
dpc-3629	31	26	,	,	PUNCT
dpc-3629	31	27	telangiectasia	telangiectasia	NOUN
dpc-3629	31	28	,	,	PUNCT
dpc-3629	31	29	and	and	CCONJ
dpc-3629	31	30	papulopustular	papulopustular	ADJ
dpc-3629	31	31	lesions	lesion	NOUN
dpc-3629	31	32	.	.	PUNCT
dpc-3629	32	1	rosacea	rosacea	NOUN
dpc-3629	32	2	affects	affect	VERB
dpc-3629	32	3	5–10	5–10	ADJ
dpc-3629	32	4	%	%	NOUN
dpc-3629	32	5	of	of	ADP
dpc-3629	32	6	the	the	DET
dpc-3629	32	7	population	population	NOUN
dpc-3629	32	8	and	and	CCONJ
dpc-3629	32	9	is	be	AUX
dpc-3629	32	10	usually	usually	ADV
dpc-3629	32	11	seen	see	VERB
dpc-3629	32	12	after	after	ADP
dpc-3629	32	13	the	the	DET
dpc-3629	32	14	third	third	ADJ
dpc-3629	32	15	decade	decade	NOUN
dpc-3629	32	16	of	of	ADP
dpc-3629	32	17	life	life	NOUN
dpc-3629	32	18	[	[	X
dpc-3629	32	19	1,2	1,2	NUM
dpc-3629	32	20	]	]	PUNCT
dpc-3629	32	21	.	.	PUNCT
dpc-3629	33	1	rosacea	rosacea	NOUN
dpc-3629	33	2	can	can	AUX
dpc-3629	33	3	be	be	AUX
dpc-3629	33	4	classified	classify	VERB
dpc-3629	33	5	into	into	ADP
dpc-3629	33	6	four	four	NUM
dpc-3629	33	7	subtypes	subtype	NOUN
dpc-3629	33	8	;	;	PUNCT
dpc-3629	33	9	erythematotelangiectatic	erythematotelangiectatic	ADJ
dpc-3629	33	10	,	,	PUNCT
dpc-3629	33	11	papulopustular	papulopustular	ADJ
dpc-3629	33	12	,	,	PUNCT
dpc-3629	33	13	phymatous	phymatous	ADJ
dpc-3629	33	14	,	,	PUNCT
dpc-3629	33	15	and	and	CCONJ
dpc-3629	33	16	ocular	ocular	ADJ
dpc-3629	33	17	rosacea	rosacea	NOUN
dpc-3629	33	18	 	 	SPACE
dpc-3629	34	1	[	[	X
dpc-3629	34	2	3	3	NUM
dpc-3629	34	3	]	]	PUNCT
dpc-3629	34	4	.	.	PUNCT
dpc-3629	35	1	erythematotelangiectatic	erythematotelangiectatic	PROPN
dpc-3629	35	2	rosacea	rosacea	PROPN
dpc-3629	35	3	(	(	PUNCT
dpc-3629	35	4	etr	etr	PROPN
dpc-3629	35	5	)	)	PUNCT
dpc-3629	35	6	is	be	AUX
dpc-3629	35	7	the	the	DET
dpc-3629	35	8	most	most	ADV
dpc-3629	35	9	common	common	ADJ
dpc-3629	35	10	and	and	CCONJ
dpc-3629	35	11	has	have	VERB
dpc-3629	35	12	the	the	DET
dpc-3629	35	13	most	most	ADV
dpc-3629	35	14	prominent	prominent	ADJ
dpc-3629	35	15	vascular	vascular	ADJ
dpc-3629	35	16	component	component	NOUN
dpc-3629	35	17	among	among	ADP
dpc-3629	35	18	the	the	DET
dpc-3629	35	19	other	other	ADJ
dpc-3629	35	20	subtypes	subtype	NOUN
dpc-3629	35	21	[	[	X
dpc-3629	35	22	4	4	NUM
dpc-3629	35	23	]	]	PUNCT
dpc-3629	35	24	.	.	PUNCT
dpc-3629	36	1	an	an	DET
dpc-3629	36	2	exaggerated	exaggerated	ADJ
dpc-3629	36	3	innate	innate	ADJ
dpc-3629	36	4	immune	immune	ADJ
dpc-3629	36	5	response	response	NOUN
dpc-3629	36	6	and	and	CCONJ
dpc-3629	36	7	neurovascular	neurovascular	ADJ
dpc-3629	36	8	dysregulation	dysregulation	NOUN
dpc-3629	36	9	are	be	AUX
dpc-3629	36	10	the	the	DET
dpc-3629	36	11	two	two	NUM
dpc-3629	36	12	main	main	ADJ
dpc-3629	36	13	pathophysiological	pathophysiological	ADJ
dpc-3629	36	14	factors	factor	NOUN
dpc-3629	36	15	in	in	ADP
dpc-3629	36	16	the	the	DET
dpc-3629	36	17	emergence	emergence	NOUN
dpc-3629	36	18	of	of	ADP
dpc-3629	36	19	etr	etr	PROPN
dpc-3629	37	1	[	[	X
dpc-3629	37	2	5	5	NUM
dpc-3629	37	3	]	]	PUNCT
dpc-3629	37	4	.	.	PUNCT
dpc-3629	38	1	bacterial	bacterial	ADJ
dpc-3629	38	2	proteases	protease	NOUN
dpc-3629	38	3	,	,	PUNCT
dpc-3629	38	4	products	product	NOUN
dpc-3629	38	5	of	of	ADP
dpc-3629	38	6	demodex	demodex	NOUN
dpc-3629	38	7	folliculorum	folliculorum	NOUN
dpc-3629	38	8	and	and	CCONJ
dpc-3629	38	9	staphylococcus	staphylococcus	NOUN
dpc-3629	38	10	epidermidis	epidermidi	NOUN
dpc-3629	38	11	,	,	PUNCT
dpc-3629	38	12	heat	heat	NOUN
dpc-3629	38	13	,	,	PUNCT
dpc-3629	38	14	stress	stress	NOUN
dpc-3629	38	15	,	,	PUNCT
dpc-3629	38	16	irritants	irritant	NOUN
dpc-3629	38	17	,	,	PUNCT
dpc-3629	38	18	ultraviolet	ultraviolet	NOUN
dpc-3629	38	19	b	b	PROPN
dpc-3629	38	20	radiation	radiation	NOUN
dpc-3629	38	21	,	,	PUNCT
dpc-3629	38	22	products	product	NOUN
dpc-3629	38	23	of	of	ADP
dpc-3629	38	24	cellular	cellular	ADJ
dpc-3629	38	25	metabolism	metabolism	NOUN
dpc-3629	38	26	such	such	ADJ
dpc-3629	38	27	as	as	ADP
dpc-3629	38	28	reactive	reactive	ADJ
dpc-3629	38	29	oxygen	oxygen	NOUN
dpc-3629	38	30	species	specie	NOUN
dpc-3629	38	31	(	(	PUNCT
dpc-3629	38	32	ros	ros	PROPN
dpc-3629	38	33	)	)	PUNCT
dpc-3629	38	34	,	,	PUNCT
dpc-3629	38	35	other	other	ADJ
dpc-3629	38	36	known	know	VERB
dpc-3629	38	37	triggers	trigger	NOUN
dpc-3629	38	38	such	such	ADJ
dpc-3629	38	39	as	as	ADP
dpc-3629	38	40	spicy	spicy	ADJ
dpc-3629	38	41	food	food	NOUN
dpc-3629	38	42	,	,	PUNCT
dpc-3629	38	43	strenuous	strenuous	ADJ
dpc-3629	38	44	exercise	exercise	NOUN
dpc-3629	38	45	activate	activate	VERB
dpc-3629	38	46	certain	certain	ADJ
dpc-3629	38	47	specific	specific	ADJ
dpc-3629	38	48	receptors	receptor	NOUN
dpc-3629	38	49	and	and	CCONJ
dpc-3629	38	50	channel	channel	NOUN
dpc-3629	38	51	over	over	ADP
dpc-3629	38	52	the	the	DET
dpc-3629	38	53	skin	skin	NOUN
dpc-3629	38	54	.	.	PUNCT
dpc-3629	39	1	all	all	PRON
dpc-3629	39	2	of	of	ADP
dpc-3629	39	3	these	these	DET
dpc-3629	39	4	triggers	trigger	NOUN
dpc-3629	39	5	lead	lead	VERB
dpc-3629	39	6	to	to	ADP
dpc-3629	39	7	the	the	DET
dpc-3629	39	8	secretion	secretion	NOUN
dpc-3629	39	9	of	of	ADP
dpc-3629	39	10	proinflammatory	proinflammatory	ADJ
dpc-3629	39	11	cytokines	cytokine	NOUN
dpc-3629	39	12	,	,	PUNCT
dpc-3629	39	13	chemokines	chemokine	NOUN
dpc-3629	39	14	,	,	PUNCT
dpc-3629	39	15	proteases	protease	NOUN
dpc-3629	39	16	,	,	PUNCT
dpc-3629	39	17	and	and	CCONJ
dpc-3629	39	18	pro	pro	ADJ
dpc-3629	39	19	-	-	ADJ
dpc-3629	39	20	angiogenic	angiogenic	ADJ
dpc-3629	39	21	factors	factor	NOUN
dpc-3629	39	22	[	[	X
dpc-3629	39	23	1,6	1,6	NUM
dpc-3629	39	24	]	]	PUNCT
dpc-3629	39	25	.	.	PUNCT
dpc-3629	40	1	these	these	DET
dpc-3629	40	2	factors	factor	NOUN
dpc-3629	40	3	cause	cause	VERB
dpc-3629	40	4	inflammation	inflammation	NOUN
dpc-3629	40	5	in	in	ADP
dpc-3629	40	6	the	the	DET
dpc-3629	40	7	dermis	dermis	NOUN
dpc-3629	40	8	,	,	PUNCT
dpc-3629	40	9	which	which	PRON
dpc-3629	40	10	play	play	VERB
dpc-3629	40	11	a	a	DET
dpc-3629	40	12	major	major	ADJ
dpc-3629	40	13	role	role	NOUN
dpc-3629	40	14	in	in	ADP
dpc-3629	40	15	the	the	DET
dpc-3629	40	16	occurrence	occurrence	NOUN
dpc-3629	40	17	of	of	ADP
dpc-3629	40	18	rosacea	rosacea	NOUN
dpc-3629	40	19	[	[	X
dpc-3629	40	20	6	6	NUM
dpc-3629	40	21	]	]	PUNCT
dpc-3629	40	22	.	.	PUNCT
dpc-3629	41	1	density	density	NOUN
dpc-3629	41	2	of	of	ADP
dpc-3629	41	3	inflammation	inflammation	NOUN
dpc-3629	41	4	in	in	ADP
dpc-3629	41	5	the	the	DET
dpc-3629	41	6	dermis	dermis	NOUN
dpc-3629	41	7	varies	vary	VERB
dpc-3629	41	8	in	in	ADP
dpc-3629	41	9	rosacea	rosacea	NOUN
dpc-3629	41	10	between	between	ADP
dpc-3629	41	11	individuals	individual	NOUN
dpc-3629	41	12	and	and	CCONJ
dpc-3629	41	13	over	over	ADP
dpc-3629	41	14	time	time	NOUN
dpc-3629	41	15	.	.	PUNCT
dpc-3629	42	1	in	in	ADP
dpc-3629	42	2	the	the	DET
dpc-3629	42	3	etr	etr	NOUN
dpc-3629	42	4	subtype	subtype	NOUN
dpc-3629	42	5	of	of	ADP
dpc-3629	42	6	rosacea	rosacea	NOUN
dpc-3629	42	7	,	,	PUNCT
dpc-3629	42	8	inflammation	inflammation	NOUN
dpc-3629	42	9	is	be	AUX
dpc-3629	42	10	seen	see	VERB
dpc-3629	42	11	in	in	ADP
dpc-3629	42	12	both	both	CCONJ
dpc-3629	42	13	perivascular	perivascular	ADJ
dpc-3629	42	14	and	and	CCONJ
dpc-3629	42	15	interstitial	interstitial	ADJ
dpc-3629	42	16	regions	region	NOUN
dpc-3629	42	17	[	[	X
dpc-3629	42	18	5	5	NUM
dpc-3629	42	19	]	]	PUNCT
dpc-3629	42	20	.	.	PUNCT
dpc-3629	43	1	cytokines	cytokine	NOUN
dpc-3629	43	2	such	such	ADJ
dpc-3629	43	3	as	as	ADP
dpc-3629	43	4	vascular	vascular	ADJ
dpc-3629	43	5	endothelial	endothelial	ADJ
dpc-3629	43	6	growth	growth	NOUN
dpc-3629	43	7	factor	factor	NOUN
dpc-3629	43	8	(	(	PUNCT
dpc-3629	43	9	vegf	vegf	PROPN
dpc-3629	43	10	)	)	PUNCT
dpc-3629	43	11	,	,	PUNCT
dpc-3629	43	12	and	and	CCONJ
dpc-3629	43	13	proangiogenic	proangiogenic	ADJ
dpc-3629	43	14	factors	factor	NOUN
dpc-3629	43	15	contribute	contribute	VERB
dpc-3629	43	16	to	to	ADP
dpc-3629	43	17	angiogenesis	angiogenesis	NOUN
dpc-3629	43	18	by	by	ADP
dpc-3629	43	19	both	both	CCONJ
dpc-3629	43	20	direct	direct	ADJ
dpc-3629	43	21	and	and	CCONJ
dpc-3629	43	22	indirect	indirect	ADJ
dpc-3629	43	23	mechanisms	mechanism	NOUN
dpc-3629	43	24	[	[	X
dpc-3629	43	25	7	7	NUM
dpc-3629	43	26	]	]	PUNCT
dpc-3629	43	27	.	.	PUNCT
dpc-3629	44	1	many	many	ADJ
dpc-3629	44	2	evidences	evidence	NOUN
dpc-3629	44	3	shows	show	VERB
dpc-3629	44	4	that	that	SCONJ
dpc-3629	44	5	there	there	PRON
dpc-3629	44	6	is	be	VERB
dpc-3629	44	7	an	an	DET
dpc-3629	44	8	association	association	NOUN
dpc-3629	44	9	between	between	ADP
dpc-3629	44	10	inflammation	inflammation	NOUN
dpc-3629	44	11	and	and	CCONJ
dpc-3629	44	12	angiogenesis	angiogenesis	NOUN
dpc-3629	45	1	[	[	X
dpc-3629	45	2	6	6	NUM
dpc-3629	45	3	]	]	PUNCT
dpc-3629	45	4	.	.	PUNCT
dpc-3629	46	1	the	the	DET
dpc-3629	46	2	molecular	molecular	ADJ
dpc-3629	46	3	mechanisms	mechanism	NOUN
dpc-3629	46	4	underlying	underlie	VERB
dpc-3629	46	5	the	the	DET
dpc-3629	46	6	relationship	relationship	NOUN
dpc-3629	46	7	between	between	ADP
dpc-3629	46	8	chronic	chronic	ADJ
dpc-3629	46	9	inflammation	inflammation	NOUN
dpc-3629	46	10	and	and	CCONJ
dpc-3629	46	11	angiogenesis	angiogenesis	NOUN
dpc-3629	46	12	in	in	ADP
dpc-3629	46	13	rosacea	rosacea	NOUN
dpc-3629	46	14	have	have	AUX
dpc-3629	46	15	been	be	AUX
dpc-3629	46	16	clearly	clearly	ADV
dpc-3629	46	17	demonstrated	demonstrate	VERB
dpc-3629	46	18	[	[	PUNCT
dpc-3629	46	19	6	6	NUM
dpc-3629	46	20	]	]	PUNCT
dpc-3629	46	21	.	.	PUNCT
dpc-3629	47	1	dapsone	dapsone	PROPN
dpc-3629	47	2	is	be	AUX
dpc-3629	47	3	an	an	DET
dpc-3629	47	4	antibiotic	antibiotic	NOUN
dpc-3629	47	5	which	which	PRON
dpc-3629	47	6	is	be	AUX
dpc-3629	47	7	a	a	DET
dpc-3629	47	8	member	member	NOUN
dpc-3629	47	9	of	of	ADP
dpc-3629	47	10	the	the	DET
dpc-3629	47	11	sulfone	sulfone	NOUN
dpc-3629	47	12	family	family	NOUN
dpc-3629	48	1	[	[	X
dpc-3629	48	2	8	8	NUM
dpc-3629	48	3	]	]	PUNCT
dpc-3629	48	4	.	.	PUNCT
dpc-3629	49	1	dapsone	dapsone	PROPN
dpc-3629	49	2	has	have	VERB
dpc-3629	49	3	anti	anti	ADJ
dpc-3629	49	4	-	-	ADJ
dpc-3629	49	5	inflammatory	inflammatory	ADJ
dpc-3629	49	6	activity	activity	NOUN
dpc-3629	49	7	in	in	ADP
dpc-3629	49	8	addition	addition	NOUN
dpc-3629	49	9	to	to	ADP
dpc-3629	49	10	its	its	PRON
dpc-3629	49	11	antibiotic	antibiotic	ADJ
dpc-3629	49	12	activity	activity	NOUN
dpc-3629	49	13	.	.	PUNCT
dpc-3629	50	1	dapsone	dapsone	PROPN
dpc-3629	50	2	also	also	ADV
dpc-3629	50	3	blocks	block	VERB
dpc-3629	50	4	angiogenesis	angiogenesis	NOUN
dpc-3629	50	5	by	by	ADP
dpc-3629	50	6	inhibiting	inhibit	VERB
dpc-3629	50	7	some	some	DET
dpc-3629	50	8	molecular	molecular	ADJ
dpc-3629	50	9	mechanisms	mechanism	NOUN
dpc-3629	50	10	such	such	ADJ
dpc-3629	50	11	as	as	ADP
dpc-3629	50	12	vegf	vegf	NOUN
dpc-3629	50	13	formation	formation	NOUN
dpc-3629	51	1	[	[	X
dpc-3629	51	2	9	9	X
dpc-3629	51	3	]	]	PUNCT
dpc-3629	51	4	in	in	ADP
dpc-3629	51	5	the	the	DET
dpc-3629	51	6	light	light	NOUN
dpc-3629	51	7	of	of	ADP
dpc-3629	51	8	this	this	DET
dpc-3629	51	9	knowledge	knowledge	NOUN
dpc-3629	51	10	,	,	PUNCT
dpc-3629	51	11	we	we	PRON
dpc-3629	51	12	used	use	VERB
dpc-3629	51	13	topical	topical	ADJ
dpc-3629	51	14	dapsone	dapsone	NOUN
dpc-3629	51	15	to	to	PART
dpc-3629	51	16	treat	treat	VERB
dpc-3629	51	17	etr	etr	PROPN
dpc-3629	51	18	by	by	ADP
dpc-3629	51	19	targeting	target	VERB
dpc-3629	51	20	chronic	chronic	ADJ
dpc-3629	51	21	inflammation	inflammation	NOUN
dpc-3629	51	22	and	and	CCONJ
dpc-3629	51	23	angiogenesis	angiogenesis	NOUN
dpc-3629	51	24	.	.	PUNCT
dpc-3629	52	1	the	the	DET
dpc-3629	52	2	absence	absence	NOUN
dpc-3629	52	3	of	of	ADP
dpc-3629	52	4	a	a	DET
dpc-3629	52	5	study	study	NOUN
dpc-3629	52	6	in	in	ADP
dpc-3629	52	7	the	the	DET
dpc-3629	52	8	literature	literature	NOUN
dpc-3629	52	9	investigating	investigate	VERB
dpc-3629	52	10	the	the	DET
dpc-3629	52	11	effectiveness	effectiveness	NOUN
dpc-3629	52	12	of	of	ADP
dpc-3629	52	13	topical	topical	ADJ
dpc-3629	52	14	dapsone	dapsone	NOUN
dpc-3629	52	15	on	on	ADP
dpc-3629	52	16	etr	etr	PROPN
dpc-3629	52	17	makes	make	VERB
dpc-3629	52	18	our	our	PRON
dpc-3629	52	19	study	study	NOUN
dpc-3629	52	20	a	a	DET
dpc-3629	52	21	first	first	ADJ
dpc-3629	52	22	.	.	PUNCT
dpc-3629	53	1	objectives	objective	NOUN
dpc-3629	53	2	in	in	ADP
dpc-3629	53	3	this	this	DET
dpc-3629	53	4	study	study	NOUN
dpc-3629	53	5	,	,	PUNCT
dpc-3629	53	6	we	we	PRON
dpc-3629	53	7	primarily	primarily	ADV
dpc-3629	53	8	evaluated	evaluate	VERB
dpc-3629	53	9	the	the	DET
dpc-3629	53	10	efficacy	efficacy	NOUN
dpc-3629	53	11	of	of	ADP
dpc-3629	53	12	dapsone	dapsone	PROPN
dpc-3629	53	13	5	5	NUM
dpc-3629	53	14	%	%	NOUN
dpc-3629	53	15	gel	gel	NOUN
dpc-3629	53	16	in	in	ADP
dpc-3629	53	17	treatment	treatment	NOUN
dpc-3629	53	18	of	of	ADP
dpc-3629	53	19	etr	etr	PROPN
dpc-3629	53	20	and	and	CCONJ
dpc-3629	53	21	additionally	additionally	ADV
dpc-3629	53	22	aimed	aim	VERB
dpc-3629	53	23	to	to	PART
dpc-3629	53	24	determine	determine	VERB
dpc-3629	53	25	the	the	DET
dpc-3629	53	26	side	side	NOUN
dpc-3629	53	27	effects	effect	NOUN
dpc-3629	53	28	during	during	ADP
dpc-3629	53	29	treatment	treatment	NOUN
dpc-3629	53	30	in	in	ADP
dpc-3629	53	31	this	this	DET
dpc-3629	53	32	patient	patient	NOUN
dpc-3629	53	33	’s	’s	PART
dpc-3629	53	34	group	group	NOUN
dpc-3629	53	35	.	.	PUNCT
dpc-3629	54	1	methods	method	NOUN
dpc-3629	54	2	study	study	VERB
dpc-3629	54	3	design	design	NOUN
dpc-3629	54	4	and	and	CCONJ
dpc-3629	54	5	patient	patient	ADJ
dpc-3629	54	6	population	population	NOUN
dpc-3629	54	7	this	this	PRON
dpc-3629	54	8	is	be	AUX
dpc-3629	54	9	a	a	DET
dpc-3629	54	10	single	single	ADJ
dpc-3629	54	11	-	-	PUNCT
dpc-3629	54	12	centre	centre	NOUN
dpc-3629	54	13	prospective	prospective	ADJ
dpc-3629	54	14	experimental	experimental	ADJ
dpc-3629	54	15	clinical	clinical	ADJ
dpc-3629	54	16	study	study	NOUN
dpc-3629	54	17	.	.	PUNCT
dpc-3629	55	1	a	a	DET
dpc-3629	55	2	total	total	NOUN
dpc-3629	55	3	of	of	ADP
dpc-3629	55	4	35	35	NUM
dpc-3629	55	5	patients	patient	NOUN
dpc-3629	55	6	with	with	ADP
dpc-3629	55	7	etr	etr	PROPN
dpc-3629	55	8	who	who	PRON
dpc-3629	55	9	applied	apply	VERB
dpc-3629	55	10	to	to	ADP
dpc-3629	55	11	the	the	DET
dpc-3629	55	12	outpatient	outpatient	NOUN
dpc-3629	55	13	clinic	clinic	NOUN
dpc-3629	55	14	between	between	ADP
dpc-3629	55	15	march	march	PROPN
dpc-3629	55	16	and	and	CCONJ
dpc-3629	55	17	november	november	PROPN
dpc-3629	55	18	2022	2022	NUM
dpc-3629	55	19	were	be	AUX
dpc-3629	55	20	enrolled	enrol	VERB
dpc-3629	55	21	in	in	ADP
dpc-3629	55	22	the	the	DET
dpc-3629	55	23	study	study	NOUN
dpc-3629	55	24	.	.	PUNCT
dpc-3629	56	1	diagnosis	diagnosis	NOUN
dpc-3629	56	2	,	,	PUNCT
dpc-3629	56	3	classification	classification	NOUN
dpc-3629	56	4	,	,	PUNCT
dpc-3629	56	5	and	and	CCONJ
dpc-3629	56	6	staging	staging	NOUN
dpc-3629	56	7	of	of	ADP
dpc-3629	56	8	the	the	DET
dpc-3629	56	9	disease	disease	NOUN
dpc-3629	56	10	rosacea	rosacea	NOUN
dpc-3629	56	11	diagnosis	diagnosis	NOUN
dpc-3629	56	12	,	,	PUNCT
dpc-3629	56	13	classification	classification	NOUN
dpc-3629	56	14	,	,	PUNCT
dpc-3629	56	15	and	and	CCONJ
dpc-3629	56	16	staging	staging	NOUN
dpc-3629	56	17	was	be	AUX
dpc-3629	56	18	done	do	VERB
dpc-3629	56	19	according	accord	VERB
dpc-3629	56	20	to	to	ADP
dpc-3629	56	21	the	the	DET
dpc-3629	56	22	criteria	criterion	NOUN
dpc-3629	56	23	of	of	ADP
dpc-3629	56	24	the	the	DET
dpc-3629	56	25	national	national	PROPN
dpc-3629	56	26	rosacea	rosacea	PROPN
dpc-3629	56	27	society	society	PROPN
dpc-3629	56	28	expert	expert	PROPN
dpc-3629	56	29	committee	committee	PROPN
dpc-3629	56	30	[	[	X
dpc-3629	56	31	10	10	NUM
dpc-3629	56	32	]	]	PUNCT
dpc-3629	56	33	.	.	PUNCT
dpc-3629	57	1	inclusion	inclusion	NOUN
dpc-3629	57	2	criteria	criterion	NOUN
dpc-3629	57	3	of	of	ADP
dpc-3629	57	4	the	the	DET
dpc-3629	57	5	patients	patient	NOUN
dpc-3629	57	6	patients	patient	NOUN
dpc-3629	57	7	over	over	ADP
dpc-3629	57	8	16	16	NUM
dpc-3629	57	9	years	year	NOUN
dpc-3629	57	10	old	old	ADJ
dpc-3629	57	11	diagnosed	diagnose	VERB
dpc-3629	57	12	with	with	ADP
dpc-3629	57	13	etr	etr	PROPN
dpc-3629	57	14	by	by	ADP
dpc-3629	57	15	at	at	ADV
dpc-3629	57	16	least	least	ADV
dpc-3629	57	17	two	two	NUM
dpc-3629	57	18	dermatologists	dermatologist	NOUN
dpc-3629	57	19	were	be	AUX
dpc-3629	57	20	included	include	VERB
dpc-3629	57	21	in	in	ADP
dpc-3629	57	22	the	the	DET
dpc-3629	57	23	study	study	NOUN
dpc-3629	57	24	.	.	PUNCT
dpc-3629	58	1	the	the	DET
dpc-3629	58	2	diagnosis	diagnosis	NOUN
dpc-3629	58	3	of	of	ADP
dpc-3629	58	4	rosacea	rosacea	NOUN
dpc-3629	58	5	was	be	AUX
dpc-3629	58	6	made	make	VERB
dpc-3629	58	7	after	after	ADP
dpc-3629	58	8	comprehensive	comprehensive	ADJ
dpc-3629	58	9	clinical	clinical	ADJ
dpc-3629	58	10	and	and	CCONJ
dpc-3629	58	11	dermoscopic	dermoscopic	ADJ
dpc-3629	58	12	evaluation	evaluation	NOUN
dpc-3629	58	13	,	,	PUNCT
dpc-3629	58	14	including	include	VERB
dpc-3629	58	15	histopathologic	histopathologic	NOUN
dpc-3629	58	16	evaluation	evaluation	NOUN
dpc-3629	58	17	when	when	SCONJ
dpc-3629	58	18	needed	need	VERB
dpc-3629	58	19	.	.	PUNCT
dpc-3629	59	1	exclusion	exclusion	NOUN
dpc-3629	59	2	criteria	criterion	NOUN
dpc-3629	59	3	of	of	ADP
dpc-3629	59	4	the	the	DET
dpc-3629	59	5	patients	patient	NOUN
dpc-3629	59	6	the	the	DET
dpc-3629	59	7	exclusion	exclusion	NOUN
dpc-3629	59	8	criteria	criterion	NOUN
dpc-3629	59	9	included	include	VERB
dpc-3629	59	10	pregnancy	pregnancy	NOUN
dpc-3629	59	11	,	,	PUNCT
dpc-3629	59	12	lactation	lactation	NOUN
dpc-3629	59	13	,	,	PUNCT
dpc-3629	59	14	immunosuppression	immunosuppression	NOUN
dpc-3629	59	15	,	,	PUNCT
dpc-3629	59	16	glucose	glucose	NOUN
dpc-3629	59	17	6	6	NUM
dpc-3629	59	18	phosphate	phosphate	ADJ
dpc-3629	59	19	dehydrogenase	dehydrogenase	NOUN
dpc-3629	59	20	enzyme	enzyme	NOUN
dpc-3629	59	21	deficiency	deficiency	NOUN
dpc-3629	59	22	,	,	PUNCT
dpc-3629	59	23	anemia	anemia	NOUN
dpc-3629	59	24	,	,	PUNCT
dpc-3629	59	25	and	and	CCONJ
dpc-3629	59	26	methemoglobinemia	methemoglobinemia	NOUN
dpc-3629	59	27	.	.	PUNCT
dpc-3629	60	1	ethics	ethic	NOUN
dpc-3629	60	2	committee	committee	PROPN
dpc-3629	60	3	approval	approval	NOUN
dpc-3629	60	4	and	and	CCONJ
dpc-3629	60	5	informed	inform	VERB
dpc-3629	60	6	consent	consent	NOUN
dpc-3629	60	7	approval	approval	NOUN
dpc-3629	60	8	of	of	ADP
dpc-3629	60	9	the	the	DET
dpc-3629	60	10	ethics	ethic	NOUN
dpc-3629	60	11	committee	committee	PROPN
dpc-3629	60	12	of	of	ADP
dpc-3629	60	13	the	the	DET
dpc-3629	60	14	non	non	ADJ
dpc-3629	60	15	-	-	ADJ
dpc-3629	60	16	invasive	invasive	ADJ
dpc-3629	60	17	clinical	clinical	ADJ
dpc-3629	60	18	research	research	NOUN
dpc-3629	60	19	was	be	AUX
dpc-3629	60	20	taken	take	VERB
dpc-3629	60	21	for	for	ADP
dpc-3629	60	22	this	this	DET
dpc-3629	60	23	study	study	NOUN
dpc-3629	60	24	(	(	PUNCT
dpc-3629	60	25	decision	decision	NOUN
dpc-3629	60	26	number	number	NOUN
dpc-3629	60	27	/	/	SYM
dpc-3629	60	28	year	year	NOUN
dpc-3629	60	29	,	,	PUNCT
dpc-3629	60	30	e-60116787	e-60116787	PROPN
dpc-3629	60	31	-	-	PUNCT
dpc-3629	60	32	020	020	NUM
dpc-3629	60	33	-	-	PUNCT
dpc-3629	60	34	258589	258589	NUM
dpc-3629	60	35	/	/	SYM
dpc-3629	60	36	2022	2022	NUM
dpc-3629	60	37	)	)	PUNCT
dpc-3629	60	38	.	.	PUNCT
dpc-3629	61	1	informed	informed	ADJ
dpc-3629	61	2	consent	consent	NOUN
dpc-3629	61	3	was	be	AUX
dpc-3629	61	4	taken	take	VERB
dpc-3629	61	5	for	for	ADP
dpc-3629	61	6	all	all	PRON
dpc-3629	61	7	of	of	ADP
dpc-3629	61	8	the	the	DET
dpc-3629	61	9	patients	patient	NOUN
dpc-3629	61	10	.	.	PUNCT
dpc-3629	62	1	this	this	DET
dpc-3629	62	2	study	study	NOUN
dpc-3629	62	3	has	have	AUX
dpc-3629	62	4	been	be	AUX
dpc-3629	62	5	conducted	conduct	VERB
dpc-3629	62	6	in	in	ADP
dpc-3629	62	7	accordance	accordance	NOUN
dpc-3629	62	8	with	with	ADP
dpc-3629	62	9	the	the	DET
dpc-3629	62	10	principles	principle	NOUN
dpc-3629	62	11	of	of	ADP
dpc-3629	62	12	the	the	DET
dpc-3629	62	13	declaration	declaration	NOUN
dpc-3629	62	14	of	of	ADP
dpc-3629	62	15	helsinki	helsinki	PROPN
dpc-3629	62	16	.	.	PUNCT
dpc-3629	63	1	treatment	treatment	NOUN
dpc-3629	63	2	method	method	NOUN
dpc-3629	63	3	only	only	ADV
dpc-3629	63	4	topical	topical	ADJ
dpc-3629	63	5	dapsone	dapsone	NOUN
dpc-3629	63	6	5	5	NUM
dpc-3629	63	7	%	%	NOUN
dpc-3629	63	8	gel	gel	NOUN
dpc-3629	63	9	was	be	AUX
dpc-3629	63	10	used	use	VERB
dpc-3629	63	11	in	in	ADP
dpc-3629	63	12	the	the	DET
dpc-3629	63	13	treatment	treatment	NOUN
dpc-3629	63	14	of	of	ADP
dpc-3629	63	15	etr	etr	PROPN
dpc-3629	63	16	without	without	ADP
dpc-3629	63	17	any	any	DET
dpc-3629	63	18	topical	topical	ADJ
dpc-3629	63	19	or	or	CCONJ
dpc-3629	63	20	systemic	systemic	ADJ
dpc-3629	63	21	agent	agent	NOUN
dpc-3629	63	22	.	.	PUNCT
dpc-3629	64	1	dapson	dapson	NOUN
dpc-3629	64	2	5	5	NUM
dpc-3629	64	3	%	%	NOUN
dpc-3629	64	4	gel	gel	NOUN
dpc-3629	64	5	application	application	NOUN
dpc-3629	64	6	dapson	dapson	NOUN
dpc-3629	64	7	5	5	NUM
dpc-3629	64	8	%	%	NOUN
dpc-3629	64	9	gel	gel	NOUN
dpc-3629	64	10	was	be	AUX
dpc-3629	64	11	applied	apply	VERB
dpc-3629	64	12	on	on	ADP
dpc-3629	64	13	the	the	DET
dpc-3629	64	14	facial	facial	ADJ
dpc-3629	64	15	lesion	lesion	NOUN
dpc-3629	64	16	(	(	PUNCT
dpc-3629	64	17	right	right	ADJ
dpc-3629	64	18	and	and	CCONJ
dpc-3629	64	19	left	leave	VERB
dpc-3629	64	20	cheeks	cheek	NOUN
dpc-3629	64	21	,	,	PUNCT
dpc-3629	64	22	forehead	forehead	NOUN
dpc-3629	64	23	,	,	PUNCT
dpc-3629	64	24	chin	chin	NOUN
dpc-3629	64	25	and	and	CCONJ
dpc-3629	64	26	nose	nose	NOUN
dpc-3629	64	27	)	)	PUNCT
dpc-3629	64	28	as	as	ADP
dpc-3629	64	29	a	a	DET
dpc-3629	64	30	thin	thin	ADJ
dpc-3629	64	31	layer	layer	NOUN
dpc-3629	64	32	twice	twice	DET
dpc-3629	64	33	a	a	DET
dpc-3629	64	34	day	day	NOUN
dpc-3629	64	35	for	for	ADP
dpc-3629	64	36	12	12	NUM
dpc-3629	64	37	weeks	week	NOUN
dpc-3629	64	38	by	by	ADP
dpc-3629	64	39	sparing	spare	VERB
dpc-3629	64	40	the	the	DET
dpc-3629	64	41	perioral	perioral	NOUN
dpc-3629	64	42	,	,	PUNCT
dpc-3629	64	43	periorbital	periorbital	ADJ
dpc-3629	64	44	regions	region	NOUN
dpc-3629	64	45	.	.	PUNCT
dpc-3629	65	1	determination	determination	NOUN
dpc-3629	65	2	of	of	ADP
dpc-3629	65	3	clinical	clinical	ADJ
dpc-3629	65	4	status	status	NOUN
dpc-3629	65	5	and	and	CCONJ
dpc-3629	65	6	 	 	SPACE
dpc-3629	65	7	treatment	treatment	NOUN
dpc-3629	65	8	 	 	SPACE
dpc-3629	65	9	efficacy	efficacy	NOUN
dpc-3629	65	10	patients	patient	NOUN
dpc-3629	65	11	underwent	undergo	VERB
dpc-3629	65	12	4	4	NUM
dpc-3629	65	13	visits	visit	NOUN
dpc-3629	65	14	:	:	PUNCT
dpc-3629	65	15	a	a	DET
dpc-3629	65	16	baseline	baseline	ADJ
dpc-3629	65	17	evaluation	evaluation	NOUN
dpc-3629	65	18	and	and	CCONJ
dpc-3629	65	19	visits	visit	NOUN
dpc-3629	65	20	at	at	ADP
dpc-3629	65	21	weeks	week	NOUN
dpc-3629	65	22	2	2	NUM
dpc-3629	65	23	,	,	PUNCT
dpc-3629	65	24	6	6	NUM
dpc-3629	65	25	,	,	PUNCT
dpc-3629	65	26	and	and	CCONJ
dpc-3629	65	27	12	12	NUM
dpc-3629	65	28	.	.	PUNCT
dpc-3629	66	1	clinical	clinical	ADJ
dpc-3629	66	2	status	status	NOUN
dpc-3629	66	3	of	of	ADP
dpc-3629	66	4	the	the	DET
dpc-3629	66	5	patients	patient	NOUN
dpc-3629	66	6	and	and	CCONJ
dpc-3629	66	7	treatment	treatment	NOUN
dpc-3629	66	8	efficacy	efficacy	NOUN
dpc-3629	66	9	were	be	AUX
dpc-3629	66	10	evaluated	evaluate	VERB
dpc-3629	66	11	by	by	ADP
dpc-3629	66	12	investigator	investigator	NOUN
dpc-3629	66	13	’s	’s	PART
dpc-3629	66	14	global	global	ADJ
dpc-3629	66	15	assessment	assessment	NOUN
dpc-3629	66	16	(	(	PUNCT
dpc-3629	66	17	iga	iga	PROPN
dpc-3629	66	18	)	)	PUNCT
dpc-3629	66	19	,	,	PUNCT
dpc-3629	66	20	visual	visual	ADJ
dpc-3629	66	21	analogue	analogue	NOUN
dpc-3629	66	22	scale	scale	NOUN
dpc-3629	66	23	(	(	PUNCT
dpc-3629	66	24	vas	vas	NOUN
dpc-3629	66	25	)	)	PUNCT
dpc-3629	66	26	,	,	PUNCT
dpc-3629	66	27	and	and	CCONJ
dpc-3629	66	28	and	and	CCONJ
dpc-3629	66	29	dermatology	dermatology	NOUN
dpc-3629	66	30	life	life	NOUN
dpc-3629	66	31	quality	quality	NOUN
dpc-3629	66	32	index	index	NOUN
dpc-3629	66	33	(	(	PUNCT
dpc-3629	66	34	dlqi	dlqi	ADJ
dpc-3629	66	35	)	)	PUNCT
dpc-3629	66	36	scales	scale	NOUN
dpc-3629	66	37	.	.	PUNCT
dpc-3629	67	1	the	the	DET
dpc-3629	67	2	iga	iga	PROPN
dpc-3629	67	3	was	be	AUX
dpc-3629	67	4	a	a	DET
dpc-3629	67	5	grading	grade	VERB
dpc-3629	67	6	method	method	NOUN
dpc-3629	67	7	used	use	VERB
dpc-3629	67	8	by	by	ADP
dpc-3629	67	9	the	the	DET
dpc-3629	67	10	physician	physician	NOUN
dpc-3629	67	11	to	to	PART
dpc-3629	67	12	show	show	VERB
dpc-3629	67	13	the	the	DET
dpc-3629	67	14	severity	severity	NOUN
dpc-3629	67	15	of	of	ADP
dpc-3629	67	16	skin	skin	NOUN
dpc-3629	67	17	disease	disease	NOUN
dpc-3629	67	18	.	.	PUNCT
dpc-3629	68	1	zero	zero	NUM
dpc-3629	68	2	to	to	ADP
dpc-3629	68	3	4	4	NUM
dpc-3629	68	4	point	point	NOUN
dpc-3629	68	5	scale	scale	NOUN
dpc-3629	68	6	original	original	ADJ
dpc-3629	68	7	article	article	NOUN
dpc-3629	68	8	|	|	ADV
dpc-3629	68	9	dermatol	dermatol	ADJ
dpc-3629	68	10	pract	pract	NOUN
dpc-3629	68	11	concept	concept	NOUN
dpc-3629	68	12	.	.	PUNCT
dpc-3629	69	1	2024;14(1):e2024034	2024;14(1):e2024034	NUM
dpc-3629	69	2	3	3	NUM
dpc-3629	69	3	was	be	AUX
dpc-3629	69	4	used	use	VERB
dpc-3629	69	5	for	for	ADP
dpc-3629	69	6	determining	determine	VERB
dpc-3629	69	7	the	the	DET
dpc-3629	69	8	severity	severity	NOUN
dpc-3629	69	9	of	of	ADP
dpc-3629	69	10	etr	etr	PROPN
dpc-3629	69	11	and	and	CCONJ
dpc-3629	69	12	clinical	clinical	ADJ
dpc-3629	69	13	status	status	NOUN
dpc-3629	69	14	for	for	ADP
dpc-3629	69	15	each	each	DET
dpc-3629	69	16	patient	patient	NOUN
dpc-3629	69	17	(	(	PUNCT
dpc-3629	69	18	grade	grade	NOUN
dpc-3629	69	19	;	;	PUNCT
dpc-3629	69	20	0	0	NUM
dpc-3629	69	21	→	→	SYM
dpc-3629	69	22	clean	clean	ADJ
dpc-3629	69	23	,	,	PUNCT
dpc-3629	69	24	1	1	NUM
dpc-3629	69	25	→	→	SYM
dpc-3629	69	26	mild	mild	ADJ
dpc-3629	69	27	,	,	PUNCT
dpc-3629	69	28	2	2	NUM
dpc-3629	69	29	 	 	SPACE
dpc-3629	69	30	→	→	NOUN
dpc-3629	69	31	 	 	SPACE
dpc-3629	69	32	moderate	moderate	ADJ
dpc-3629	69	33	,	,	PUNCT
dpc-3629	69	34	3	3	NUM
dpc-3629	69	35	→	→	SYM
dpc-3629	69	36	severe	severe	ADJ
dpc-3629	69	37	,	,	PUNCT
dpc-3629	69	38	4	4	NUM
dpc-3629	69	39	→	→	SYM
dpc-3629	69	40	very	very	ADV
dpc-3629	69	41	severe	severe	ADJ
dpc-3629	69	42	)	)	PUNCT
dpc-3629	70	1	[	[	X
dpc-3629	70	2	11	11	NUM
dpc-3629	70	3	-	-	SYM
dpc-3629	70	4	13	13	NUM
dpc-3629	70	5	]	]	PUNCT
dpc-3629	70	6	.	.	PUNCT
dpc-3629	71	1	to	to	PART
dpc-3629	71	2	assess	assess	VERB
dpc-3629	71	3	subjective	subjective	ADJ
dpc-3629	71	4	disease	disease	NOUN
dpc-3629	71	5	perception	perception	NOUN
dpc-3629	71	6	,	,	PUNCT
dpc-3629	71	7	participants	participant	NOUN
dpc-3629	71	8	were	be	AUX
dpc-3629	71	9	asked	ask	VERB
dpc-3629	71	10	to	to	PART
dpc-3629	71	11	mark	mark	VERB
dpc-3629	71	12	on	on	ADP
dpc-3629	71	13	a	a	DET
dpc-3629	71	14	10	10	NUM
dpc-3629	71	15	-	-	PUNCT
dpc-3629	71	16	cm	cm	NOUN
dpc-3629	71	17	continuous	continuous	ADJ
dpc-3629	71	18	vas	vas	NOUN
dpc-3629	71	19	how	how	SCONJ
dpc-3629	71	20	disturbing	disturbing	ADJ
dpc-3629	71	21	their	their	PRON
dpc-3629	71	22	rosacea	rosacea	NOUN
dpc-3629	71	23	had	have	AUX
dpc-3629	71	24	been	be	AUX
dpc-3629	71	25	during	during	ADP
dpc-3629	71	26	the	the	DET
dpc-3629	71	27	past	past	ADJ
dpc-3629	71	28	4	4	NUM
dpc-3629	71	29	weeks	week	NOUN
dpc-3629	71	30	.	.	PUNCT
dpc-3629	72	1	the	the	DET
dpc-3629	72	2	place	place	NOUN
dpc-3629	72	3	of	of	ADP
dpc-3629	72	4	every	every	DET
dpc-3629	72	5	mark	mark	NOUN
dpc-3629	72	6	on	on	ADP
dpc-3629	72	7	vas	vas	PROPN
dpc-3629	72	8	was	be	AUX
dpc-3629	72	9	measured	measure	VERB
dpc-3629	72	10	to	to	ADP
dpc-3629	72	11	1	1	NUM
dpc-3629	72	12	mm	mm	NUM
dpc-3629	72	13	and	and	CCONJ
dpc-3629	72	14	was	be	AUX
dpc-3629	72	15	scored	score	VERB
dpc-3629	72	16	from	from	ADP
dpc-3629	72	17	0	0	NUM
dpc-3629	72	18	to	to	ADP
dpc-3629	72	19	10	10	NUM
dpc-3629	72	20	(	(	PUNCT
dpc-3629	72	21	0	0	NUM
dpc-3629	72	22	=	=	SYM
dpc-3629	72	23	not	not	PART
dpc-3629	72	24	at	at	ADV
dpc-3629	72	25	all	all	ADV
dpc-3629	72	26	disturbing	disturbing	ADJ
dpc-3629	72	27	;	;	PUNCT
dpc-3629	72	28	10	10	NUM
dpc-3629	72	29	=	=	NOUN
dpc-3629	72	30	maximally	maximally	ADV
dpc-3629	72	31	disturbing	disturbing	ADJ
dpc-3629	72	32	)	)	PUNCT
dpc-3629	73	1	[	[	X
dpc-3629	73	2	14	14	NUM
dpc-3629	73	3	]	]	PUNCT
dpc-3629	73	4	.	.	PUNCT
dpc-3629	74	1	the	the	DET
dpc-3629	74	2	dlqi	dlqi	PROPN
dpc-3629	74	3	is	be	AUX
dpc-3629	74	4	planned	plan	VERB
dpc-3629	74	5	to	to	PART
dpc-3629	74	6	evaluate	evaluate	VERB
dpc-3629	74	7	the	the	DET
dpc-3629	74	8	health	health	NOUN
dpc-3629	74	9	-	-	PUNCT
dpc-3629	74	10	related	relate	VERB
dpc-3629	74	11	quality	quality	NOUN
dpc-3629	74	12	of	of	ADP
dpc-3629	74	13	life	life	NOUN
dpc-3629	74	14	of	of	ADP
dpc-3629	74	15	adult	adult	NOUN
dpc-3629	74	16	patients	patient	NOUN
dpc-3629	74	17	complaining	complain	VERB
dpc-3629	74	18	of	of	ADP
dpc-3629	74	19	skin	skin	NOUN
dpc-3629	74	20	disease	disease	NOUN
dpc-3629	74	21	.	.	PUNCT
dpc-3629	75	1	the	the	DET
dpc-3629	75	2	dlqi	dlqi	PROPN
dpc-3629	75	3	occurs	occur	VERB
dpc-3629	75	4	10	10	NUM
dpc-3629	75	5	questions	question	NOUN
dpc-3629	75	6	regarding	regard	VERB
dpc-3629	75	7	patients	patient	NOUN
dpc-3629	75	8	’	'	PUNCT
dpc-3629	75	9	perception	perception	NOUN
dpc-3629	75	10	of	of	ADP
dpc-3629	75	11	the	the	DET
dpc-3629	75	12	effect	effect	NOUN
dpc-3629	75	13	of	of	ADP
dpc-3629	75	14	skin	skin	NOUN
dpc-3629	75	15	diseases	disease	NOUN
dpc-3629	75	16	on	on	ADP
dpc-3629	75	17	different	different	ADJ
dpc-3629	75	18	aspects	aspect	NOUN
dpc-3629	75	19	of	of	ADP
dpc-3629	75	20	their	their	PRON
dpc-3629	75	21	health	health	NOUN
dpc-3629	75	22	-	-	PUNCT
dpc-3629	75	23	related	relate	VERB
dpc-3629	75	24	quality	quality	NOUN
dpc-3629	75	25	of	of	ADP
dpc-3629	75	26	life	life	NOUN
dpc-3629	75	27	over	over	ADP
dpc-3629	75	28	the	the	DET
dpc-3629	75	29	last	last	ADJ
dpc-3629	75	30	week	week	NOUN
dpc-3629	75	31	.	.	PUNCT
dpc-3629	76	1	each	each	DET
dpc-3629	76	2	question	question	NOUN
dpc-3629	76	3	is	be	AUX
dpc-3629	76	4	scored	score	VERB
dpc-3629	76	5	on	on	ADP
dpc-3629	76	6	a	a	DET
dpc-3629	76	7	four	four	NUM
dpc-3629	76	8	-	-	PUNCT
dpc-3629	76	9	point	point	NOUN
dpc-3629	76	10	likert	likert	ADJ
dpc-3629	76	11	scale	scale	NOUN
dpc-3629	76	12	(	(	PUNCT
dpc-3629	76	13	very	very	ADV
dpc-3629	76	14	much	much	ADV
dpc-3629	76	15	=	=	SYM
dpc-3629	76	16	3	3	NUM
dpc-3629	76	17	,	,	PUNCT
dpc-3629	76	18	lot	lot	NOUN
dpc-3629	76	19	=	=	SYM
dpc-3629	76	20	2	2	NUM
dpc-3629	76	21	,	,	PUNCT
dpc-3629	76	22	little	little	ADJ
dpc-3629	76	23	=	=	SYM
dpc-3629	76	24	1	1	NUM
dpc-3629	76	25	,	,	PUNCT
dpc-3629	76	26	not	not	PART
dpc-3629	76	27	at	at	ADV
dpc-3629	76	28	all	all	ADV
dpc-3629	76	29	=	=	SYM
dpc-3629	76	30	0	0	NUM
dpc-3629	76	31	,	,	PUNCT
dpc-3629	76	32	not	not	PART
dpc-3629	76	33	relevant	relevant	ADJ
dpc-3629	76	34	=	=	SYM
dpc-3629	76	35	0	0	NUM
dpc-3629	76	36	,	,	PUNCT
dpc-3629	76	37	question	question	NOUN
dpc-3629	76	38	unanswered	unanswered	ADJ
dpc-3629	76	39	=	=	NOUN
dpc-3629	76	40	0	0	NUM
dpc-3629	76	41	)	)	PUNCT
dpc-3629	76	42	.	.	PUNCT
dpc-3629	77	1	the	the	DET
dpc-3629	77	2	dlqi	dlqi	ADJ
dpc-3629	77	3	questionnaire	questionnaire	NOUN
dpc-3629	77	4	(	(	PUNCT
dpc-3629	77	5	10	10	NUM
dpc-3629	77	6	questions	question	NOUN
dpc-3629	77	7	,	,	PUNCT
dpc-3629	77	8	maximum	maximum	ADJ
dpc-3629	77	9	30	30	NUM
dpc-3629	77	10	points	point	NOUN
dpc-3629	77	11	)	)	PUNCT
dpc-3629	77	12	was	be	AUX
dpc-3629	77	13	administered	administer	VERB
dpc-3629	77	14	to	to	ADP
dpc-3629	77	15	all	all	DET
dpc-3629	77	16	patients	patient	NOUN
dpc-3629	77	17	at	at	ADP
dpc-3629	77	18	baseline	baseline	NOUN
dpc-3629	77	19	and	and	CCONJ
dpc-3629	77	20	at	at	ADP
dpc-3629	77	21	each	each	DET
dpc-3629	77	22	visit	visit	NOUN
dpc-3629	78	1	[	[	X
dpc-3629	78	2	15	15	NUM
dpc-3629	78	3	]	]	PUNCT
dpc-3629	78	4	.	.	PUNCT
dpc-3629	79	1	treatment	treatment	NOUN
dpc-3629	79	2	success	success	NOUN
dpc-3629	79	3	treatment	treatment	NOUN
dpc-3629	79	4	success	success	NOUN
dpc-3629	79	5	was	be	AUX
dpc-3629	79	6	accepted	accept	VERB
dpc-3629	79	7	as	as	ADP
dpc-3629	79	8	an	an	DET
dpc-3629	79	9	iga	iga	PROPN
dpc-3629	79	10	score	score	NOUN
dpc-3629	79	11	of	of	ADP
dpc-3629	79	12	0	0	NUM
dpc-3629	79	13	or	or	CCONJ
dpc-3629	79	14	1	1	NUM
dpc-3629	79	15	,	,	PUNCT
dpc-3629	79	16	or	or	CCONJ
dpc-3629	79	17	a	a	DET
dpc-3629	79	18	two	two	NUM
dpc-3629	79	19	-	-	PUNCT
dpc-3629	79	20	point	point	NOUN
dpc-3629	79	21	reduction	reduction	NOUN
dpc-3629	79	22	in	in	ADP
dpc-3629	79	23	score	score	NOUN
dpc-3629	79	24	.	.	PUNCT
dpc-3629	80	1	adverse	adverse	ADJ
dpc-3629	80	2	events	event	NOUN
dpc-3629	80	3	adverse	adverse	ADJ
dpc-3629	80	4	events	event	NOUN
dpc-3629	80	5	were	be	AUX
dpc-3629	80	6	recorded	record	VERB
dpc-3629	80	7	at	at	ADP
dpc-3629	80	8	each	each	DET
dpc-3629	80	9	visit	visit	NOUN
dpc-3629	80	10	.	.	PUNCT
dpc-3629	81	1	statistical	statistical	ADJ
dpc-3629	81	2	analysis	analysis	NOUN
dpc-3629	81	3	analyses	analysis	NOUN
dpc-3629	81	4	were	be	AUX
dpc-3629	81	5	performed	perform	VERB
dpc-3629	81	6	with	with	ADP
dpc-3629	81	7	ibm	ibm	PROPN
dpc-3629	81	8	statistical	statistical	ADJ
dpc-3629	81	9	package	package	NOUN
dpc-3629	81	10	for	for	ADP
dpc-3629	81	11	the	the	DET
dpc-3629	81	12	social	social	ADJ
dpc-3629	81	13	sciences	sciences	PROPN
dpc-3629	81	14	(	(	PUNCT
dpc-3629	81	15	spss	spss	PROPN
dpc-3629	81	16	)	)	PUNCT
dpc-3629	81	17	for	for	ADP
dpc-3629	81	18	windows	window	NOUN
dpc-3629	81	19	23.0	23.0	NUM
dpc-3629	81	20	(	(	PUNCT
dpc-3629	81	21	ibm	ibm	PROPN
dpc-3629	81	22	corp	corp	PROPN
dpc-3629	81	23	)	)	PUNCT
dpc-3629	81	24	.	.	PUNCT
dpc-3629	82	1	continuous	continuous	ADJ
dpc-3629	82	2	variables	variable	NOUN
dpc-3629	82	3	were	be	AUX
dpc-3629	82	4	stated	state	VERB
dpc-3629	82	5	as	as	ADP
dpc-3629	82	6	median	median	ADJ
dpc-3629	82	7	,	,	PUNCT
dpc-3629	82	8	minimum	minimum	ADJ
dpc-3629	82	9	,	,	PUNCT
dpc-3629	82	10	maximum	maximum	ADJ
dpc-3629	82	11	,	,	PUNCT
dpc-3629	82	12	descriptive	descriptive	ADJ
dpc-3629	82	13	values	value	NOUN
dpc-3629	82	14	,	,	PUNCT
dpc-3629	82	15	while	while	SCONJ
dpc-3629	82	16	categorical	categorical	ADJ
dpc-3629	82	17	variables	variable	NOUN
dpc-3629	82	18	were	be	AUX
dpc-3629	82	19	stated	state	VERB
dpc-3629	82	20	as	as	ADP
dpc-3629	82	21	number	number	NOUN
dpc-3629	82	22	and	and	CCONJ
dpc-3629	82	23	frequency	frequency	NOUN
dpc-3629	82	24	.	.	PUNCT
dpc-3629	83	1	in	in	ADP
dpc-3629	83	2	addition	addition	NOUN
dpc-3629	83	3	to	to	ADP
dpc-3629	83	4	qualitative	qualitative	ADJ
dpc-3629	83	5	statistical	statistical	ADJ
dpc-3629	83	6	methods	method	NOUN
dpc-3629	83	7	,	,	PUNCT
dpc-3629	83	8	the	the	DET
dpc-3629	83	9	wilcoxon	wilcoxon	ADJ
dpc-3629	83	10	signed	sign	VERB
dpc-3629	83	11	-	-	PUNCT
dpc-3629	83	12	rank	rank	NOUN
dpc-3629	83	13	test	test	NOUN
dpc-3629	83	14	was	be	AUX
dpc-3629	83	15	used	use	VERB
dpc-3629	83	16	to	to	PART
dpc-3629	83	17	compare	compare	VERB
dpc-3629	83	18	the	the	DET
dpc-3629	83	19	quantitative	quantitative	ADJ
dpc-3629	83	20	data	datum	NOUN
dpc-3629	83	21	.	.	PUNCT
dpc-3629	84	1	the	the	DET
dpc-3629	84	2	risk	risk	NOUN
dpc-3629	84	3	factors	factor	NOUN
dpc-3629	84	4	affecting	affect	VERB
dpc-3629	84	5	the	the	DET
dpc-3629	84	6	efficacy	efficacy	NOUN
dpc-3629	84	7	of	of	ADP
dpc-3629	84	8	therapy	therapy	NOUN
dpc-3629	84	9	were	be	AUX
dpc-3629	84	10	established	establish	VERB
dpc-3629	84	11	by	by	ADP
dpc-3629	84	12	using	use	VERB
dpc-3629	84	13	logistic	logistic	ADJ
dpc-3629	84	14	regression	regression	NOUN
dpc-3629	84	15	analysis	analysis	NOUN
dpc-3629	84	16	.	.	PUNCT
dpc-3629	85	1	the	the	DET
dpc-3629	85	2	statistical	statistical	ADJ
dpc-3629	85	3	significance	significance	NOUN
dpc-3629	85	4	was	be	AUX
dpc-3629	85	5	accepted	accept	VERB
dpc-3629	85	6	as	as	ADP
dpc-3629	85	7	p	p	NOUN
dpc-3629	85	8	<	<	X
dpc-3629	85	9	0.05	0.05	NUM
dpc-3629	85	10	.	.	PUNCT
dpc-3629	86	1	results	result	VERB
dpc-3629	86	2	patient	patient	ADJ
dpc-3629	86	3	data	datum	NOUN
dpc-3629	86	4	analysis	analysis	NOUN
dpc-3629	86	5	the	the	DET
dpc-3629	86	6	mean	mean	ADJ
dpc-3629	86	7	age	age	NOUN
dpc-3629	86	8	of	of	ADP
dpc-3629	86	9	ert	ert	NOUN
dpc-3629	86	10	onset	onset	NOUN
dpc-3629	86	11	was	be	AUX
dpc-3629	86	12	34	34	NUM
dpc-3629	86	13	.	.	PUNCT
dpc-3629	87	1	female	female	ADJ
dpc-3629	87	2	patients	patient	NOUN
dpc-3629	87	3	were	be	AUX
dpc-3629	87	4	more	more	ADV
dpc-3629	87	5	common	common	ADJ
dpc-3629	87	6	(	(	PUNCT
dpc-3629	87	7	female	female	ADJ
dpc-3629	87	8	to	to	ADP
dpc-3629	87	9	male	male	ADJ
dpc-3629	87	10	ratio:1.7	ratio:1.7	NOUN
dpc-3629	87	11	)	)	PUNCT
dpc-3629	87	12	.	.	PUNCT
dpc-3629	88	1	all	all	DET
dpc-3629	88	2	patients	patient	NOUN
dpc-3629	88	3	had	have	VERB
dpc-3629	88	4	cheek	cheek	NOUN
dpc-3629	88	5	involvement	involvement	NOUN
dpc-3629	88	6	.	.	PUNCT
dpc-3629	89	1	almost	almost	ADV
dpc-3629	89	2	all	all	DET
dpc-3629	89	3	patients	patient	NOUN
dpc-3629	89	4	had	have	VERB
dpc-3629	89	5	a	a	DET
dpc-3629	89	6	triggering	trigger	VERB
dpc-3629	89	7	cause	cause	NOUN
dpc-3629	89	8	.	.	PUNCT
dpc-3629	90	1	detailed	detailed	ADJ
dpc-3629	90	2	baseline	baseline	ADJ
dpc-3629	90	3	demographic	demographic	ADJ
dpc-3629	90	4	and	and	CCONJ
dpc-3629	90	5	clinical	clinical	ADJ
dpc-3629	90	6	characteristics	characteristic	NOUN
dpc-3629	90	7	of	of	ADP
dpc-3629	90	8	the	the	DET
dpc-3629	90	9	patients	patient	NOUN
dpc-3629	90	10	have	have	AUX
dpc-3629	90	11	been	be	AUX
dpc-3629	90	12	shown	show	VERB
dpc-3629	90	13	in	in	ADP
dpc-3629	90	14	table	table	NOUN
dpc-3629	90	15	1	1	NUM
dpc-3629	90	16	.	.	PUNCT
dpc-3629	91	1	response	response	NOUN
dpc-3629	91	2	to	to	ADP
dpc-3629	91	3	treatment	treatment	NOUN
dpc-3629	91	4	while	while	SCONJ
dpc-3629	91	5	all	all	DET
dpc-3629	91	6	patients	patient	NOUN
dpc-3629	91	7	had	have	VERB
dpc-3629	91	8	an	an	DET
dpc-3629	91	9	iga	iga	PROPN
dpc-3629	91	10	score	score	NOUN
dpc-3629	91	11	of	of	ADP
dpc-3629	91	12	2	2	NUM
dpc-3629	91	13	or	or	CCONJ
dpc-3629	91	14	higher	high	ADJ
dpc-3629	91	15	at	at	ADP
dpc-3629	91	16	baseline	baseline	NOUN
dpc-3629	91	17	,	,	PUNCT
dpc-3629	91	18	there	there	PRON
dpc-3629	91	19	was	be	VERB
dpc-3629	91	20	no	no	DET
dpc-3629	91	21	patient	patient	NOUN
dpc-3629	91	22	with	with	ADP
dpc-3629	91	23	an	an	DET
dpc-3629	91	24	iga	iga	PROPN
dpc-3629	91	25	score	score	NOUN
dpc-3629	91	26	of	of	ADP
dpc-3629	91	27	3	3	NUM
dpc-3629	91	28	or	or	CCONJ
dpc-3629	91	29	4	4	NUM
dpc-3629	91	30	at	at	ADP
dpc-3629	91	31	the	the	DET
dpc-3629	91	32	12th	12th	ADJ
dpc-3629	91	33	week	week	NOUN
dpc-3629	91	34	of	of	ADP
dpc-3629	91	35	treatment	treatment	NOUN
dpc-3629	91	36	(	(	PUNCT
dpc-3629	91	37	table	table	NOUN
dpc-3629	91	38	2	2	NUM
dpc-3629	91	39	)	)	PUNCT
dpc-3629	91	40	.	.	PUNCT
dpc-3629	92	1	the	the	DET
dpc-3629	92	2	decrease	decrease	NOUN
dpc-3629	92	3	in	in	ADP
dpc-3629	92	4	iga	iga	PROPN
dpc-3629	92	5	score	score	NOUN
dpc-3629	92	6	during	during	ADP
dpc-3629	92	7	and	and	CCONJ
dpc-3629	92	8	at	at	ADP
dpc-3629	92	9	the	the	DET
dpc-3629	92	10	end	end	NOUN
dpc-3629	92	11	of	of	ADP
dpc-3629	92	12	the	the	DET
dpc-3629	92	13	treatment	treatment	NOUN
dpc-3629	92	14	was	be	AUX
dpc-3629	92	15	statistically	statistically	ADV
dpc-3629	92	16	significant	significant	ADJ
dpc-3629	92	17	according	accord	VERB
dpc-3629	92	18	to	to	ADP
dpc-3629	92	19	baseline	baseline	PROPN
dpc-3629	92	20	(	(	PUNCT
dpc-3629	92	21	p	p	X
dpc-3629	92	22	<	<	X
dpc-3629	92	23	0.001	0.001	NUM
dpc-3629	92	24	)	)	PUNCT
dpc-3629	92	25	.	.	PUNCT
dpc-3629	93	1	treatment	treatment	NOUN
dpc-3629	93	2	success	success	NOUN
dpc-3629	93	3	rate	rate	NOUN
dpc-3629	93	4	was	be	AUX
dpc-3629	93	5	62.9	62.9	NUM
dpc-3629	93	6	%	%	NOUN
dpc-3629	93	7	at	at	ADP
dpc-3629	93	8	the	the	DET
dpc-3629	93	9	end	end	NOUN
dpc-3629	93	10	of	of	ADP
dpc-3629	93	11	treatment	treatment	NOUN
dpc-3629	93	12	.	.	PUNCT
dpc-3629	94	1	the	the	DET
dpc-3629	94	2	clinical	clinical	ADJ
dpc-3629	94	3	improvement	improvement	NOUN
dpc-3629	94	4	in	in	ADP
dpc-3629	94	5	ert	ert	NOUN
dpc-3629	94	6	with	with	ADP
dpc-3629	94	7	dapsone	dapsone	PROPN
dpc-3629	94	8	5	5	NUM
dpc-3629	94	9	%	%	NOUN
dpc-3629	94	10	gel	gel	NOUN
dpc-3629	94	11	treatment	treatment	NOUN
dpc-3629	94	12	in	in	ADP
dpc-3629	94	13	two	two	NUM
dpc-3629	94	14	different	different	ADJ
dpc-3629	94	15	patients	patient	NOUN
dpc-3629	94	16	has	have	AUX
dpc-3629	94	17	been	be	AUX
dpc-3629	94	18	shown	show	VERB
dpc-3629	94	19	in	in	ADP
dpc-3629	94	20	figure	figure	NOUN
dpc-3629	94	21	1	1	NUM
dpc-3629	94	22	.	.	PUNCT
dpc-3629	94	23	vas	vas	NOUN
dpc-3629	94	24	score	score	NOUN
dpc-3629	94	25	started	start	VERB
dpc-3629	94	26	to	to	PART
dpc-3629	94	27	decrease	decrease	VERB
dpc-3629	94	28	after	after	ADP
dpc-3629	94	29	the	the	DET
dpc-3629	94	30	2nd	2nd	ADJ
dpc-3629	94	31	week	week	NOUN
dpc-3629	94	32	of	of	ADP
dpc-3629	94	33	treatment	treatment	NOUN
dpc-3629	94	34	and	and	CCONJ
dpc-3629	94	35	reached	reach	VERB
dpc-3629	94	36	lower	low	ADJ
dpc-3629	94	37	values	value	NOUN
dpc-3629	94	38	at	at	ADP
dpc-3629	94	39	the	the	DET
dpc-3629	94	40	end	end	NOUN
dpc-3629	94	41	of	of	ADP
dpc-3629	94	42	the	the	DET
dpc-3629	94	43	treatment	treatment	NOUN
dpc-3629	94	44	(	(	PUNCT
dpc-3629	94	45	table	table	NOUN
dpc-3629	94	46	3	3	NUM
dpc-3629	94	47	)	)	PUNCT
dpc-3629	94	48	.	.	PUNCT
dpc-3629	95	1	the	the	DET
dpc-3629	95	2	decrease	decrease	NOUN
dpc-3629	95	3	in	in	ADP
dpc-3629	95	4	vas	vas	X
dpc-3629	95	5	score	score	NOUN
dpc-3629	95	6	during	during	ADP
dpc-3629	95	7	and	and	CCONJ
dpc-3629	95	8	at	at	ADP
dpc-3629	95	9	the	the	DET
dpc-3629	95	10	end	end	NOUN
dpc-3629	95	11	of	of	ADP
dpc-3629	95	12	the	the	DET
dpc-3629	95	13	treatment	treatment	NOUN
dpc-3629	95	14	was	be	AUX
dpc-3629	95	15	statistically	statistically	ADV
dpc-3629	95	16	significant	significant	ADJ
dpc-3629	95	17	according	accord	VERB
dpc-3629	95	18	to	to	ADP
dpc-3629	95	19	baseline	baseline	PROPN
dpc-3629	95	20	(	(	PUNCT
dpc-3629	95	21	p	p	X
dpc-3629	95	22	<	<	X
dpc-3629	95	23	0.001	0.001	NUM
dpc-3629	95	24	)	)	PUNCT
dpc-3629	95	25	.	.	PUNCT
dpc-3629	96	1	the	the	DET
dpc-3629	96	2	increase	increase	NOUN
dpc-3629	96	3	in	in	ADP
dpc-3629	96	4	dlqi	dlqi	NOUN
dpc-3629	96	5	after	after	ADP
dpc-3629	96	6	using	use	VERB
dpc-3629	96	7	topical	topical	ADJ
dpc-3629	96	8	dapsone	dapsone	NOUN
dpc-3629	96	9	5	5	NUM
dpc-3629	96	10	%	%	NOUN
dpc-3629	96	11	gel	gel	NOUN
dpc-3629	96	12	treatment	treatment	NOUN
dpc-3629	96	13	was	be	AUX
dpc-3629	96	14	statistically	statistically	ADV
dpc-3629	96	15	significant	significant	ADJ
dpc-3629	96	16	(	(	PUNCT
dpc-3629	96	17	p	p	X
dpc-3629	96	18	<	<	X
dpc-3629	96	19	0.001	0.001	NUM
dpc-3629	96	20	)	)	PUNCT
dpc-3629	96	21	(	(	PUNCT
dpc-3629	96	22	table	table	NOUN
dpc-3629	96	23	4	4	NUM
dpc-3629	96	24	)	)	PUNCT
dpc-3629	96	25	.	.	PUNCT
dpc-3629	97	1	table	table	NOUN
dpc-3629	97	2	1	1	NUM
dpc-3629	97	3	.	.	PUNCT
dpc-3629	97	4	baseline	baseline	VERB
dpc-3629	97	5	demographic	demographic	ADJ
dpc-3629	97	6	and	and	CCONJ
dpc-3629	97	7	clinical	clinical	ADJ
dpc-3629	97	8	characteristics	characteristic	NOUN
dpc-3629	97	9	of	of	ADP
dpc-3629	97	10	the	the	DET
dpc-3629	97	11	patients	patient	NOUN
dpc-3629	97	12	.	.	PUNCT
dpc-3629	98	1	parameters	parameter	NOUN
dpc-3629	98	2	n	n	CCONJ
dpc-3629	98	3	(	(	PUNCT
dpc-3629	98	4	%	%	INTJ
dpc-3629	98	5	)	)	PUNCT
dpc-3629	98	6	or	or	CCONJ
dpc-3629	98	7	median	median	ADJ
dpc-3629	98	8	(	(	PUNCT
dpc-3629	98	9	min	min	NOUN
dpc-3629	98	10	-	-	PUNCT
dpc-3629	98	11	max	max	NOUN
dpc-3629	98	12	)	)	PUNCT
dpc-3629	98	13	age	age	NOUN
dpc-3629	98	14	38	38	NUM
dpc-3629	98	15	(	(	PUNCT
dpc-3629	98	16	19	19	NUM
dpc-3629	98	17	-	-	SYM
dpc-3629	98	18	62	62	NUM
dpc-3629	98	19	)	)	PUNCT
dpc-3629	98	20	gender	gender	NOUN
dpc-3629	98	21	•	•	ADP
dpc-3629	98	22	male	male	NOUN
dpc-3629	98	23	13	13	NUM
dpc-3629	98	24	(	(	PUNCT
dpc-3629	98	25	37.1	37.1	NUM
dpc-3629	98	26	)	)	PUNCT
dpc-3629	98	27	•	•	NUM
dpc-3629	98	28	female	female	NOUN
dpc-3629	98	29	22	22	NUM
dpc-3629	98	30	(	(	PUNCT
dpc-3629	98	31	62.9	62.9	NUM
dpc-3629	98	32	)	)	PUNCT
dpc-3629	98	33	onset	onset	NOUN
dpc-3629	98	34	age	age	NOUN
dpc-3629	98	35	of	of	ADP
dpc-3629	98	36	rosacea	rosacea	PROPN
dpc-3629	98	37	34	34	NUM
dpc-3629	98	38	(	(	PUNCT
dpc-3629	98	39	16	16	NUM
dpc-3629	98	40	-	-	SYM
dpc-3629	98	41	57	57	NUM
dpc-3629	98	42	)	)	PUNCT
dpc-3629	98	43	disease	disease	NOUN
dpc-3629	98	44	duration	duration	NOUN
dpc-3629	98	45	,	,	PUNCT
dpc-3629	98	46	month	month	NOUN
dpc-3629	98	47	4	4	NUM
dpc-3629	98	48	(	(	PUNCT
dpc-3629	98	49	2	2	NUM
dpc-3629	98	50	-	-	SYM
dpc-3629	98	51	10	10	NUM
dpc-3629	98	52	)	)	PUNCT
dpc-3629	98	53	rosacea	rosacea	NOUN
dpc-3629	98	54	involvement	involvement	NOUN
dpc-3629	98	55	site	site	NOUN
dpc-3629	98	56	•	•	NUM
dpc-3629	98	57	cheek	cheek	NOUN
dpc-3629	98	58	35	35	NUM
dpc-3629	98	59	(	(	PUNCT
dpc-3629	98	60	100	100	NUM
dpc-3629	98	61	)	)	PUNCT
dpc-3629	98	62	•	•	NOUN
dpc-3629	98	63	forehead	forehead	NOUN
dpc-3629	98	64	15	15	NUM
dpc-3629	98	65	(	(	PUNCT
dpc-3629	98	66	42.9	42.9	NUM
dpc-3629	98	67	)	)	PUNCT
dpc-3629	98	68	•	•	NUM
dpc-3629	98	69	nose	nose	NOUN
dpc-3629	98	70	24	24	NUM
dpc-3629	98	71	(	(	PUNCT
dpc-3629	98	72	68.6	68.6	NUM
dpc-3629	98	73	)	)	PUNCT
dpc-3629	98	74	•	•	NOUN
dpc-3629	98	75	chin	chin	NOUN
dpc-3629	98	76	8	8	NUM
dpc-3629	98	77	(	(	PUNCT
dpc-3629	98	78	22.9	22.9	NUM
dpc-3629	98	79	)	)	PUNCT
dpc-3629	98	80	smoking	smoking	NOUN
dpc-3629	98	81	•	•	NOUN
dpc-3629	98	82	no	no	DET
dpc-3629	98	83	24	24	NUM
dpc-3629	98	84	(	(	PUNCT
dpc-3629	98	85	68.6	68.6	NUM
dpc-3629	98	86	)	)	PUNCT
dpc-3629	98	87	•	•	NOUN
dpc-3629	99	1	yes	yes	INTJ
dpc-3629	99	2	11	11	NUM
dpc-3629	99	3	(	(	PUNCT
dpc-3629	99	4	31.4	31.4	NUM
dpc-3629	99	5	)	)	PUNCT
dpc-3629	99	6	alcohol	alcohol	NOUN
dpc-3629	99	7	•	•	NOUN
dpc-3629	99	8	no	no	DET
dpc-3629	99	9	19	19	NUM
dpc-3629	99	10	(	(	PUNCT
dpc-3629	99	11	54.3	54.3	NUM
dpc-3629	99	12	)	)	PUNCT
dpc-3629	99	13	•	•	NOUN
dpc-3629	100	1	yes	yes	INTJ
dpc-3629	100	2	16	16	NUM
dpc-3629	100	3	(	(	PUNCT
dpc-3629	100	4	45.7	45.7	NUM
dpc-3629	100	5	)	)	PUNCT
dpc-3629	100	6	triggering	trigger	VERB
dpc-3629	100	7	factorsa	factorsa	NOUN
dpc-3629	100	8	34	34	NUM
dpc-3629	100	9	(	(	PUNCT
dpc-3629	100	10	97.1	97.1	NUM
dpc-3629	100	11	)	)	PUNCT
dpc-3629	100	12	skin	skin	NOUN
dpc-3629	100	13	type	type	NOUN
dpc-3629	100	14	•	•	NOUN
dpc-3629	100	15	type	type	NOUN
dpc-3629	100	16	i	i	PRON
dpc-3629	100	17	15	15	NUM
dpc-3629	100	18	(	(	PUNCT
dpc-3629	100	19	42.9	42.9	NUM
dpc-3629	100	20	)	)	PUNCT
dpc-3629	100	21	•	•	NOUN
dpc-3629	100	22	type	type	NOUN
dpc-3629	100	23	ii	ii	PROPN
dpc-3629	100	24	19	19	NUM
dpc-3629	100	25	(	(	PUNCT
dpc-3629	100	26	54.3	54.3	NUM
dpc-3629	100	27	)	)	PUNCT
dpc-3629	100	28	•	•	NUM
dpc-3629	100	29	type	type	NOUN
dpc-3629	100	30	iii	iii	PROPN
dpc-3629	100	31	1	1	NUM
dpc-3629	100	32	(	(	PUNCT
dpc-3629	100	33	2.9	2.9	NUM
dpc-3629	100	34	)	)	PUNCT
dpc-3629	100	35	systemic	systemic	ADJ
dpc-3629	100	36	diseaseb	diseaseb	NOUN
dpc-3629	100	37	11	11	NUM
dpc-3629	100	38	(	(	PUNCT
dpc-3629	100	39	31.4	31.4	NUM
dpc-3629	100	40	)	)	PUNCT
dpc-3629	100	41	additional	additional	ADJ
dpc-3629	100	42	dermatological	dermatological	ADJ
dpc-3629	100	43	disease	disease	NOUN
dpc-3629	100	44	19	19	NUM
dpc-3629	100	45	(	(	PUNCT
dpc-3629	100	46	54.3	54.3	NUM
dpc-3629	100	47	)	)	PUNCT
dpc-3629	100	48	systemic	systemic	ADJ
dpc-3629	100	49	drug	drug	NOUN
dpc-3629	100	50	use	use	NOUN
dpc-3629	100	51	9	9	NUM
dpc-3629	100	52	(	(	PUNCT
dpc-3629	100	53	25.7	25.7	NUM
dpc-3629	100	54	)	)	PUNCT
dpc-3629	100	55	asunlight	asunlight	NOUN
dpc-3629	100	56	exposure	exposure	NOUN
dpc-3629	100	57	,	,	PUNCT
dpc-3629	100	58	psychological	psychological	ADJ
dpc-3629	100	59	stress	stress	NOUN
dpc-3629	100	60	,	,	PUNCT
dpc-3629	100	61	warm	warm	ADJ
dpc-3629	100	62	environment	environment	NOUN
dpc-3629	100	63	,	,	PUNCT
dpc-3629	100	64	hot	hot	ADJ
dpc-3629	100	65	beverages	beverage	NOUN
dpc-3629	100	66	,	,	PUNCT
dpc-3629	100	67	spicy	spicy	ADJ
dpc-3629	100	68	food	food	NOUN
dpc-3629	100	69	alcohol	alcohol	NOUN
dpc-3629	100	70	intake	intake	NOUN
dpc-3629	100	71	,	,	PUNCT
dpc-3629	100	72	strenuous	strenuous	ADJ
dpc-3629	100	73	exercise	exercise	NOUN
dpc-3629	100	74	,	,	PUNCT
dpc-3629	100	75	cold	cold	ADJ
dpc-3629	100	76	weather	weather	NOUN
dpc-3629	100	77	.	.	PUNCT
dpc-3629	101	1	bcardiovascular	bcardiovascular	ADJ
dpc-3629	101	2	disease	disease	NOUN
dpc-3629	101	3	,	,	PUNCT
dpc-3629	101	4	diabetes	diabetes	NOUN
dpc-3629	101	5	mellitus	mellitus	NOUN
dpc-3629	101	6	,	,	PUNCT
dpc-3629	101	7	hypertension	hypertension	NOUN
dpc-3629	101	8	,	,	PUNCT
dpc-3629	101	9	lung	lung	NOUN
dpc-3629	101	10	diseases	disease	NOUN
dpc-3629	101	11	,	,	PUNCT
dpc-3629	101	12	endocrine	endocrine	NOUN
dpc-3629	101	13	and	and	CCONJ
dpc-3629	101	14	metabolic	metabolic	NOUN
dpc-3629	101	15	problems	problem	NOUN
dpc-3629	101	16	…	…	PUNCT
dpc-3629	101	17	etc	etc	X
dpc-3629	101	18	.	.	X
dpc-3629	101	19	hypothyroidism	hypothyroidism	NOUN
dpc-3629	101	20	is	be	AUX
dpc-3629	101	21	the	the	DET
dpc-3629	101	22	most	most	ADV
dpc-3629	101	23	common	common	ADJ
dpc-3629	101	24	(	(	PUNCT
dpc-3629	101	25	11.4	11.4	NUM
dpc-3629	101	26	%	%	NOUN
dpc-3629	101	27	)	)	PUNCT
dpc-3629	101	28	.	.	PUNCT
dpc-3629	102	1	4	4	NUM
dpc-3629	102	2	original	original	ADJ
dpc-3629	102	3	article	article	NOUN
dpc-3629	102	4	|	|	ADV
dpc-3629	102	5	dermatol	dermatol	ADJ
dpc-3629	102	6	pract	pract	NOUN
dpc-3629	102	7	concept	concept	NOUN
dpc-3629	102	8	.	.	PUNCT
dpc-3629	103	1	2024;14(1):e2024034	2024;14(1):e2024034	NUM
dpc-3629	103	2	conclusions	conclusion	NOUN
dpc-3629	103	3	the	the	DET
dpc-3629	103	4	current	current	ADJ
dpc-3629	103	5	study	study	NOUN
dpc-3629	103	6	demonstrated	demonstrate	VERB
dpc-3629	103	7	that	that	SCONJ
dpc-3629	103	8	dapsone	dapsone	PROPN
dpc-3629	103	9	5	5	NUM
dpc-3629	103	10	%	%	NOUN
dpc-3629	103	11	gel	gel	NOUN
dpc-3629	103	12	was	be	AUX
dpc-3629	103	13	effective	effective	ADJ
dpc-3629	103	14	in	in	ADP
dpc-3629	103	15	the	the	DET
dpc-3629	103	16	treatment	treatment	NOUN
dpc-3629	103	17	of	of	ADP
dpc-3629	103	18	etr	etr	PROPN
dpc-3629	103	19	.	.	PUNCT
dpc-3629	104	1	iga	iga	PROPN
dpc-3629	104	2	scores	score	NOUN
dpc-3629	104	3	and	and	CCONJ
dpc-3629	104	4	patient	patient	NOUN
dpc-3629	104	5	-	-	PUNCT
dpc-3629	104	6	assessed	assess	VERB
dpc-3629	104	7	vas	vas	NOUN
dpc-3629	104	8	scores	score	NOUN
dpc-3629	104	9	showed	show	VERB
dpc-3629	104	10	a	a	DET
dpc-3629	104	11	significant	significant	ADJ
dpc-3629	104	12	improvement	improvement	NOUN
dpc-3629	104	13	and	and	CCONJ
dpc-3629	104	14	good	good	ADJ
dpc-3629	104	15	results	result	NOUN
dpc-3629	104	16	during	during	ADP
dpc-3629	104	17	and	and	CCONJ
dpc-3629	104	18	after	after	ADP
dpc-3629	104	19	dapsone	dapsone	PROPN
dpc-3629	104	20	5	5	NUM
dpc-3629	104	21	%	%	NOUN
dpc-3629	104	22	gel	gel	NOUN
dpc-3629	104	23	treatment	treatment	NOUN
dpc-3629	104	24	in	in	ADP
dpc-3629	104	25	patients	patient	NOUN
dpc-3629	104	26	with	with	ADP
dpc-3629	104	27	etr	etr	PROPN
dpc-3629	104	28	.	.	PUNCT
dpc-3629	105	1	adverse	adverse	ADJ
dpc-3629	105	2	events	event	NOUN
dpc-3629	105	3	mild	mild	ADJ
dpc-3629	105	4	adverse	adverse	ADJ
dpc-3629	105	5	events	event	NOUN
dpc-3629	105	6	were	be	AUX
dpc-3629	105	7	observed	observe	VERB
dpc-3629	105	8	in	in	ADP
dpc-3629	105	9	3	3	NUM
dpc-3629	105	10	patients	patient	NOUN
dpc-3629	105	11	(	(	PUNCT
dpc-3629	105	12	totally	totally	ADV
dpc-3629	105	13	8.5	8.5	NUM
dpc-3629	105	14	%	%	NOUN
dpc-3629	105	15	,	,	PUNCT
dpc-3629	105	16	itching	itch	VERB
dpc-3629	105	17	in	in	ADP
dpc-3629	105	18	two	two	NUM
dpc-3629	105	19	,	,	PUNCT
dpc-3629	105	20	burning	burn	VERB
dpc-3629	105	21	in	in	ADP
dpc-3629	105	22	one	one	NUM
dpc-3629	105	23	)	)	PUNCT
dpc-3629	105	24	during	during	ADP
dpc-3629	105	25	treatment	treatment	NOUN
dpc-3629	105	26	.	.	PUNCT
dpc-3629	106	1	risk	risk	NOUN
dpc-3629	106	2	factor	factor	NOUN
dpc-3629	106	3	analysis	analysis	NOUN
dpc-3629	106	4	the	the	DET
dpc-3629	106	5	absence	absence	NOUN
dpc-3629	106	6	of	of	ADP
dpc-3629	106	7	systemic	systemic	ADJ
dpc-3629	106	8	disease	disease	NOUN
dpc-3629	106	9	increased	increase	VERB
dpc-3629	106	10	the	the	DET
dpc-3629	106	11	success	success	NOUN
dpc-3629	106	12	rate	rate	NOUN
dpc-3629	106	13	of	of	ADP
dpc-3629	106	14	the	the	DET
dpc-3629	106	15	treatment	treatment	NOUN
dpc-3629	106	16	(	(	PUNCT
dpc-3629	106	17	p	p	NOUN
dpc-3629	106	18	=	=	NOUN
dpc-3629	106	19	0.034	0.034	NUM
dpc-3629	106	20	)	)	PUNCT
dpc-3629	106	21	(	(	PUNCT
dpc-3629	106	22	table	table	NOUN
dpc-3629	106	23	5	5	NUM
dpc-3629	106	24	)	)	PUNCT
dpc-3629	106	25	.	.	PUNCT
dpc-3629	107	1	table	table	NOUN
dpc-3629	107	2	2	2	NUM
dpc-3629	107	3	.	.	PUNCT
dpc-3629	108	1	investigators	investigator	NOUN
dpc-3629	108	2	global	global	ADJ
dpc-3629	108	3	assessment	assessment	NOUN
dpc-3629	108	4	score	score	NOUN
dpc-3629	108	5	of	of	ADP
dpc-3629	108	6	erythematotelangiectatic	erythematotelangiectatic	ADJ
dpc-3629	108	7	rosacea	rosacea	NOUN
dpc-3629	108	8	patients	patient	NOUN
dpc-3629	108	9	in	in	ADP
dpc-3629	108	10	 	 	SPACE
dpc-3629	108	11	baseline	baseline	NOUN
dpc-3629	108	12	and	and	CCONJ
dpc-3629	108	13	second	second	ADJ
dpc-3629	108	14	,	,	PUNCT
dpc-3629	108	15	sixth	sixth	ADJ
dpc-3629	108	16	and	and	CCONJ
dpc-3629	108	17	twelfth	twelfth	ADJ
dpc-3629	108	18	weeks	week	NOUN
dpc-3629	108	19	of	of	ADP
dpc-3629	108	20	treatment	treatment	NOUN
dpc-3629	108	21	.	.	PUNCT
dpc-3629	109	1	iga	iga	PROPN
dpc-3629	109	2	-	-	PUNCT
dpc-3629	109	3	etr	etr	PROPN
dpc-3629	109	4	scale	scale	PROPN
dpc-3629	109	5	baseline	baseline	NOUN
dpc-3629	109	6	2nd	2nd	ADJ
dpc-3629	109	7	week	week	NOUN
dpc-3629	109	8	6th	6th	ADJ
dpc-3629	109	9	week	week	NOUN
dpc-3629	109	10	12th	12th	NOUN
dpc-3629	109	11	week	week	NOUN
dpc-3629	109	12	clinical	clinical	ADJ
dpc-3629	109	13	grade	grade	NOUN
dpc-3629	109	14	score	score	NOUN
dpc-3629	109	15	n	n	PROPN
dpc-3629	109	16	(	(	PUNCT
dpc-3629	109	17	%	%	NOUN
dpc-3629	109	18	)	)	PUNCT
dpc-3629	110	1	n	n	CCONJ
dpc-3629	110	2	(	(	PUNCT
dpc-3629	110	3	%	%	NOUN
dpc-3629	110	4	)	)	PUNCT
dpc-3629	110	5	n	n	CCONJ
dpc-3629	110	6	(	(	PUNCT
dpc-3629	110	7	%	%	NOUN
dpc-3629	110	8	)	)	PUNCT
dpc-3629	111	1	n	n	CCONJ
dpc-3629	111	2	(	(	PUNCT
dpc-3629	111	3	%	%	INTJ
dpc-3629	111	4	)	)	PUNCT
dpc-3629	111	5	clean	clean	ADJ
dpc-3629	111	6	0	0	NUM
dpc-3629	111	7	0	0	NUM
dpc-3629	111	8	(	(	PUNCT
dpc-3629	111	9	0	0	NUM
dpc-3629	111	10	)	)	PUNCT
dpc-3629	111	11	0	0	NUM
dpc-3629	112	1	(	(	PUNCT
dpc-3629	112	2	0	0	NUM
dpc-3629	112	3	)	)	PUNCT
dpc-3629	112	4	0	0	NUM
dpc-3629	113	1	(	(	PUNCT
dpc-3629	113	2	0	0	NUM
dpc-3629	113	3	)	)	PUNCT
dpc-3629	113	4	0	0	NUM
dpc-3629	114	1	(	(	PUNCT
dpc-3629	114	2	0	0	NUM
dpc-3629	114	3	)	)	PUNCT
dpc-3629	114	4	mild	mild	ADJ
dpc-3629	114	5	1	1	NUM
dpc-3629	114	6	0	0	NUM
dpc-3629	114	7	(	(	PUNCT
dpc-3629	114	8	0	0	NUM
dpc-3629	114	9	)	)	SYM
dpc-3629	114	10	5	5	NUM
dpc-3629	114	11	(	(	PUNCT
dpc-3629	114	12	14,3	14,3	NUM
dpc-3629	114	13	)	)	PUNCT
dpc-3629	114	14	16	16	NUM
dpc-3629	114	15	(	(	PUNCT
dpc-3629	114	16	45,7	45,7	NUM
dpc-3629	114	17	)	)	PUNCT
dpc-3629	114	18	22	22	NUM
dpc-3629	114	19	(	(	PUNCT
dpc-3629	114	20	62,9	62,9	ADV
dpc-3629	114	21	)	)	PUNCT
dpc-3629	114	22	moderate	moderate	ADJ
dpc-3629	114	23	2	2	NUM
dpc-3629	114	24	22	22	NUM
dpc-3629	114	25	(	(	PUNCT
dpc-3629	114	26	62,9	62,9	NOUN
dpc-3629	114	27	)	)	PUNCT
dpc-3629	114	28	27	27	NUM
dpc-3629	114	29	(	(	PUNCT
dpc-3629	114	30	77,1	77,1	NUM
dpc-3629	114	31	)	)	PUNCT
dpc-3629	114	32	19	19	NUM
dpc-3629	114	33	(	(	PUNCT
dpc-3629	114	34	54,3	54,3	NUM
dpc-3629	114	35	)	)	PUNCT
dpc-3629	114	36	13	13	NUM
dpc-3629	114	37	(	(	PUNCT
dpc-3629	114	38	37,1	37,1	NUM
dpc-3629	114	39	)	)	PUNCT
dpc-3629	114	40	severe	severe	ADJ
dpc-3629	114	41	3	3	NUM
dpc-3629	114	42	12	12	NUM
dpc-3629	114	43	(	(	PUNCT
dpc-3629	114	44	34,3	34,3	NUM
dpc-3629	114	45	)	)	PUNCT
dpc-3629	114	46	3	3	NUM
dpc-3629	114	47	(	(	PUNCT
dpc-3629	114	48	8,6	8,6	NUM
dpc-3629	114	49	)	)	PUNCT
dpc-3629	114	50	0	0	NUM
dpc-3629	115	1	(	(	PUNCT
dpc-3629	115	2	0	0	NUM
dpc-3629	115	3	)	)	PUNCT
dpc-3629	115	4	0	0	NUM
dpc-3629	116	1	(	(	PUNCT
dpc-3629	116	2	0	0	NUM
dpc-3629	116	3	)	)	PUNCT
dpc-3629	116	4	very	very	ADV
dpc-3629	116	5	severe	severe	ADJ
dpc-3629	116	6	4	4	NUM
dpc-3629	116	7	1	1	NUM
dpc-3629	116	8	(	(	PUNCT
dpc-3629	116	9	2,9	2,9	NUM
dpc-3629	116	10	)	)	PUNCT
dpc-3629	116	11	0	0	NUM
dpc-3629	117	1	(	(	PUNCT
dpc-3629	117	2	0	0	NUM
dpc-3629	117	3	)	)	PUNCT
dpc-3629	117	4	0	0	NUM
dpc-3629	118	1	(	(	PUNCT
dpc-3629	118	2	0	0	NUM
dpc-3629	118	3	)	)	PUNCT
dpc-3629	118	4	0	0	NUM
dpc-3629	119	1	(	(	PUNCT
dpc-3629	119	2	0	0	NUM
dpc-3629	119	3	)	)	PUNCT
dpc-3629	119	4	p	p	X
dpc-3629	119	5	<	<	X
dpc-3629	119	6	0,001	0,001	NUM
dpc-3629	119	7	<	<	NOUN
dpc-3629	119	8	0,001	0,001	NUM
dpc-3629	119	9	<	<	NOUN
dpc-3629	119	10	0,001	0,001	NUM
dpc-3629	119	11	etr	etr	NOUN
dpc-3629	119	12	=	=	PUNCT
dpc-3629	119	13	erythematotelangiectatic	erythematotelangiectatic	PROPN
dpc-3629	119	14	rosacea	rosacea	PROPN
dpc-3629	119	15	;	;	PUNCT
dpc-3629	119	16	iga	iga	PROPN
dpc-3629	119	17	=	=	PUNCT
dpc-3629	119	18	investigators	investigator	NOUN
dpc-3629	119	19	global	global	ADJ
dpc-3629	119	20	assessment	assessment	NOUN
dpc-3629	119	21	.	.	PUNCT
dpc-3629	120	1	figure	figure	NOUN
dpc-3629	120	2	1	1	NUM
dpc-3629	120	3	.	.	PUNCT
dpc-3629	121	1	clinical	clinical	ADJ
dpc-3629	121	2	improvement	improvement	NOUN
dpc-3629	121	3	in	in	ADP
dpc-3629	121	4	erythematotelangiectatic	erythematotelangiectatic	ADJ
dpc-3629	121	5	rosacea	rosacea	PROPN
dpc-3629	121	6	with	with	ADP
dpc-3629	121	7	dapsone	dapsone	PROPN
dpc-3629	121	8	5	5	NUM
dpc-3629	121	9	%	%	NOUN
dpc-3629	121	10	gel	gel	NOUN
dpc-3629	121	11	treatment	treatment	NOUN
dpc-3629	121	12	.	.	PUNCT
dpc-3629	122	1	clinical	clinical	ADJ
dpc-3629	122	2	improvement	improvement	NOUN
dpc-3629	122	3	is	be	AUX
dpc-3629	122	4	seen	see	VERB
dpc-3629	122	5	from	from	ADP
dpc-3629	122	6	grade	grade	NOUN
dpc-3629	122	7	3	3	NUM
dpc-3629	122	8	to	to	ADP
dpc-3629	122	9	2	2	NUM
dpc-3629	122	10	in	in	ADP
dpc-3629	122	11	the	the	DET
dpc-3629	122	12	first	first	ADJ
dpc-3629	122	13	patient	patient	NOUN
dpc-3629	122	14	and	and	CCONJ
dpc-3629	122	15	from	from	ADP
dpc-3629	122	16	grade	grade	NOUN
dpc-3629	122	17	2	2	NUM
dpc-3629	122	18	to	to	ADP
dpc-3629	122	19	1	1	NUM
dpc-3629	122	20	in	in	ADP
dpc-3629	122	21	the	the	DET
dpc-3629	122	22	second	second	ADJ
dpc-3629	122	23	patient	patient	NOUN
dpc-3629	122	24	.	.	PUNCT
dpc-3629	123	1	original	original	ADJ
dpc-3629	123	2	article	article	NOUN
dpc-3629	123	3	|	|	ADV
dpc-3629	123	4	dermatol	dermatol	ADJ
dpc-3629	123	5	pract	pract	NOUN
dpc-3629	123	6	concept	concept	NOUN
dpc-3629	123	7	.	.	PUNCT
dpc-3629	124	1	2024;14(1):e2024034	2024;14(1):e2024034	NUM
dpc-3629	124	2	5	5	NUM
dpc-3629	124	3	furthermore	furthermore	ADV
dpc-3629	124	4	,	,	PUNCT
dpc-3629	124	5	burning	burn	VERB
dpc-3629	124	6	sensation	sensation	NOUN
dpc-3629	124	7	and	and	CCONJ
dpc-3629	124	8	erythema	erythema	ADJ
dpc-3629	124	9	were	be	AUX
dpc-3629	124	10	significantly	significantly	ADV
dpc-3629	124	11	reduced	reduce	VERB
dpc-3629	124	12	after	after	ADP
dpc-3629	124	13	dapsone	dapsone	PROPN
dpc-3629	124	14	5	5	NUM
dpc-3629	124	15	%	%	NOUN
dpc-3629	124	16	gel	gel	NOUN
dpc-3629	124	17	treatment	treatment	NOUN
dpc-3629	124	18	even	even	ADV
dpc-3629	124	19	in	in	ADP
dpc-3629	124	20	the	the	DET
dpc-3629	124	21	second	second	ADJ
dpc-3629	124	22	week	week	NOUN
dpc-3629	124	23	compared	compare	VERB
dpc-3629	124	24	to	to	PART
dpc-3629	124	25	baseline	baseline	VERB
dpc-3629	124	26	.	.	PUNCT
dpc-3629	125	1	moreover	moreover	ADV
dpc-3629	125	2	,	,	PUNCT
dpc-3629	125	3	the	the	DET
dpc-3629	125	4	side	side	NOUN
dpc-3629	125	5	effects	effect	NOUN
dpc-3629	125	6	of	of	ADP
dpc-3629	125	7	the	the	DET
dpc-3629	125	8	drug	drug	NOUN
dpc-3629	125	9	were	be	AUX
dpc-3629	125	10	subtle	subtle	ADJ
dpc-3629	125	11	,	,	PUNCT
dpc-3629	125	12	like	like	ADP
dpc-3629	125	13	only	only	ADV
dpc-3629	125	14	mild	mild	ADJ
dpc-3629	125	15	irritation	irritation	NOUN
dpc-3629	125	16	.	.	PUNCT
dpc-3629	126	1	this	this	DET
dpc-3629	126	2	result	result	NOUN
dpc-3629	126	3	showed	show	VERB
dpc-3629	126	4	that	that	SCONJ
dpc-3629	126	5	the	the	DET
dpc-3629	126	6	tolerability	tolerability	NOUN
dpc-3629	126	7	of	of	ADP
dpc-3629	126	8	dapsone	dapsone	NOUN
dpc-3629	126	9	5	5	NUM
dpc-3629	126	10	%	%	NOUN
dpc-3629	126	11	gel	gel	NOUN
dpc-3629	126	12	was	be	AUX
dpc-3629	126	13	also	also	ADV
dpc-3629	126	14	very	very	ADV
dpc-3629	126	15	well	well	ADJ
dpc-3629	126	16	.	.	PUNCT
dpc-3629	127	1	table	table	NOUN
dpc-3629	127	2	3	3	NUM
dpc-3629	127	3	.	.	PUNCT
dpc-3629	128	1	visual	visual	ADJ
dpc-3629	128	2	analog	analog	NOUN
dpc-3629	128	3	scale	scale	NOUN
dpc-3629	128	4	scores	score	NOUN
dpc-3629	128	5	of	of	ADP
dpc-3629	128	6	the	the	DET
dpc-3629	128	7	patients	patient	NOUN
dpc-3629	128	8	at	at	ADP
dpc-3629	128	9	baseline	baseline	NOUN
dpc-3629	128	10	and	and	CCONJ
dpc-3629	128	11	second	second	ADJ
dpc-3629	128	12	,	,	PUNCT
dpc-3629	128	13	sixth	sixth	ADJ
dpc-3629	128	14	and	and	CCONJ
dpc-3629	128	15	twelfth	twelfth	ADJ
dpc-3629	128	16	weeks	week	NOUN
dpc-3629	128	17	of	of	ADP
dpc-3629	128	18	treatment	treatment	NOUN
dpc-3629	128	19	.	.	PUNCT
dpc-3629	129	1	vas	vas	PROPN
dpc-3629	129	2	scores	score	NOUN
dpc-3629	129	3	baseline	baseline	VERB
dpc-3629	129	4	2	2	NUM
dpc-3629	129	5	.	.	NOUN
dpc-3629	129	6	week	week	NOUN
dpc-3629	129	7	6	6	NUM
dpc-3629	129	8	.	.	PUNCT
dpc-3629	129	9	week	week	NOUN
dpc-3629	129	10	12	12	NUM
dpc-3629	129	11	.	.	PUNCT
dpc-3629	130	1	week	week	NOUN
dpc-3629	130	2	median	median	PROPN
dpc-3629	130	3	(	(	PUNCT
dpc-3629	130	4	min	min	NOUN
dpc-3629	130	5	-	-	PUNCT
dpc-3629	130	6	max	max	ADJ
dpc-3629	130	7	)	)	PUNCT
dpc-3629	130	8	median	median	NOUN
dpc-3629	130	9	(	(	PUNCT
dpc-3629	130	10	min	min	NOUN
dpc-3629	130	11	-	-	PUNCT
dpc-3629	130	12	max	max	ADJ
dpc-3629	130	13	)	)	PUNCT
dpc-3629	130	14	median	median	NOUN
dpc-3629	130	15	(	(	PUNCT
dpc-3629	130	16	min	min	NOUN
dpc-3629	130	17	-	-	PUNCT
dpc-3629	130	18	max	max	ADJ
dpc-3629	130	19	)	)	PUNCT
dpc-3629	130	20	median	median	NOUN
dpc-3629	130	21	(	(	PUNCT
dpc-3629	130	22	min	min	NOUN
dpc-3629	130	23	-	-	PUNCT
dpc-3629	130	24	max	max	NOUN
dpc-3629	130	25	)	)	PUNCT
dpc-3629	130	26	vas	vas	X
dpc-3629	130	27	7	7	NUM
dpc-3629	130	28	(	(	PUNCT
dpc-3629	130	29	5	5	NUM
dpc-3629	130	30	-	-	SYM
dpc-3629	130	31	9	9	NUM
dpc-3629	130	32	)	)	PUNCT
dpc-3629	130	33	5	5	NUM
dpc-3629	130	34	(	(	PUNCT
dpc-3629	130	35	3	3	NUM
dpc-3629	130	36	-	-	SYM
dpc-3629	130	37	8)	8)	NUM
dpc-3629	130	38	4	4	NUM
dpc-3629	130	39	(	(	PUNCT
dpc-3629	130	40	3	3	NUM
dpc-3629	130	41	-	-	SYM
dpc-3629	130	42	6	6	NUM
dpc-3629	130	43	)	)	PUNCT
dpc-3629	130	44	4	4	NUM
dpc-3629	130	45	(	(	PUNCT
dpc-3629	130	46	2	2	NUM
dpc-3629	130	47	-	-	SYM
dpc-3629	130	48	6	6	NUM
dpc-3629	130	49	)	)	PUNCT
dpc-3629	130	50	p	p	NOUN
dpc-3629	130	51	<	<	X
dpc-3629	130	52	0.001	0.001	NUM
dpc-3629	130	53	<	<	NOUN
dpc-3629	130	54	0.001	0.001	NUM
dpc-3629	130	55	<	<	X
dpc-3629	130	56	0.001	0.001	NUM
dpc-3629	130	57	vas	vas	ADJ
dpc-3629	130	58	-	-	ADJ
dpc-3629	130	59	burning	burn	VERB
dpc-3629	130	60	sensation	sensation	NOUN
dpc-3629	130	61	5	5	NUM
dpc-3629	130	62	(	(	PUNCT
dpc-3629	130	63	2	2	NUM
dpc-3629	130	64	-	-	SYM
dpc-3629	130	65	9	9	NUM
dpc-3629	130	66	)	)	PUNCT
dpc-3629	130	67	3	3	NUM
dpc-3629	130	68	(	(	PUNCT
dpc-3629	130	69	1	1	NUM
dpc-3629	130	70	-	-	SYM
dpc-3629	130	71	7	7	NUM
dpc-3629	130	72	)	)	PUNCT
dpc-3629	130	73	4	4	NUM
dpc-3629	130	74	(	(	PUNCT
dpc-3629	130	75	1	1	NUM
dpc-3629	130	76	-	-	SYM
dpc-3629	130	77	7	7	NUM
dpc-3629	130	78	)	)	PUNCT
dpc-3629	130	79	3	3	NUM
dpc-3629	130	80	(	(	PUNCT
dpc-3629	130	81	1	1	NUM
dpc-3629	130	82	-	-	SYM
dpc-3629	130	83	6	6	NUM
dpc-3629	130	84	)	)	PUNCT
dpc-3629	130	85	p	p	NOUN
dpc-3629	130	86	<	<	X
dpc-3629	130	87	0.001	0.001	NUM
dpc-3629	130	88	<	<	NOUN
dpc-3629	130	89	0.001	0.001	NUM
dpc-3629	130	90	<	<	X
dpc-3629	130	91	0.001	0.001	NUM
dpc-3629	130	92	vas	vas	X
dpc-3629	130	93	-	-	NOUN
dpc-3629	130	94	erythema	erythema	ADJ
dpc-3629	130	95	6	6	NUM
dpc-3629	130	96	(	(	PUNCT
dpc-3629	130	97	4	4	NUM
dpc-3629	130	98	-	-	SYM
dpc-3629	130	99	10	10	NUM
dpc-3629	130	100	)	)	PUNCT
dpc-3629	130	101	4	4	NUM
dpc-3629	130	102	(	(	PUNCT
dpc-3629	130	103	2	2	NUM
dpc-3629	130	104	-	-	SYM
dpc-3629	130	105	7	7	NUM
dpc-3629	130	106	)	)	PUNCT
dpc-3629	130	107	4	4	NUM
dpc-3629	130	108	(	(	PUNCT
dpc-3629	130	109	2	2	NUM
dpc-3629	130	110	-	-	SYM
dpc-3629	130	111	6	6	NUM
dpc-3629	130	112	)	)	PUNCT
dpc-3629	130	113	3	3	NUM
dpc-3629	130	114	(	(	PUNCT
dpc-3629	130	115	2	2	NUM
dpc-3629	130	116	-	-	SYM
dpc-3629	130	117	6	6	NUM
dpc-3629	130	118	)	)	PUNCT
dpc-3629	130	119	p	p	NOUN
dpc-3629	130	120	<	<	X
dpc-3629	130	121	0.001	0.001	NUM
dpc-3629	130	122	<	<	NOUN
dpc-3629	130	123	0.001	0.001	NUM
dpc-3629	130	124	<	<	X
dpc-3629	130	125	0.001	0.001	NUM
dpc-3629	130	126	vas	vas	ADJ
dpc-3629	130	127	-	-	ADJ
dpc-3629	130	128	pruritus	pruritus	ADJ
dpc-3629	130	129	2	2	NUM
dpc-3629	130	130	(	(	PUNCT
dpc-3629	130	131	1	1	NUM
dpc-3629	130	132	-	-	SYM
dpc-3629	130	133	9	9	NUM
dpc-3629	130	134	)	)	PUNCT
dpc-3629	130	135	3	3	NUM
dpc-3629	130	136	(	(	PUNCT
dpc-3629	130	137	0	0	NUM
dpc-3629	130	138	-	-	SYM
dpc-3629	130	139	6	6	NUM
dpc-3629	130	140	)	)	PUNCT
dpc-3629	130	141	2	2	NUM
dpc-3629	130	142	(	(	PUNCT
dpc-3629	130	143	0	0	NUM
dpc-3629	130	144	-	-	SYM
dpc-3629	130	145	5	5	NUM
dpc-3629	130	146	)	)	PUNCT
dpc-3629	130	147	2	2	NUM
dpc-3629	130	148	(	(	PUNCT
dpc-3629	130	149	0	0	NUM
dpc-3629	130	150	-	-	SYM
dpc-3629	130	151	4	4	NUM
dpc-3629	130	152	)	)	PUNCT
dpc-3629	130	153	p	p	NOUN
dpc-3629	130	154	0.232	0.232	NUM
dpc-3629	130	155	0.018	0.018	NUM
dpc-3629	130	156	0.005	0.005	NUM
dpc-3629	130	157	vas	va	NOUN
dpc-3629	130	158	-	-	NOUN
dpc-3629	130	159	edema	edema	NOUN
dpc-3629	130	160	2	2	NUM
dpc-3629	130	161	(	(	PUNCT
dpc-3629	130	162	1	1	NUM
dpc-3629	130	163	-	-	SYM
dpc-3629	130	164	6	6	NUM
dpc-3629	130	165	)	)	PUNCT
dpc-3629	130	166	2	2	NUM
dpc-3629	130	167	(	(	PUNCT
dpc-3629	130	168	0	0	NUM
dpc-3629	130	169	-	-	SYM
dpc-3629	130	170	6	6	NUM
dpc-3629	130	171	)	)	PUNCT
dpc-3629	130	172	2	2	NUM
dpc-3629	130	173	(	(	PUNCT
dpc-3629	130	174	0	0	NUM
dpc-3629	130	175	-	-	SYM
dpc-3629	130	176	4	4	NUM
dpc-3629	130	177	)	)	PUNCT
dpc-3629	130	178	2	2	NUM
dpc-3629	130	179	(	(	PUNCT
dpc-3629	130	180	0	0	NUM
dpc-3629	130	181	-	-	SYM
dpc-3629	130	182	5	5	NUM
dpc-3629	130	183	)	)	PUNCT
dpc-3629	130	184	p	p	NOUN
dpc-3629	130	185	0.080	0.080	NUM
dpc-3629	130	186	0.005	0.005	NUM
dpc-3629	130	187	0.005	0.005	NUM
dpc-3629	130	188	vas	vas	X
dpc-3629	130	189	=	=	SYM
dpc-3629	130	190	visual	visual	ADJ
dpc-3629	130	191	analog	analog	NOUN
dpc-3629	130	192	scale	scale	NOUN
dpc-3629	130	193	.	.	PUNCT
dpc-3629	131	1	table	table	NOUN
dpc-3629	131	2	4	4	NUM
dpc-3629	131	3	.	.	PUNCT
dpc-3629	131	4	dermatology	dermatology	NOUN
dpc-3629	131	5	life	life	NOUN
dpc-3629	131	6	quality	quality	NOUN
dpc-3629	131	7	index	index	NOUN
dpc-3629	131	8	(	(	PUNCT
dpc-3629	131	9	dlqi	dlqi	ADJ
dpc-3629	131	10	)	)	PUNCT
dpc-3629	131	11	score	score	NOUN
dpc-3629	131	12	of	of	ADP
dpc-3629	131	13	the	the	DET
dpc-3629	131	14	patients	patient	NOUN
dpc-3629	131	15	at	at	ADP
dpc-3629	131	16	baseline	baseline	NOUN
dpc-3629	131	17	and	and	CCONJ
dpc-3629	131	18	second	second	ADJ
dpc-3629	131	19	,	,	PUNCT
dpc-3629	131	20	sixth	sixth	ADJ
dpc-3629	131	21	 	 	SPACE
dpc-3629	131	22	and	and	CCONJ
dpc-3629	131	23	twelfth	twelfth	ADJ
dpc-3629	131	24	weeks	week	NOUN
dpc-3629	131	25	of	of	ADP
dpc-3629	131	26	treatment	treatment	NOUN
dpc-3629	131	27	.	.	PUNCT
dpc-3629	132	1	baseline	baseline	PROPN
dpc-3629	132	2	2	2	NUM
dpc-3629	132	3	.	.	NOUN
dpc-3629	132	4	week	week	NOUN
dpc-3629	132	5	6	6	NUM
dpc-3629	132	6	.	.	PUNCT
dpc-3629	132	7	week	week	NOUN
dpc-3629	132	8	12	12	NUM
dpc-3629	132	9	.	.	PUNCT
dpc-3629	133	1	week	week	NOUN
dpc-3629	133	2	median	median	PROPN
dpc-3629	133	3	(	(	PUNCT
dpc-3629	133	4	min	min	NOUN
dpc-3629	133	5	-	-	PUNCT
dpc-3629	133	6	max	max	ADJ
dpc-3629	133	7	)	)	PUNCT
dpc-3629	133	8	median	median	NOUN
dpc-3629	133	9	(	(	PUNCT
dpc-3629	133	10	min	min	NOUN
dpc-3629	133	11	-	-	PUNCT
dpc-3629	133	12	max	max	ADJ
dpc-3629	133	13	)	)	PUNCT
dpc-3629	133	14	median	median	NOUN
dpc-3629	133	15	(	(	PUNCT
dpc-3629	133	16	min	min	NOUN
dpc-3629	133	17	-	-	PUNCT
dpc-3629	133	18	max	max	ADJ
dpc-3629	133	19	)	)	PUNCT
dpc-3629	133	20	median	median	NOUN
dpc-3629	133	21	(	(	PUNCT
dpc-3629	133	22	min	min	NOUN
dpc-3629	133	23	-	-	PUNCT
dpc-3629	133	24	max	max	NOUN
dpc-3629	133	25	)	)	PUNCT
dpc-3629	133	26	dlqi	dlqi	VERB
dpc-3629	133	27	score	score	NOUN
dpc-3629	133	28	8	8	NUM
dpc-3629	133	29	(	(	PUNCT
dpc-3629	133	30	6	6	NUM
dpc-3629	133	31	-	-	SYM
dpc-3629	133	32	14	14	NUM
dpc-3629	133	33	)	)	PUNCT
dpc-3629	133	34	5	5	NUM
dpc-3629	133	35	(	(	PUNCT
dpc-3629	133	36	3	3	NUM
dpc-3629	133	37	-	-	SYM
dpc-3629	133	38	11	11	NUM
dpc-3629	133	39	)	)	PUNCT
dpc-3629	133	40	5	5	NUM
dpc-3629	133	41	(	(	PUNCT
dpc-3629	133	42	3	3	NUM
dpc-3629	133	43	-	-	SYM
dpc-3629	133	44	11	11	NUM
dpc-3629	133	45	)	)	PUNCT
dpc-3629	133	46	4	4	NUM
dpc-3629	133	47	(	(	PUNCT
dpc-3629	133	48	2	2	NUM
dpc-3629	133	49	-	-	SYM
dpc-3629	133	50	9	9	NUM
dpc-3629	133	51	)	)	PUNCT
dpc-3629	133	52	p	p	NOUN
dpc-3629	133	53	<	<	X
dpc-3629	133	54	0.001	0.001	NUM
dpc-3629	133	55	0.001	0.001	NUM
dpc-3629	133	56	<	<	NOUN
dpc-3629	133	57	0.001	0.001	NUM
dpc-3629	133	58	dlqi	dlqi	ADJ
dpc-3629	133	59	=	=	PUNCT
dpc-3629	133	60	dermatology	dermatology	NOUN
dpc-3629	133	61	life	life	NOUN
dpc-3629	133	62	quality	quality	NOUN
dpc-3629	133	63	index	index	NOUN
dpc-3629	133	64	.	.	PUNCT
dpc-3629	134	1	table	table	NOUN
dpc-3629	134	2	5	5	NUM
dpc-3629	134	3	.	.	PUNCT
dpc-3629	135	1	risk	risk	NOUN
dpc-3629	135	2	factors	factor	VERB
dpc-3629	135	3	analysis	analysis	NOUN
dpc-3629	135	4	for	for	ADP
dpc-3629	135	5	 	 	SPACE
dpc-3629	135	6	treatment	treatment	NOUN
dpc-3629	135	7	 	 	SPACE
dpc-3629	135	8	efficacy	efficacy	NOUN
dpc-3629	135	9	.	.	PUNCT
dpc-3629	136	1	variables	variable	NOUN
dpc-3629	136	2	odds	odd	VERB
dpc-3629	136	3	ratio	ratio	NOUN
dpc-3629	136	4	(	(	PUNCT
dpc-3629	136	5	95	95	NUM
dpc-3629	136	6	%	%	NOUN
dpc-3629	136	7	ci	ci	NOUN
dpc-3629	136	8	)	)	PUNCT
dpc-3629	136	9	p	p	NOUN
dpc-3629	136	10	age	age	NOUN
dpc-3629	136	11	0.96	0.96	NUM
dpc-3629	136	12	(	(	PUNCT
dpc-3629	136	13	0.90	0.90	NUM
dpc-3629	136	14	-	-	SYM
dpc-3629	136	15	1.02	1.02	NUM
dpc-3629	136	16	)	)	PUNCT
dpc-3629	136	17	0.153	0.153	NUM
dpc-3629	136	18	gender	gender	NOUN
dpc-3629	136	19	0.64	0.64	NUM
dpc-3629	136	20	(	(	PUNCT
dpc-3629	136	21	0.15	0.15	NUM
dpc-3629	136	22	-	-	SYM
dpc-3629	136	23	2.74	2.74	NUM
dpc-3629	136	24	)	)	PUNCT
dpc-3629	136	25	0.550	0.550	NUM
dpc-3629	136	26	onset	onset	ADJ
dpc-3629	136	27	age	age	NOUN
dpc-3629	136	28	of	of	ADP
dpc-3629	136	29	rosacea	rosacea	PROPN
dpc-3629	136	30	0.96	0.96	NUM
dpc-3629	136	31	(	(	PUNCT
dpc-3629	136	32	0.90	0.90	NUM
dpc-3629	136	33	-	-	SYM
dpc-3629	136	34	1.02	1.02	NUM
dpc-3629	136	35	)	)	PUNCT
dpc-3629	136	36	0.214	0.214	NUM
dpc-3629	136	37	disease	disease	NOUN
dpc-3629	136	38	duration	duration	NOUN
dpc-3629	136	39	0.81	0.81	NUM
dpc-3629	136	40	(	(	PUNCT
dpc-3629	136	41	0.58	0.58	NUM
dpc-3629	136	42	-	-	NUM
dpc-3629	136	43	1.12	1.12	NUM
dpc-3629	136	44	)	)	PUNCT
dpc-3629	136	45	0.197	0.197	NUM
dpc-3629	136	46	smoking	smoking	NOUN
dpc-3629	136	47	0.53	0.53	NUM
dpc-3629	136	48	(	(	PUNCT
dpc-3629	136	49	0.11	0.11	NUM
dpc-3629	136	50	-	-	SYM
dpc-3629	136	51	2.49	2.49	NUM
dpc-3629	136	52	)	)	PUNCT
dpc-3629	136	53	0.417	0.417	NUM
dpc-3629	136	54	alcohol	alcohol	NOUN
dpc-3629	136	55	0.63	0.63	NUM
dpc-3629	136	56	(	(	PUNCT
dpc-3629	136	57	0.16	0.16	NUM
dpc-3629	136	58	-	-	SYM
dpc-3629	136	59	2.52	2.52	NUM
dpc-3629	136	60	)	)	PUNCT
dpc-3629	136	61	0.509	0.509	NUM
dpc-3629	136	62	concomitant	concomitant	ADJ
dpc-3629	136	63	systemic	systemic	ADJ
dpc-3629	136	64	disease	disease	NOUN
dpc-3629	136	65	5.25	5.25	NUM
dpc-3629	136	66	(	(	PUNCT
dpc-3629	136	67	1.13	1.13	NUM
dpc-3629	136	68	-	-	SYM
dpc-3629	136	69	24.42	24.42	NUM
dpc-3629	136	70	)	)	PUNCT
dpc-3629	136	71	0.034	0.034	NUM
dpc-3629	136	72	additional	additional	ADJ
dpc-3629	136	73	dermatologic	dermatologic	ADJ
dpc-3629	136	74	diseases	disease	NOUN
dpc-3629	136	75	2.70	2.70	NUM
dpc-3629	136	76	(	(	PUNCT
dpc-3629	136	77	0.64	0.64	NUM
dpc-3629	136	78	-	-	SYM
dpc-3629	136	79	11.47	11.47	NUM
dpc-3629	136	80	)	)	PUNCT
dpc-3629	136	81	0.178	0.178	NUM
dpc-3629	136	82	skin	skin	NOUN
dpc-3629	136	83	type	type	NOUN
dpc-3629	136	84	0.49	0.49	NUM
dpc-3629	136	85	(	(	PUNCT
dpc-3629	136	86	0.12	0.12	NUM
dpc-3629	136	87	-	-	NUM
dpc-3629	136	88	1.98	1.98	NUM
dpc-3629	136	89	)	)	PUNCT
dpc-3629	136	90	0.316	0.316	NUM
dpc-3629	136	91	ci	ci	NOUN
dpc-3629	136	92	=	=	NOUN
dpc-3629	136	93	confidence	confidence	NOUN
dpc-3629	136	94	interval	interval	NOUN
dpc-3629	136	95	.	.	PUNCT
dpc-3629	137	1	rosacea	rosacea	NOUN
dpc-3629	137	2	treatment	treatment	NOUN
dpc-3629	137	3	starts	start	VERB
dpc-3629	137	4	with	with	ADP
dpc-3629	137	5	avoidance	avoidance	NOUN
dpc-3629	137	6	of	of	ADP
dpc-3629	137	7	triggers	trigger	NOUN
dpc-3629	137	8	and	and	CCONJ
dpc-3629	137	9	use	use	NOUN
dpc-3629	137	10	of	of	ADP
dpc-3629	137	11	mild	mild	ADJ
dpc-3629	137	12	cleansing	cleansing	NOUN
dpc-3629	137	13	and	and	CCONJ
dpc-3629	137	14	moisturizing	moisturizing	NOUN
dpc-3629	137	15	agents	agent	NOUN
dpc-3629	137	16	,	,	PUNCT
dpc-3629	137	17	as	as	ADV
dpc-3629	137	18	well	well	ADV
dpc-3629	137	19	as	as	ADP
dpc-3629	137	20	photoprotection	photoprotection	NOUN
dpc-3629	137	21	[	[	X
dpc-3629	137	22	3	3	NUM
dpc-3629	137	23	]	]	PUNCT
dpc-3629	137	24	.	.	PUNCT
dpc-3629	138	1	topical	topical	ADJ
dpc-3629	138	2	,	,	PUNCT
dpc-3629	138	3	oral	oral	ADJ
dpc-3629	138	4	medications	medication	NOUN
dpc-3629	138	5	,	,	PUNCT
dpc-3629	138	6	laser	laser	NOUN
dpc-3629	138	7	or	or	CCONJ
dpc-3629	138	8	lightbased	lightbase	VERB
dpc-3629	138	9	treatments	treatment	NOUN
dpc-3629	138	10	,	,	PUNCT
dpc-3629	138	11	and	and	CCONJ
dpc-3629	138	12	injection	injection	NOUN
dpc-3629	138	13	therapies	therapy	NOUN
dpc-3629	138	14	are	be	AUX
dpc-3629	138	15	used	use	VERB
dpc-3629	138	16	alone	alone	ADV
dpc-3629	138	17	or	or	CCONJ
dpc-3629	138	18	in	in	ADP
dpc-3629	138	19	combination	combination	NOUN
dpc-3629	138	20	in	in	ADP
dpc-3629	138	21	the	the	DET
dpc-3629	138	22	treatment	treatment	NOUN
dpc-3629	138	23	of	of	ADP
dpc-3629	138	24	rosacea	rosacea	NOUN
dpc-3629	139	1	[	[	X
dpc-3629	139	2	3,16,17	3,16,17	NUM
dpc-3629	139	3	]	]	PUNCT
dpc-3629	139	4	.	.	PUNCT
dpc-3629	140	1	metronidazole	metronidazole	NOUN
dpc-3629	140	2	,	,	PUNCT
dpc-3629	140	3	azelaic	azelaic	PROPN
dpc-3629	140	4	acid	acid	NOUN
dpc-3629	140	5	;	;	PUNCT
dpc-3629	140	6	sulfacetamide	sulfacetamide	ADV
dpc-3629	140	7	/	/	SYM
dpc-3629	140	8	sülfür	sülfür	PROPN
dpc-3629	140	9	,	,	PUNCT
dpc-3629	140	10	brimonidine	brimonidine	PROPN
dpc-3629	140	11	,	,	PUNCT
dpc-3629	140	12	oxymetazoline	oxymetazoline	NOUN
dpc-3629	140	13	have	have	AUX
dpc-3629	140	14	been	be	AUX
dpc-3629	140	15	approved	approve	VERB
dpc-3629	140	16	by	by	ADP
dpc-3629	140	17	fda	fda	PROPN
dpc-3629	140	18	in	in	ADP
dpc-3629	140	19	the	the	DET
dpc-3629	140	20	treatment	treatment	NOUN
dpc-3629	140	21	of	of	ADP
dpc-3629	140	22	erythema	erythema	NOUN
dpc-3629	140	23	in	in	ADP
dpc-3629	140	24	rosacea	rosacea	NOUN
dpc-3629	141	1	[	[	X
dpc-3629	141	2	3,18	3,18	X
dpc-3629	141	3	]	]	X
dpc-3629	141	4	.	.	PUNCT
dpc-3629	142	1	vascular	vascular	ADJ
dpc-3629	142	2	laser	laser	NOUN
dpc-3629	142	3	and	and	CCONJ
dpc-3629	142	4	light	light	NOUN
dpc-3629	142	5	-	-	PUNCT
dpc-3629	142	6	based	base	VERB
dpc-3629	142	7	therapies	therapy	NOUN
dpc-3629	142	8	(	(	PUNCT
dpc-3629	142	9	pulsed	pulse	VERB
dpc-3629	142	10	dye	dye	NOUN
dpc-3629	142	11	laser	laser	NOUN
dpc-3629	142	12	,	,	PUNCT
dpc-3629	142	13	intense	intense	ADJ
dpc-3629	142	14	pulsed	pulsed	ADJ
dpc-3629	142	15	light	light	NOUN
dpc-3629	142	16	,	,	PUNCT
dpc-3629	142	17	nd	nd	PRON
dpc-3629	142	18	:	:	PUNCT
dpc-3629	142	19	yag	yag	NOUN
dpc-3629	142	20	laser	laser	NOUN
dpc-3629	142	21	)	)	PUNCT
dpc-3629	142	22	can	can	AUX
dpc-3629	142	23	be	be	AUX
dpc-3629	142	24	used	use	VERB
dpc-3629	142	25	for	for	ADP
dpc-3629	142	26	erythema	erythema	ADJ
dpc-3629	142	27	and	and	CCONJ
dpc-3629	142	28	telangiectasia	telangiectasia	VERB
dpc-3629	142	29	as	as	ADP
dpc-3629	142	30	a	a	DET
dpc-3629	142	31	second	second	ADJ
dpc-3629	142	32	step	step	NOUN
dpc-3629	142	33	or	or	CCONJ
dpc-3629	142	34	combined	combine	VERB
dpc-3629	142	35	with	with	ADP
dpc-3629	142	36	topical	topical	ADJ
dpc-3629	142	37	therapy	therapy	NOUN
dpc-3629	142	38	[	[	X
dpc-3629	142	39	3,5,18	3,5,18	NUM
dpc-3629	142	40	]	]	PUNCT
dpc-3629	142	41	.	.	PUNCT
dpc-3629	143	1	various	various	ADJ
dpc-3629	143	2	therapeutic	therapeutic	ADJ
dpc-3629	143	3	strategies	strategy	NOUN
dpc-3629	143	4	may	may	AUX
dpc-3629	143	5	be	be	AUX
dpc-3629	143	6	needed	need	VERB
dpc-3629	143	7	to	to	PART
dpc-3629	143	8	achieve	achieve	VERB
dpc-3629	143	9	a	a	DET
dpc-3629	143	10	better	well	ADJ
dpc-3629	143	11	clinical	clinical	ADJ
dpc-3629	143	12	outcome	outcome	NOUN
dpc-3629	143	13	in	in	ADP
dpc-3629	143	14	patients	patient	NOUN
dpc-3629	143	15	with	with	ADP
dpc-3629	143	16	rosacea	rosacea	NOUN
dpc-3629	143	17	because	because	SCONJ
dpc-3629	143	18	of	of	ADP
dpc-3629	143	19	 	 	SPACE
dpc-3629	143	20	an	an	DET
dpc-3629	143	21	overlapping	overlap	VERB
dpc-3629	143	22	clinical	clinical	ADJ
dpc-3629	143	23	feature	feature	NOUN
dpc-3629	143	24	of	of	ADP
dpc-3629	143	25	the	the	DET
dpc-3629	143	26	subtypes	subtype	NOUN
dpc-3629	143	27	[	[	X
dpc-3629	143	28	3	3	NUM
dpc-3629	143	29	]	]	PUNCT
dpc-3629	143	30	.	.	PUNCT
dpc-3629	144	1	physicians	physician	NOUN
dpc-3629	144	2	should	should	AUX
dpc-3629	144	3	individualize	individualize	VERB
dpc-3629	144	4	the	the	DET
dpc-3629	144	5	treatment	treatment	NOUN
dpc-3629	144	6	according	accord	VERB
dpc-3629	144	7	to	to	ADP
dpc-3629	144	8	the	the	DET
dpc-3629	144	9	subtype	subtype	NOUN
dpc-3629	144	10	and	and	CCONJ
dpc-3629	144	11	severity	severity	NOUN
dpc-3629	144	12	of	of	ADP
dpc-3629	144	13	the	the	DET
dpc-3629	144	14	disease	disease	NOUN
dpc-3629	144	15	,	,	PUNCT
dpc-3629	144	16	clinical	clinical	ADJ
dpc-3629	144	17	grade	grade	NOUN
dpc-3629	144	18	of	of	ADP
dpc-3629	144	19	inflammation	inflammation	NOUN
dpc-3629	144	20	and	and	CCONJ
dpc-3629	144	21	erythema	erythema	ADJ
dpc-3629	144	22	,	,	PUNCT
dpc-3629	144	23	presence	presence	NOUN
dpc-3629	144	24	of	of	ADP
dpc-3629	144	25	telangiectasia	telangiectasia	NOUN
dpc-3629	144	26	,	,	PUNCT
dpc-3629	144	27	triggering	trigger	VERB
dpc-3629	144	28	factors	factor	NOUN
dpc-3629	144	29	,	,	PUNCT
dpc-3629	144	30	and	and	CCONJ
dpc-3629	144	31	comorbidities	comorbiditie	NOUN
dpc-3629	144	32	.	.	PUNCT
dpc-3629	145	1	the	the	DET
dpc-3629	145	2	efficacy	efficacy	NOUN
dpc-3629	145	3	of	of	ADP
dpc-3629	145	4	combined	combined	ADJ
dpc-3629	145	5	treatments	treatment	NOUN
dpc-3629	145	6	in	in	ADP
dpc-3629	145	7	rosacea	rosacea	NOUN
dpc-3629	145	8	has	have	AUX
dpc-3629	145	9	been	be	AUX
dpc-3629	145	10	shown	show	VERB
dpc-3629	145	11	to	to	PART
dpc-3629	145	12	be	be	AUX
dpc-3629	145	13	better	well	ADJ
dpc-3629	145	14	than	than	ADP
dpc-3629	145	15	monotherapy	monotherapy	NOUN
dpc-3629	145	16	[	[	X
dpc-3629	145	17	19	19	NUM
dpc-3629	145	18	-	-	SYM
dpc-3629	145	19	23	23	NUM
dpc-3629	145	20	]	]	PUNCT
dpc-3629	145	21	.	.	PUNCT
dpc-3629	146	1	topical	topical	ADJ
dpc-3629	146	2	treatments	treatment	NOUN
dpc-3629	146	3	are	be	AUX
dpc-3629	146	4	usually	usually	ADV
dpc-3629	146	5	preferred	prefer	VERB
dpc-3629	146	6	in	in	ADP
dpc-3629	146	7	etr	etr	PROPN
dpc-3629	147	1	[	[	X
dpc-3629	147	2	3	3	NUM
dpc-3629	147	3	]	]	PUNCT
dpc-3629	147	4	.	.	PUNCT
dpc-3629	148	1	topical	topical	ADJ
dpc-3629	148	2	treatments	treatment	NOUN
dpc-3629	148	3	were	be	AUX
dpc-3629	148	4	generally	generally	ADV
dpc-3629	148	5	used	use	VERB
dpc-3629	148	6	for	for	ADP
dpc-3629	148	7	an	an	DET
dpc-3629	148	8	average	average	NOUN
dpc-3629	148	9	of	of	ADP
dpc-3629	148	10	12	12	NUM
dpc-3629	148	11	-	-	SYM
dpc-3629	148	12	16	16	NUM
dpc-3629	148	13	weeks	week	NOUN
dpc-3629	148	14	in	in	ADP
dpc-3629	148	15	the	the	DET
dpc-3629	148	16	studies	study	NOUN
dpc-3629	148	17	[	[	X
dpc-3629	148	18	3,23,24	3,23,24	NUM
dpc-3629	148	19	]	]	PUNCT
dpc-3629	148	20	.	.	PUNCT
dpc-3629	149	1	we	we	PRON
dpc-3629	149	2	used	use	VERB
dpc-3629	149	3	topical	topical	ADJ
dpc-3629	149	4	dapsone	dapsone	NOUN
dpc-3629	149	5	5	5	NUM
dpc-3629	149	6	%	%	NOUN
dpc-3629	149	7	gel	gel	NOUN
dpc-3629	149	8	for	for	ADP
dpc-3629	149	9	12	12	NUM
dpc-3629	149	10	weeks	week	NOUN
dpc-3629	149	11	.	.	PUNCT
dpc-3629	150	1	we	we	PRON
dpc-3629	150	2	found	find	VERB
dpc-3629	150	3	that	that	SCONJ
dpc-3629	150	4	the	the	DET
dpc-3629	150	5	success	success	NOUN
dpc-3629	150	6	rate	rate	NOUN
dpc-3629	150	7	of	of	ADP
dpc-3629	150	8	treatment	treatment	NOUN
dpc-3629	150	9	was	be	AUX
dpc-3629	150	10	14.3	14.3	NUM
dpc-3629	150	11	%	%	NOUN
dpc-3629	150	12	at	at	ADP
dpc-3629	150	13	the	the	DET
dpc-3629	150	14	end	end	NOUN
dpc-3629	150	15	of	of	ADP
dpc-3629	150	16	the	the	DET
dpc-3629	150	17	2nd	2nd	ADJ
dpc-3629	150	18	week	week	NOUN
dpc-3629	150	19	,	,	PUNCT
dpc-3629	150	20	45.7	45.7	NUM
dpc-3629	150	21	%	%	NOUN
dpc-3629	150	22	6	6	NUM
dpc-3629	150	23	original	original	ADJ
dpc-3629	150	24	article	article	NOUN
dpc-3629	150	25	|	|	ADV
dpc-3629	150	26	dermatol	dermatol	ADJ
dpc-3629	150	27	pract	pract	NOUN
dpc-3629	150	28	concept	concept	NOUN
dpc-3629	150	29	.	.	PUNCT
dpc-3629	151	1	2024;14(1):e2024034	2024;14(1):e2024034	NUM
dpc-3629	151	2	to	to	PART
dpc-3629	151	3	sum	sum	VERB
dpc-3629	151	4	up	up	ADP
dpc-3629	151	5	,	,	PUNCT
dpc-3629	151	6	using	use	VERB
dpc-3629	151	7	dapsone	dapsone	NOUN
dpc-3629	151	8	5	5	NUM
dpc-3629	151	9	%	%	NOUN
dpc-3629	151	10	gel	gel	NOUN
dpc-3629	151	11	was	be	AUX
dpc-3629	151	12	safe	safe	ADJ
dpc-3629	151	13	,	,	PUNCT
dpc-3629	151	14	effective	effective	ADJ
dpc-3629	151	15	,	,	PUNCT
dpc-3629	151	16	and	and	CCONJ
dpc-3629	151	17	well	well	ADV
dpc-3629	151	18	tolerated	tolerate	VERB
dpc-3629	151	19	in	in	ADP
dpc-3629	151	20	the	the	DET
dpc-3629	151	21	treatment	treatment	NOUN
dpc-3629	151	22	of	of	ADP
dpc-3629	151	23	etr	etr	PROPN
dpc-3629	151	24	.	.	PUNCT
dpc-3629	152	1	we	we	PRON
dpc-3629	152	2	conclude	conclude	VERB
dpc-3629	152	3	that	that	SCONJ
dpc-3629	152	4	dapsone	dapsone	PROPN
dpc-3629	152	5	5	5	NUM
dpc-3629	152	6	%	%	NOUN
dpc-3629	152	7	gel	gel	NOUN
dpc-3629	152	8	treatment	treatment	NOUN
dpc-3629	152	9	in	in	ADP
dpc-3629	152	10	etr	etr	PROPN
dpc-3629	152	11	can	can	AUX
dpc-3629	152	12	be	be	AUX
dpc-3629	152	13	acceptable	acceptable	ADJ
dpc-3629	152	14	.	.	PUNCT
dpc-3629	153	1	however	however	ADV
dpc-3629	153	2	,	,	PUNCT
dpc-3629	153	3	we	we	PRON
dpc-3629	153	4	think	think	VERB
dpc-3629	153	5	that	that	SCONJ
dpc-3629	153	6	further	further	ADJ
dpc-3629	153	7	multicentered	multicentere	VERB
dpc-3629	153	8	,	,	PUNCT
dpc-3629	153	9	randomized	randomize	VERB
dpc-3629	153	10	,	,	PUNCT
dpc-3629	153	11	controlled	control	VERB
dpc-3629	153	12	,	,	PUNCT
dpc-3629	153	13	large	large	ADJ
dpc-3629	153	14	-	-	PUNCT
dpc-3629	153	15	scale	scale	NOUN
dpc-3629	153	16	studies	study	NOUN
dpc-3629	153	17	with	with	ADP
dpc-3629	153	18	longer	long	ADJ
dpc-3629	153	19	follow	follow	VERB
dpc-3629	153	20	-	-	PUNCT
dpc-3629	153	21	up	up	ADP
dpc-3629	153	22	period	period	NOUN
dpc-3629	153	23	are	be	AUX
dpc-3629	153	24	needed	need	VERB
dpc-3629	153	25	.	.	PUNCT
dpc-3629	154	1	references	reference	NOUN
dpc-3629	154	2	1	1	NUM
dpc-3629	154	3	.	.	PUNCT
dpc-3629	154	4	lee	lee	PROPN
dpc-3629	154	5	hj	hj	PROPN
dpc-3629	154	6	,	,	PUNCT
dpc-3629	154	7	hong	hong	PROPN
dpc-3629	154	8	yj	yj	PROPN
dpc-3629	154	9	,	,	PUNCT
dpc-3629	154	10	kim	kim	PROPN
dpc-3629	154	11	m.	m.	NOUN
dpc-3629	154	12	angiogenesis	angiogenesis	NOUN
dpc-3629	154	13	in	in	ADP
dpc-3629	154	14	chronic	chronic	ADJ
dpc-3629	154	15	inflammatory	inflammatory	ADJ
dpc-3629	154	16	skin	skin	NOUN
dpc-3629	154	17	disorders	disorder	NOUN
dpc-3629	154	18	.	.	PUNCT
dpc-3629	155	1	int	int	PROPN
dpc-3629	155	2	j	j	PROPN
dpc-3629	155	3	mol	mol	ADP
dpc-3629	155	4	sci	sci	PROPN
dpc-3629	155	5	.	.	PUNCT
dpc-3629	156	1	2021;22(21):12035	2021;22(21):12035	X
dpc-3629	156	2	.	.	PUNCT
dpc-3629	157	1	doi	doi	NOUN
dpc-3629	157	2	:	:	PUNCT
dpc-3629	157	3	10.3390	10.3390	NUM
dpc-3629	157	4	/ijms222112035	/ijms222112035	PUNCT
dpc-3629	157	5	.	.	PUNCT
dpc-3629	158	1	pmid	pmid	NOUN
dpc-3629	158	2	:	:	PUNCT
dpc-3629	158	3	34769465	34769465	NUM
dpc-3629	158	4	.	.	PUNCT
dpc-3629	159	1	pmcid	pmcid	ADJ
dpc-3629	159	2	:	:	PUNCT
dpc-3629	159	3	pmc8584589	pmc8584589	NOUN
dpc-3629	159	4	.	.	PUNCT
dpc-3629	160	1	2	2	X
dpc-3629	160	2	.	.	X
dpc-3629	160	3	dall’oglio	dall’oglio	PROPN
dpc-3629	160	4	f	f	PROPN
dpc-3629	160	5	,	,	PUNCT
dpc-3629	160	6	nasca	nasca	PROPN
dpc-3629	160	7	mr	mr	PROPN
dpc-3629	160	8	,	,	PUNCT
dpc-3629	160	9	micali	micali	NOUN
dpc-3629	160	10	g.	g.	NOUN
dpc-3629	160	11	emerging	emerge	VERB
dpc-3629	160	12	topical	topical	ADJ
dpc-3629	160	13	drugs	drug	NOUN
dpc-3629	160	14	for	for	ADP
dpc-3629	160	15	the	the	DET
dpc-3629	160	16	treatment	treatment	NOUN
dpc-3629	160	17	of	of	ADP
dpc-3629	160	18	rosacea	rosacea	NOUN
dpc-3629	160	19	.	.	PUNCT
dpc-3629	161	1	expert	expert	NOUN
dpc-3629	161	2	opin	opin	NOUN
dpc-3629	161	3	emerg	emerg	NOUN
dpc-3629	161	4	drugs	drug	NOUN
dpc-3629	161	5	.	.	PUNCT
dpc-3629	162	1	2021;26(1):2738	2021;26(1):2738	NOUN
dpc-3629	162	2	.	.	PUNCT
dpc-3629	163	1	doi	doi	NOUN
dpc-3629	163	2	:	:	PUNCT
dpc-3629	163	3	10.1080/14728214.2021.1887138	10.1080/14728214.2021.1887138	NUM
dpc-3629	163	4	.	.	PUNCT
dpc-3629	164	1	pmid	pmid	NOUN
dpc-3629	164	2	:	:	PUNCT
dpc-3629	164	3	33596752	33596752	NUM
dpc-3629	164	4	.	.	PUNCT
dpc-3629	165	1	3	3	X
dpc-3629	165	2	.	.	NUM
dpc-3629	165	3	abokwidir	abokwidir	PROPN
dpc-3629	165	4	m	m	PROPN
dpc-3629	165	5	,	,	PUNCT
dpc-3629	165	6	feldman	feldman	PROPN
dpc-3629	165	7	sr	sr	PROPN
dpc-3629	165	8	.	.	PUNCT
dpc-3629	166	1	rosacea	rosacea	PROPN
dpc-3629	166	2	management	management	PROPN
dpc-3629	166	3	.	.	PUNCT
dpc-3629	167	1	skin	skin	NOUN
dpc-3629	167	2	appendage	appendage	NOUN
dpc-3629	167	3	disord	disord	NOUN
dpc-3629	167	4	.	.	PUNCT
dpc-3629	168	1	2016;2(1	2016;2(1	NUM
dpc-3629	168	2	-	-	PUNCT
dpc-3629	168	3	2):26	2):26	NUM
dpc-3629	168	4	-	-	SYM
dpc-3629	168	5	34	34	NUM
dpc-3629	168	6	.	.	PUNCT
dpc-3629	168	7	doi	doi	NOUN
dpc-3629	168	8	:	:	PUNCT
dpc-3629	168	9	10.1159/000446215	10.1159/000446215	NUM
dpc-3629	168	10	.	.	PUNCT
dpc-3629	169	1	pmid	pmid	NOUN
dpc-3629	169	2	:	:	PUNCT
dpc-3629	169	3	27843919	27843919	NUM
dpc-3629	169	4	.	.	PUNCT
dpc-3629	170	1	pmcid	pmcid	ADJ
dpc-3629	170	2	:	:	PUNCT
dpc-3629	170	3	pmc5096126	pmc5096126	NOUN
dpc-3629	170	4	.	.	PUNCT
dpc-3629	171	1	4	4	X
dpc-3629	171	2	.	.	X
dpc-3629	171	3	lim	lim	PROPN
dpc-3629	171	4	hs	hs	PROPN
dpc-3629	171	5	,	,	PUNCT
dpc-3629	171	6	lee	lee	PROPN
dpc-3629	171	7	sc	sc	PROPN
dpc-3629	171	8	,	,	PUNCT
dpc-3629	171	9	won	win	VERB
dpc-3629	171	10	yh	yh	PROPN
dpc-3629	171	11	,	,	PUNCT
dpc-3629	171	12	lee	lee	PROPN
dpc-3629	171	13	jb	jb	PROPN
dpc-3629	171	14	.	.	PUNCT
dpc-3629	172	1	the	the	DET
dpc-3629	172	2	efficacy	efficacy	NOUN
dpc-3629	172	3	of	of	ADP
dpc-3629	172	4	intense	intense	ADJ
dpc-3629	172	5	pulsed	pulsed	ADJ
dpc-3629	172	6	light	light	NOUN
dpc-3629	172	7	for	for	ADP
dpc-3629	172	8	treating	treat	VERB
dpc-3629	172	9	erythematotelangiectatic	erythematotelangiectatic	ADJ
dpc-3629	172	10	rosacea	rosacea	NOUN
dpc-3629	172	11	is	be	AUX
dpc-3629	172	12	related	relate	VERB
dpc-3629	172	13	to	to	ADP
dpc-3629	172	14	severity	severity	NOUN
dpc-3629	172	15	and	and	CCONJ
dpc-3629	172	16	age	age	NOUN
dpc-3629	172	17	.	.	PUNCT
dpc-3629	173	1	ann	ann	PROPN
dpc-3629	173	2	dermatol	dermatol	NOUN
dpc-3629	173	3	.	.	PUNCT
dpc-3629	174	1	2014;26(4):491	2014;26(4):491	NOUN
dpc-3629	174	2	-	-	SYM
dpc-3629	174	3	495	495	NUM
dpc-3629	174	4	.	.	PUNCT
dpc-3629	175	1	doi	doi	NOUN
dpc-3629	175	2	:	:	PUNCT
dpc-3629	175	3	10.5021	10.5021	NUM
dpc-3629	175	4	/	/	SYM
dpc-3629	175	5	ad.2014.26.4.491	ad.2014.26.4.491	NOUN
dpc-3629	175	6	.	.	PUNCT
dpc-3629	176	1	pmid	pmid	NOUN
dpc-3629	176	2	:	:	PUNCT
dpc-3629	176	3	25143679	25143679	NUM
dpc-3629	176	4	.	.	PUNCT
dpc-3629	177	1	pmcid	pmcid	ADJ
dpc-3629	177	2	:	:	PUNCT
dpc-3629	177	3	pmc4135105	pmc4135105	NOUN
dpc-3629	177	4	.	.	PUNCT
dpc-3629	178	1	5	5	X
dpc-3629	178	2	.	.	X
dpc-3629	178	3	micali	micali	NOUN
dpc-3629	178	4	g	g	PROPN
dpc-3629	178	5	,	,	PUNCT
dpc-3629	178	6	gerber	gerber	PROPN
dpc-3629	178	7	pa	pa	PROPN
dpc-3629	178	8	,	,	PUNCT
dpc-3629	178	9	lacarrubba	lacarrubba	PROPN
dpc-3629	178	10	f	f	PROPN
dpc-3629	178	11	,	,	PUNCT
dpc-3629	178	12	schäfer	schäfer	NOUN
dpc-3629	178	13	g.	g.	NOUN
dpc-3629	178	14	improving	improve	VERB
dpc-3629	178	15	treatment	treatment	NOUN
dpc-3629	178	16	of	of	ADP
dpc-3629	178	17	erythematotelangiectatic	erythematotelangiectatic	ADJ
dpc-3629	178	18	rosacea	rosacea	NOUN
dpc-3629	178	19	with	with	ADP
dpc-3629	178	20	laser	laser	NOUN
dpc-3629	178	21	and/or	and/or	CCONJ
dpc-3629	178	22	topical	topical	ADJ
dpc-3629	178	23	therapy	therapy	NOUN
dpc-3629	178	24	through	through	ADP
dpc-3629	178	25	enhanced	enhanced	ADJ
dpc-3629	178	26	discrimination	discrimination	NOUN
dpc-3629	178	27	of	of	ADP
dpc-3629	178	28	its	its	PRON
dpc-3629	178	29	clinical	clinical	ADJ
dpc-3629	178	30	features	feature	NOUN
dpc-3629	178	31	.	.	PUNCT
dpc-3629	179	1	j	j	PROPN
dpc-3629	179	2	clin	clin	PROPN
dpc-3629	179	3	aesthet	aesthet	PROPN
dpc-3629	179	4	dermatol	dermatol	PROPN
dpc-3629	179	5	.	.	PUNCT
dpc-3629	180	1	2016;9(7):30	2016;9(7):30	NUM
dpc-3629	180	2	-	-	SYM
dpc-3629	180	3	39	39	NUM
dpc-3629	180	4	.	.	PUNCT
dpc-3629	181	1	pmid	pmid	NOUN
dpc-3629	181	2	:	:	PUNCT
dpc-3629	181	3	27672409	27672409	NUM
dpc-3629	181	4	.	.	PUNCT
dpc-3629	182	1	pmcid	pmcid	ADJ
dpc-3629	182	2	:	:	PUNCT
dpc-3629	182	3	pmc5023001	pmc5023001	NOUN
dpc-3629	182	4	.	.	PUNCT
dpc-3629	183	1	6	6	X
dpc-3629	183	2	.	.	X
dpc-3629	183	3	buddenkotte	buddenkotte	PROPN
dpc-3629	183	4	j	j	PROPN
dpc-3629	183	5	,	,	PUNCT
dpc-3629	183	6	steinhoff	steinhoff	PROPN
dpc-3629	183	7	m.	m.	NOUN
dpc-3629	183	8	recent	recent	ADJ
dpc-3629	183	9	advances	advance	NOUN
dpc-3629	183	10	in	in	ADP
dpc-3629	183	11	understanding	understanding	NOUN
dpc-3629	183	12	and	and	CCONJ
dpc-3629	183	13	managing	manage	VERB
dpc-3629	183	14	rosacea	rosacea	NOUN
dpc-3629	183	15	.	.	PUNCT
dpc-3629	184	1	f1000res	f1000res	PROPN
dpc-3629	184	2	.	.	PUNCT
dpc-3629	185	1	2018;7	2018;7	NUM
dpc-3629	185	2	:	:	PUNCT
dpc-3629	185	3	f1000	f1000	ADJ
dpc-3629	185	4	faculty	faculty	NOUN
dpc-3629	185	5	rev-1885	rev-1885	NOUN
dpc-3629	185	6	.	.	PUNCT
dpc-3629	186	1	doi	doi	NOUN
dpc-3629	186	2	:	:	PUNCT
dpc-3629	186	3	10.12688	10.12688	NUM
dpc-3629	186	4	/	/	SYM
dpc-3629	186	5	f1000research.16537.1	f1000research.16537.1	NOUN
dpc-3629	186	6	.	.	PUNCT
dpc-3629	187	1	pmid	pmid	NOUN
dpc-3629	187	2	:	:	PUNCT
dpc-3629	187	3	30631431	30631431	NUM
dpc-3629	187	4	.	.	PUNCT
dpc-3629	188	1	pmcid	pmcid	NOUN
dpc-3629	188	2	:	:	PUNCT
dpc-3629	188	3	pmc6281021	pmc6281021	PROPN
dpc-3629	188	4	.	.	PUNCT
dpc-3629	189	1	7	7	X
dpc-3629	189	2	.	.	X
dpc-3629	189	3	brown	brown	PROPN
dpc-3629	189	4	lf	lf	PROPN
dpc-3629	189	5	,	,	PUNCT
dpc-3629	189	6	detmar	detmar	PROPN
dpc-3629	189	7	m	m	PROPN
dpc-3629	189	8	,	,	PUNCT
dpc-3629	189	9	claffey	claffey	PROPN
dpc-3629	189	10	k	k	PROPN
dpc-3629	189	11	,	,	PUNCT
dpc-3629	189	12	et	et	PROPN
dpc-3629	189	13	al	al	PROPN
dpc-3629	189	14	.	.	PROPN
dpc-3629	189	15	vascular	vascular	ADJ
dpc-3629	189	16	permeability	permeability	NOUN
dpc-3629	189	17	factor	factor	NOUN
dpc-3629	189	18	/	/	SYM
dpc-3629	189	19	vascular	vascular	ADJ
dpc-3629	189	20	endothelial	endothelial	ADJ
dpc-3629	189	21	growth	growth	NOUN
dpc-3629	189	22	factor	factor	NOUN
dpc-3629	189	23	:	:	PUNCT
dpc-3629	189	24	a	a	DET
dpc-3629	189	25	multifunctional	multifunctional	ADJ
dpc-3629	189	26	angiogenic	angiogenic	ADJ
dpc-3629	189	27	cytokine	cytokine	NOUN
dpc-3629	189	28	.	.	PUNCT
dpc-3629	190	1	exs	exs	PROPN
dpc-3629	190	2	.	.	PUNCT
dpc-3629	191	1	1997;79:233	1997;79:233	PROPN
dpc-3629	191	2	-	-	SYM
dpc-3629	191	3	69	69	NUM
dpc-3629	191	4	.	.	PUNCT
dpc-3629	192	1	doi	doi	NOUN
dpc-3629	192	2	:	:	PUNCT
dpc-3629	192	3	10.1007/978	10.1007/978	NUM
dpc-3629	192	4	-	-	SYM
dpc-3629	192	5	3	3	NUM
dpc-3629	192	6	-0348	-0348	NOUN
dpc-3629	192	7	-	-	PUNCT
dpc-3629	192	8	9006	9006	NUM
dpc-3629	192	9	-	-	PUNCT
dpc-3629	192	10	9_10	9_10	NUM
dpc-3629	192	11	.	.	PUNCT
dpc-3629	193	1	pmid	pmid	NOUN
dpc-3629	193	2	:	:	PUNCT
dpc-3629	193	3	9002222	9002222	NUM
dpc-3629	193	4	.	.	PUNCT
dpc-3629	194	1	8	8	NUM
dpc-3629	194	2	.	.	X
dpc-3629	194	3	kwon	kwon	PROPN
dpc-3629	194	4	mj	mj	PROPN
dpc-3629	194	5	,	,	PUNCT
dpc-3629	194	6	joo	joo	PROPN
dpc-3629	194	7	hg	hg	PROPN
dpc-3629	194	8	.	.	PUNCT
dpc-3629	195	1	dapsone	dapsone	PROPN
dpc-3629	195	2	modulates	modulate	NOUN
dpc-3629	195	3	lipopolysaccharide	lipopolysaccharide	VERB
dpc-3629	195	4	activated	activate	VERB
dpc-3629	195	5	bone	bone	NOUN
dpc-3629	195	6	marrow	marrow	NOUN
dpc-3629	195	7	cells	cell	NOUN
dpc-3629	195	8	by	by	ADP
dpc-3629	195	9	inducing	induce	VERB
dpc-3629	195	10	cell	cell	NOUN
dpc-3629	195	11	death	death	NOUN
dpc-3629	195	12	and	and	CCONJ
dpc-3629	195	13	down	down	ADV
dpc-3629	195	14	-	-	PUNCT
dpc-3629	195	15	regulating	regulate	VERB
dpc-3629	195	16	tumor	tumor	NOUN
dpc-3629	195	17	necrosis	necrosis	NOUN
dpc-3629	195	18	factor	factor	NOUN
dpc-3629	195	19	-	-	PUNCT
dpc-3629	195	20	α	α	NOUN
dpc-3629	195	21	production	production	NOUN
dpc-3629	195	22	.	.	PUNCT
dpc-3629	196	1	j	j	PROPN
dpc-3629	196	2	vet	vet	PROPN
dpc-3629	196	3	sci	sci	PROPN
dpc-3629	196	4	.	.	PUNCT
dpc-3629	197	1	2018;19(6):744	2018;19(6):744	PROPN
dpc-3629	197	2	-	-	PUNCT
dpc-3629	197	3	749	749	NUM
dpc-3629	197	4	.	.	PUNCT
dpc-3629	198	1	doi	doi	NOUN
dpc-3629	198	2	:	:	PUNCT
dpc-3629	198	3	10.4142	10.4142	NUM
dpc-3629	198	4	/	/	SYM
dpc-3629	198	5	jvs.2018.19.6.744	jvs.2018.19.6.744	PROPN
dpc-3629	198	6	.	.	PUNCT
dpc-3629	199	1	pmid	pmid	NOUN
dpc-3629	199	2	:	:	PUNCT
dpc-3629	199	3	30304888	30304888	NUM
dpc-3629	199	4	.	.	PUNCT
dpc-3629	200	1	pmcid	pmcid	NOUN
dpc-3629	200	2	:	:	PUNCT
dpc-3629	200	3	pmc6265590	pmc6265590	NOUN
dpc-3629	200	4	.	.	PUNCT
dpc-3629	201	1	9	9	X
dpc-3629	201	2	.	.	X
dpc-3629	201	3	kanwar	kanwar	PROPN
dpc-3629	201	4	b	b	PROPN
dpc-3629	201	5	,	,	PUNCT
dpc-3629	201	6	khattak	khattak	PROPN
dpc-3629	201	7	a	a	PROPN
dpc-3629	201	8	,	,	PUNCT
dpc-3629	201	9	kast	kast	PROPN
dpc-3629	201	10	re	re	NOUN
dpc-3629	201	11	.	.	PUNCT
dpc-3629	202	1	dapsone	dapsone	PROPN
dpc-3629	202	2	lowers	lower	VERB
dpc-3629	202	3	neutrophil	neutrophil	ADV
dpc-3629	202	4	to	to	ADP
dpc-3629	202	5	lymphocyte	lymphocyte	ADJ
dpc-3629	202	6	ratio	ratio	NOUN
dpc-3629	202	7	and	and	CCONJ
dpc-3629	202	8	mortality	mortality	NOUN
dpc-3629	202	9	in	in	ADP
dpc-3629	202	10	covid-19	covid-19	PROPN
dpc-3629	202	11	patients	patient	NOUN
dpc-3629	202	12	admitted	admit	VERB
dpc-3629	202	13	to	to	ADP
dpc-3629	202	14	the	the	DET
dpc-3629	202	15	icu	icu	PROPN
dpc-3629	202	16	.	.	PUNCT
dpc-3629	203	1	int	int	PROPN
dpc-3629	203	2	j	j	PROPN
dpc-3629	203	3	mol	mol	ADP
dpc-3629	203	4	sci	sci	PROPN
dpc-3629	203	5	.	.	PUNCT
dpc-3629	204	1	2022;23(24):15563	2022;23(24):15563	PROPN
dpc-3629	204	2	.	.	PUNCT
dpc-3629	204	3	doi	doi	PROPN
dpc-3629	204	4	:	:	PUNCT
dpc-3629	204	5	10.3390	10.3390	NUM
dpc-3629	204	6	/ijms232415563	/ijms232415563	PROPN
dpc-3629	204	7	.	.	PUNCT
dpc-3629	205	1	pmid	pmid	NOUN
dpc-3629	205	2	:	:	PUNCT
dpc-3629	205	3	36555204	36555204	NUM
dpc-3629	205	4	.	.	PUNCT
dpc-3629	206	1	pmcid	pmcid	NOUN
dpc-3629	206	2	:	:	PUNCT
dpc-3629	206	3	pmc9779021	pmc9779021	NOUN
dpc-3629	206	4	.	.	PUNCT
dpc-3629	207	1	10	10	NUM
dpc-3629	207	2	.	.	PUNCT
dpc-3629	208	1	wilkin	wilkin	PROPN
dpc-3629	208	2	j	j	PROPN
dpc-3629	208	3	,	,	PUNCT
dpc-3629	208	4	dahl	dahl	PROPN
dpc-3629	208	5	m	m	PROPN
dpc-3629	208	6	,	,	PUNCT
dpc-3629	208	7	detmar	detmar	PROPN
dpc-3629	208	8	m	m	PROPN
dpc-3629	208	9	,	,	PUNCT
dpc-3629	208	10	et	et	PROPN
dpc-3629	208	11	al	al	PROPN
dpc-3629	208	12	.	.	PROPN
dpc-3629	209	1	national	national	PROPN
dpc-3629	209	2	rosacea	rosacea	PROPN
dpc-3629	209	3	society	society	PROPN
dpc-3629	209	4	expert	expert	PROPN
dpc-3629	209	5	committee	committee	PROPN
dpc-3629	209	6	.	.	PUNCT
dpc-3629	210	1	standard	standard	ADJ
dpc-3629	210	2	grading	grade	VERB
dpc-3629	210	3	system	system	NOUN
dpc-3629	210	4	for	for	ADP
dpc-3629	210	5	rosacea	rosacea	NOUN
dpc-3629	210	6	:	:	PUNCT
dpc-3629	210	7	report	report	NOUN
dpc-3629	210	8	of	of	ADP
dpc-3629	210	9	the	the	DET
dpc-3629	210	10	national	national	PROPN
dpc-3629	210	11	rosacea	rosacea	PROPN
dpc-3629	210	12	society	society	PROPN
dpc-3629	210	13	expert	expert	PROPN
dpc-3629	210	14	committee	committee	PROPN
dpc-3629	210	15	on	on	ADP
dpc-3629	210	16	the	the	DET
dpc-3629	210	17	classification	classification	NOUN
dpc-3629	210	18	and	and	CCONJ
dpc-3629	210	19	staging	staging	NOUN
dpc-3629	210	20	of	of	ADP
dpc-3629	210	21	rosacea	rosacea	NOUN
dpc-3629	210	22	.	.	PUNCT
dpc-3629	211	1	j	j	PROPN
dpc-3629	211	2	am	be	AUX
dpc-3629	211	3	acad	acad	ADJ
dpc-3629	211	4	dermatol	dermatol	NOUN
dpc-3629	211	5	.	.	PUNCT
dpc-3629	212	1	2004;50(6):907	2004;50(6):907	PROPN
dpc-3629	212	2	-	-	SYM
dpc-3629	212	3	912	912	NUM
dpc-3629	212	4	.	.	PUNCT
dpc-3629	213	1	doi	doi	NOUN
dpc-3629	213	2	:	:	PUNCT
dpc-3629	213	3	10.1016	10.1016	NUM
dpc-3629	213	4	/	/	SYM
dpc-3629	213	5	j.jaad.2004.01.048	j.jaad.2004.01.048	PROPN
dpc-3629	213	6	.	.	PUNCT
dpc-3629	214	1	pmid	pmid	NOUN
dpc-3629	214	2	:	:	PUNCT
dpc-3629	214	3	15153893	15153893	NUM
dpc-3629	214	4	.	.	PUNCT
dpc-3629	215	1	11	11	NUM
dpc-3629	215	2	.	.	X
dpc-3629	215	3	schaller	schaller	PROPN
dpc-3629	215	4	m	m	PROPN
dpc-3629	215	5	,	,	PUNCT
dpc-3629	215	6	kemény	kemény	PROPN
dpc-3629	215	7	l	l	PROPN
dpc-3629	215	8	,	,	PUNCT
dpc-3629	215	9	havlickova	havlickova	X
dpc-3629	216	1	b	b	X
dpc-3629	216	2	,	,	PUNCT
dpc-3629	216	3	et	et	PROPN
dpc-3629	216	4	al	al	PROPN
dpc-3629	216	5	.	.	PUNCT
dpc-3629	217	1	a	a	DET
dpc-3629	217	2	randomized	randomized	ADJ
dpc-3629	217	3	phase	phase	NOUN
dpc-3629	217	4	3b/4	3b/4	NUM
dpc-3629	217	5	study	study	NOUN
dpc-3629	217	6	to	to	PART
dpc-3629	217	7	evaluate	evaluate	VERB
dpc-3629	217	8	concomitant	concomitant	ADJ
dpc-3629	217	9	use	use	NOUN
dpc-3629	217	10	of	of	ADP
dpc-3629	217	11	topical	topical	ADJ
dpc-3629	217	12	ivermectin	ivermectin	NOUN
dpc-3629	217	13	1	1	NUM
dpc-3629	217	14	%	%	NOUN
dpc-3629	217	15	cream	cream	NOUN
dpc-3629	217	16	and	and	CCONJ
dpc-3629	217	17	doxycycline	doxycycline	NOUN
dpc-3629	217	18	40	40	NUM
dpc-3629	217	19	-	-	PUNCT
dpc-3629	217	20	mg	mg	NOUN
dpc-3629	217	21	modified	modify	VERB
dpc-3629	217	22	-	-	PUNCT
dpc-3629	217	23	release	release	NOUN
dpc-3629	217	24	capsules	capsule	NOUN
dpc-3629	217	25	,	,	PUNCT
dpc-3629	217	26	versus	versus	ADP
dpc-3629	217	27	topical	topical	ADJ
dpc-3629	217	28	ivermectin	ivermectin	NOUN
dpc-3629	217	29	1	1	NUM
dpc-3629	217	30	%	%	NOUN
dpc-3629	217	31	cream	cream	NOUN
dpc-3629	217	32	and	and	CCONJ
dpc-3629	217	33	placebo	placebo	NOUN
dpc-3629	217	34	in	in	ADP
dpc-3629	217	35	the	the	DET
dpc-3629	217	36	treatment	treatment	NOUN
dpc-3629	217	37	of	of	ADP
dpc-3629	217	38	severe	severe	ADJ
dpc-3629	217	39	rosacea	rosacea	NOUN
dpc-3629	217	40	.	.	PUNCT
dpc-3629	218	1	j	j	PROPN
dpc-3629	218	2	am	be	AUX
dpc-3629	218	3	acad	acad	ADJ
dpc-3629	218	4	dermatol	dermatol	NOUN
dpc-3629	218	5	.	.	PUNCT
dpc-3629	219	1	2020;82(2):336	2020;82(2):336	NUM
dpc-3629	219	2	-	-	PUNCT
dpc-3629	219	3	343	343	NUM
dpc-3629	219	4	.	.	PUNCT
dpc-3629	220	1	doi	doi	NOUN
dpc-3629	220	2	:	:	PUNCT
dpc-3629	220	3	10.1016	10.1016	NUM
dpc-3629	220	4	/	/	SYM
dpc-3629	220	5	j.jaad.2019.05.063	j.jaad.2019.05.063	NOUN
dpc-3629	220	6	.	.	PUNCT
dpc-3629	221	1	pmid	pmid	NOUN
dpc-3629	221	2	:	:	PUNCT
dpc-3629	221	3	31150711	31150711	NUM
dpc-3629	221	4	.	.	PUNCT
dpc-3629	222	1	12	12	NUM
dpc-3629	222	2	.	.	PUNCT
dpc-3629	223	1	iskandarli	iskandarli	PROPN
dpc-3629	223	2	m	m	PROPN
dpc-3629	223	3	,	,	PUNCT
dpc-3629	223	4	ertam	ertam	PROPN
dpc-3629	223	5	i̇	i̇	PROPN
dpc-3629	223	6	,	,	PUNCT
dpc-3629	223	7	ünal	ünal	ADJ
dpc-3629	223	8	i̇.	i̇.	NOUN
dpc-3629	223	9	impact	impact	NOUN
dpc-3629	223	10	of	of	ADP
dpc-3629	223	11	intense	intense	ADJ
dpc-3629	223	12	pulse	pulse	NOUN
dpc-3629	223	13	light	light	NOUN
dpc-3629	223	14	on	on	ADP
dpc-3629	223	15	quality	quality	NOUN
dpc-3629	223	16	of	of	ADP
dpc-3629	223	17	life	life	NOUN
dpc-3629	223	18	in	in	ADP
dpc-3629	223	19	patients	patient	NOUN
dpc-3629	223	20	with	with	ADP
dpc-3629	223	21	erythematotelangiectatic	erythematotelangiectatic	PROPN
dpc-3629	223	22	rosacea	rosacea	NOUN
dpc-3629	223	23	.	.	PUNCT
dpc-3629	224	1	at	at	ADP
dpc-3629	224	2	the	the	DET
dpc-3629	224	3	6th	6th	ADJ
dpc-3629	224	4	week	week	NOUN
dpc-3629	224	5	,	,	PUNCT
dpc-3629	224	6	and	and	CCONJ
dpc-3629	224	7	62.9	62.9	NUM
dpc-3629	224	8	%	%	NOUN
dpc-3629	224	9	at	at	ADP
dpc-3629	224	10	the	the	DET
dpc-3629	224	11	end	end	NOUN
dpc-3629	224	12	of	of	ADP
dpc-3629	224	13	the	the	DET
dpc-3629	224	14	12th	12th	ADJ
dpc-3629	224	15	week	week	NOUN
dpc-3629	224	16	.	.	PUNCT
dpc-3629	225	1	overall	overall	ADJ
dpc-3629	225	2	treatment	treatment	NOUN
dpc-3629	225	3	success	success	NOUN
dpc-3629	225	4	rate	rate	NOUN
dpc-3629	225	5	in	in	ADP
dpc-3629	225	6	rosacea	rosacea	NOUN
dpc-3629	225	7	has	have	AUX
dpc-3629	225	8	been	be	AUX
dpc-3629	225	9	reported	report	VERB
dpc-3629	225	10	to	to	PART
dpc-3629	225	11	range	range	VERB
dpc-3629	225	12	from	from	ADP
dpc-3629	225	13	31.9	31.9	NUM
dpc-3629	225	14	to	to	PART
dpc-3629	225	15	80.3	80.3	NUM
dpc-3629	225	16	%	%	NOUN
dpc-3629	225	17	,	,	PUNCT
dpc-3629	225	18	similar	similar	ADJ
dpc-3629	225	19	to	to	ADP
dpc-3629	225	20	our	our	PRON
dpc-3629	225	21	study	study	NOUN
dpc-3629	225	22	result	result	VERB
dpc-3629	225	23	with	with	ADP
dpc-3629	225	24	a	a	DET
dpc-3629	225	25	quite	quite	ADV
dpc-3629	225	26	acceptable	acceptable	ADJ
dpc-3629	225	27	success	success	NOUN
dpc-3629	225	28	rate	rate	NOUN
dpc-3629	225	29	at	at	ADP
dpc-3629	225	30	the	the	DET
dpc-3629	225	31	12th	12th	ADJ
dpc-3629	225	32	week	week	NOUN
dpc-3629	226	1	[	[	X
dpc-3629	226	2	19	19	NUM
dpc-3629	226	3	-	-	SYM
dpc-3629	226	4	22	22	NUM
dpc-3629	226	5	]	]	PUNCT
dpc-3629	226	6	.	.	PUNCT
dpc-3629	227	1	in	in	ADP
dpc-3629	227	2	patients	patient	NOUN
dpc-3629	227	3	who	who	PRON
dpc-3629	227	4	recovered	recover	VERB
dpc-3629	227	5	,	,	PUNCT
dpc-3629	227	6	treatment	treatment	NOUN
dpc-3629	227	7	was	be	AUX
dpc-3629	227	8	discontinued	discontinue	VERB
dpc-3629	227	9	at	at	ADP
dpc-3629	227	10	week	week	NOUN
dpc-3629	227	11	12	12	NUM
dpc-3629	227	12	,	,	PUNCT
dpc-3629	227	13	while	while	SCONJ
dpc-3629	227	14	in	in	ADP
dpc-3629	227	15	patients	patient	NOUN
dpc-3629	227	16	who	who	PRON
dpc-3629	227	17	did	do	AUX
dpc-3629	227	18	not	not	PART
dpc-3629	227	19	improve	improve	VERB
dpc-3629	227	20	,	,	PUNCT
dpc-3629	227	21	the	the	DET
dpc-3629	227	22	duration	duration	NOUN
dpc-3629	227	23	of	of	ADP
dpc-3629	227	24	treatment	treatment	NOUN
dpc-3629	227	25	was	be	AUX
dpc-3629	227	26	extended	extend	VERB
dpc-3629	227	27	for	for	ADP
dpc-3629	227	28	another	another	DET
dpc-3629	227	29	4	4	NUM
dpc-3629	227	30	weeks	week	NOUN
dpc-3629	227	31	or	or	CCONJ
dpc-3629	227	32	alternative	alternative	ADJ
dpc-3629	227	33	treatment	treatment	NOUN
dpc-3629	227	34	was	be	AUX
dpc-3629	227	35	started	start	VERB
dpc-3629	227	36	.	.	PUNCT
dpc-3629	228	1	there	there	PRON
dpc-3629	228	2	is	be	VERB
dpc-3629	228	3	no	no	DET
dpc-3629	228	4	consensus	consensus	NOUN
dpc-3629	228	5	in	in	ADP
dpc-3629	228	6	the	the	DET
dpc-3629	228	7	literature	literature	NOUN
dpc-3629	228	8	for	for	ADP
dpc-3629	228	9	the	the	DET
dpc-3629	228	10	duration	duration	NOUN
dpc-3629	228	11	and	and	CCONJ
dpc-3629	228	12	certain	certain	ADJ
dpc-3629	228	13	algorithm	algorithm	NOUN
dpc-3629	228	14	of	of	ADP
dpc-3629	228	15	treatment	treatment	NOUN
dpc-3629	228	16	.	.	PUNCT
dpc-3629	229	1	furthermore	furthermore	ADV
dpc-3629	229	2	,	,	PUNCT
dpc-3629	229	3	the	the	DET
dpc-3629	229	4	expected	expect	VERB
dpc-3629	229	5	duration	duration	NOUN
dpc-3629	229	6	of	of	ADP
dpc-3629	229	7	maintenance	maintenance	NOUN
dpc-3629	229	8	treatment	treatment	NOUN
dpc-3629	229	9	still	still	ADV
dpc-3629	229	10	remains	remain	VERB
dpc-3629	229	11	unclear	unclear	ADJ
dpc-3629	229	12	.	.	PUNCT
dpc-3629	230	1	regardless	regardless	ADV
dpc-3629	230	2	of	of	ADP
dpc-3629	230	3	topical	topical	ADJ
dpc-3629	230	4	or	or	CCONJ
dpc-3629	230	5	systemic	systemic	ADJ
dpc-3629	230	6	treatment	treatment	NOUN
dpc-3629	230	7	,	,	PUNCT
dpc-3629	230	8	adverse	adverse	ADJ
dpc-3629	230	9	events	event	NOUN
dpc-3629	230	10	are	be	AUX
dpc-3629	230	11	inevitable	inevitable	ADJ
dpc-3629	230	12	.	.	PUNCT
dpc-3629	231	1	it	it	PRON
dpc-3629	231	2	has	have	AUX
dpc-3629	231	3	been	be	AUX
dpc-3629	231	4	reported	report	VERB
dpc-3629	231	5	that	that	SCONJ
dpc-3629	231	6	the	the	DET
dpc-3629	231	7	rates	rate	NOUN
dpc-3629	231	8	of	of	ADP
dpc-3629	231	9	adverse	adverse	ADJ
dpc-3629	231	10	events	event	NOUN
dpc-3629	231	11	are	be	AUX
dpc-3629	231	12	observed	observe	VERB
dpc-3629	231	13	higher	higher	ADV
dpc-3629	231	14	in	in	ADP
dpc-3629	231	15	combined	combine	VERB
dpc-3629	231	16	treatments	treatment	NOUN
dpc-3629	231	17	than	than	ADP
dpc-3629	231	18	topical	topical	ADJ
dpc-3629	231	19	treatments	treatment	NOUN
dpc-3629	231	20	alone	alone	ADV
dpc-3629	231	21	[	[	X
dpc-3629	231	22	17,19,23	17,19,23	NUM
dpc-3629	231	23	]	]	PUNCT
dpc-3629	231	24	.	.	PUNCT
dpc-3629	232	1	brimonidine	brimonidine	PROPN
dpc-3629	232	2	tartrate	tartrate	NOUN
dpc-3629	232	3	gel	gel	NOUN
dpc-3629	232	4	is	be	AUX
dpc-3629	232	5	the	the	DET
dpc-3629	232	6	first	first	ADJ
dpc-3629	232	7	medication	medication	NOUN
dpc-3629	232	8	approved	approve	VERB
dpc-3629	232	9	by	by	ADP
dpc-3629	232	10	the	the	DET
dpc-3629	232	11	fda	fda	PROPN
dpc-3629	232	12	for	for	ADP
dpc-3629	232	13	the	the	DET
dpc-3629	232	14	topical	topical	ADJ
dpc-3629	232	15	treatment	treatment	NOUN
dpc-3629	232	16	of	of	ADP
dpc-3629	232	17	persistent	persistent	ADJ
dpc-3629	232	18	facial	facial	ADJ
dpc-3629	232	19	erythema	erythema	NOUN
dpc-3629	232	20	associated	associate	VERB
dpc-3629	232	21	with	with	ADP
dpc-3629	232	22	rosacea	rosacea	NOUN
dpc-3629	232	23	,	,	PUNCT
dpc-3629	232	24	and	and	CCONJ
dpc-3629	232	25	has	have	AUX
dpc-3629	232	26	been	be	AUX
dpc-3629	232	27	using	use	VERB
dpc-3629	232	28	in	in	ADP
dpc-3629	232	29	the	the	DET
dpc-3629	232	30	first	first	ADJ
dpc-3629	232	31	line	line	NOUN
dpc-3629	232	32	treatment	treatment	NOUN
dpc-3629	232	33	of	of	ADP
dpc-3629	232	34	etr	etr	PROPN
dpc-3629	232	35	for	for	ADP
dpc-3629	232	36	years	year	NOUN
dpc-3629	233	1	[	[	X
dpc-3629	233	2	5,25	5,25	NUM
dpc-3629	233	3	]	]	X
dpc-3629	233	4	.	.	PUNCT
dpc-3629	234	1	the	the	DET
dpc-3629	234	2	rates	rate	NOUN
dpc-3629	234	3	of	of	ADP
dpc-3629	234	4	adverse	adverse	ADJ
dpc-3629	234	5	events	event	NOUN
dpc-3629	234	6	have	have	AUX
dpc-3629	234	7	been	be	AUX
dpc-3629	234	8	reported	report	VERB
dpc-3629	234	9	to	to	PART
dpc-3629	234	10	range	range	VERB
dpc-3629	234	11	from	from	ADP
dpc-3629	234	12	6	6	NUM
dpc-3629	234	13	to	to	PART
dpc-3629	234	14	14	14	NUM
dpc-3629	234	15	%	%	NOUN
dpc-3629	234	16	for	for	ADP
dpc-3629	234	17	various	various	ADJ
dpc-3629	234	18	concentrations	concentration	NOUN
dpc-3629	234	19	of	of	ADP
dpc-3629	234	20	brimonidine	brimonidine	NOUN
dpc-3629	234	21	tartrate	tartrate	VERB
dpc-3629	234	22	[	[	X
dpc-3629	234	23	17	17	NUM
dpc-3629	234	24	]	]	PUNCT
dpc-3629	234	25	.	.	PUNCT
dpc-3629	235	1	when	when	SCONJ
dpc-3629	235	2	its	its	PRON
dpc-3629	235	3	use	use	NOUN
dpc-3629	235	4	is	be	AUX
dpc-3629	235	5	extended	extend	VERB
dpc-3629	235	6	,	,	PUNCT
dpc-3629	235	7	these	these	DET
dpc-3629	235	8	rates	rate	NOUN
dpc-3629	235	9	increase	increase	VERB
dpc-3629	235	10	to	to	ADP
dpc-3629	235	11	11	11	NUM
dpc-3629	235	12	-	-	SYM
dpc-3629	235	13	19	19	NUM
dpc-3629	235	14	%	%	NOUN
dpc-3629	235	15	[	[	X
dpc-3629	235	16	17	17	NUM
dpc-3629	235	17	]	]	PUNCT
dpc-3629	235	18	.	.	PUNCT
dpc-3629	236	1	the	the	DET
dpc-3629	236	2	most	most	ADV
dpc-3629	236	3	commonly	commonly	ADV
dpc-3629	236	4	reported	report	VERB
dpc-3629	236	5	side	side	NOUN
dpc-3629	236	6	effects	effect	NOUN
dpc-3629	236	7	are	be	AUX
dpc-3629	236	8	irritation	irritation	NOUN
dpc-3629	236	9	,	,	PUNCT
dpc-3629	236	10	flushing	flush	VERB
dpc-3629	236	11	,	,	PUNCT
dpc-3629	236	12	worsened	worsen	VERB
dpc-3629	236	13	erythema	erythema	ADV
dpc-3629	236	14	,	,	PUNCT
dpc-3629	236	15	burning	burn	VERB
dpc-3629	236	16	sensation	sensation	NOUN
dpc-3629	236	17	,	,	PUNCT
dpc-3629	236	18	and	and	CCONJ
dpc-3629	236	19	pruritus	pruritus	PROPN
dpc-3629	236	20	[	[	X
dpc-3629	236	21	17	17	NUM
dpc-3629	236	22	]	]	PUNCT
dpc-3629	236	23	.	.	PUNCT
dpc-3629	237	1	many	many	ADJ
dpc-3629	237	2	case	case	NOUN
dpc-3629	237	3	reports	report	NOUN
dpc-3629	237	4	of	of	ADP
dpc-3629	237	5	contact	contact	NOUN
dpc-3629	237	6	dermatitis	dermatitis	NOUN
dpc-3629	237	7	and	and	CCONJ
dpc-3629	237	8	rebound	rebound	VERB
dpc-3629	237	9	erythema	erythema	ADV
dpc-3629	237	10	have	have	AUX
dpc-3629	237	11	been	be	AUX
dpc-3629	237	12	documented	document	VERB
dpc-3629	237	13	with	with	ADP
dpc-3629	237	14	regard	regard	NOUN
dpc-3629	237	15	to	to	ADP
dpc-3629	237	16	brimonidine	brimonidine	NOUN
dpc-3629	237	17	use	use	NOUN
dpc-3629	237	18	[	[	X
dpc-3629	237	19	17,26	17,26	NUM
dpc-3629	237	20	-	-	SYM
dpc-3629	237	21	28	28	NUM
dpc-3629	237	22	]	]	PUNCT
dpc-3629	237	23	.	.	PUNCT
dpc-3629	238	1	oxymetazoline	oxymetazoline	PROPN
dpc-3629	238	2	side	side	NOUN
dpc-3629	238	3	effects	effect	NOUN
dpc-3629	238	4	are	be	AUX
dpc-3629	238	5	reported	report	VERB
dpc-3629	238	6	as	as	ADP
dpc-3629	238	7	dryness	dryness	NOUN
dpc-3629	238	8	(	(	PUNCT
dpc-3629	238	9	7	7	NUM
dpc-3629	238	10	%	%	NOUN
dpc-3629	238	11	)	)	PUNCT
dpc-3629	238	12	,	,	PUNCT
dpc-3629	238	13	tingling	tingle	VERB
dpc-3629	238	14	sensation	sensation	NOUN
dpc-3629	238	15	(	(	PUNCT
dpc-3629	238	16	3	3	NUM
dpc-3629	238	17	%	%	NOUN
dpc-3629	238	18	)	)	PUNCT
dpc-3629	238	19	,	,	PUNCT
dpc-3629	238	20	and	and	CCONJ
dpc-3629	238	21	papule	papule	NOUN
dpc-3629	238	22	formation	formation	NOUN
dpc-3629	238	23	(	(	PUNCT
dpc-3629	238	24	3	3	NUM
dpc-3629	238	25	%	%	NOUN
dpc-3629	238	26	)	)	PUNCT
dpc-3629	239	1	[	[	X
dpc-3629	239	2	23	23	NUM
dpc-3629	239	3	]	]	PUNCT
dpc-3629	239	4	.	.	PUNCT
dpc-3629	240	1	metronidazole	metronidazole	PROPN
dpc-3629	240	2	is	be	AUX
dpc-3629	240	3	generally	generally	ADV
dpc-3629	240	4	well	well	ADV
dpc-3629	240	5	tolerated	tolerate	VERB
dpc-3629	240	6	.	.	PUNCT
dpc-3629	241	1	side	side	NOUN
dpc-3629	241	2	effects	effect	NOUN
dpc-3629	241	3	such	such	ADJ
dpc-3629	241	4	as	as	ADP
dpc-3629	241	5	burning	burn	VERB
dpc-3629	241	6	and	and	CCONJ
dpc-3629	241	7	stinging	stinging	ADJ
dpc-3629	241	8	,	,	PUNCT
dpc-3629	241	9	dryness	dryness	NOUN
dpc-3629	241	10	,	,	PUNCT
dpc-3629	241	11	redness	redness	NOUN
dpc-3629	241	12	,	,	PUNCT
dpc-3629	241	13	pruritus	pruritus	NOUN
dpc-3629	241	14	,	,	PUNCT
dpc-3629	241	15	and	and	CCONJ
dpc-3629	241	16	worsening	worsen	VERB
dpc-3629	241	17	of	of	ADP
dpc-3629	241	18	erythema	erythema	ADJ
dpc-3629	241	19	were	be	AUX
dpc-3629	241	20	reported	report	VERB
dpc-3629	241	21	to	to	PART
dpc-3629	241	22	be	be	AUX
dpc-3629	241	23	seen	see	VERB
dpc-3629	241	24	less	less	ADJ
dpc-3629	241	25	than	than	ADP
dpc-3629	241	26	5	5	NUM
dpc-3629	241	27	%	%	NOUN
dpc-3629	241	28	of	of	ADP
dpc-3629	241	29	the	the	DET
dpc-3629	241	30	patients	patient	NOUN
dpc-3629	241	31	[	[	X
dpc-3629	241	32	2	2	NUM
dpc-3629	241	33	]	]	PUNCT
dpc-3629	241	34	.	.	PUNCT
dpc-3629	242	1	the	the	DET
dpc-3629	242	2	common	common	ADJ
dpc-3629	242	3	side	side	NOUN
dpc-3629	242	4	effects	effect	NOUN
dpc-3629	242	5	reported	report	VERB
dpc-3629	242	6	during	during	ADP
dpc-3629	242	7	the	the	DET
dpc-3629	242	8	treatment	treatment	NOUN
dpc-3629	242	9	of	of	ADP
dpc-3629	242	10	dapsone	dapsone	NOUN
dpc-3629	242	11	5	5	NUM
dpc-3629	242	12	%	%	NOUN
dpc-3629	242	13	gel	gel	NOUN
dpc-3629	242	14	in	in	ADP
dpc-3629	242	15	acne	acne	NOUN
dpc-3629	242	16	are	be	AUX
dpc-3629	242	17	dryness	dryness	ADJ
dpc-3629	242	18	,	,	PUNCT
dpc-3629	242	19	erythema	erythema	ADJ
dpc-3629	242	20	,	,	PUNCT
dpc-3629	242	21	and	and	CCONJ
dpc-3629	242	22	burning	burn	VERB
dpc-3629	242	23	sensation	sensation	NOUN
dpc-3629	242	24	,	,	PUNCT
dpc-3629	242	25	along	along	ADP
dpc-3629	242	26	with	with	ADP
dpc-3629	242	27	systemic	systemic	ADJ
dpc-3629	242	28	symptoms	symptom	NOUN
dpc-3629	242	29	such	such	ADJ
dpc-3629	242	30	as	as	ADP
dpc-3629	242	31	rhinitis	rhinitis	NOUN
dpc-3629	242	32	,	,	PUNCT
dpc-3629	242	33	pharyngitis	pharyngitis	ADJ
dpc-3629	242	34	,	,	PUNCT
dpc-3629	242	35	upper	upper	ADJ
dpc-3629	242	36	respiratory	respiratory	ADJ
dpc-3629	242	37	tract	tract	NOUN
dpc-3629	242	38	infection	infection	NOUN
dpc-3629	242	39	,	,	PUNCT
dpc-3629	242	40	and	and	CCONJ
dpc-3629	242	41	headache	headache	NOUN
dpc-3629	242	42	 	 	SPACE
dpc-3629	243	1	[	[	X
dpc-3629	243	2	24	24	NUM
dpc-3629	243	3	]	]	PUNCT
dpc-3629	243	4	.	.	PUNCT
dpc-3629	244	1	in	in	ADP
dpc-3629	244	2	our	our	PRON
dpc-3629	244	3	study	study	NOUN
dpc-3629	244	4	,	,	PUNCT
dpc-3629	244	5	adverse	adverse	ADJ
dpc-3629	244	6	events	event	NOUN
dpc-3629	244	7	were	be	AUX
dpc-3629	244	8	mild	mild	ADJ
dpc-3629	244	9	,	,	PUNCT
dpc-3629	244	10	transient	transient	NOUN
dpc-3629	244	11	,	,	PUNCT
dpc-3629	244	12	and	and	CCONJ
dpc-3629	244	13	skin	skin	NOUN
dpc-3629	244	14	-	-	PUNCT
dpc-3629	244	15	limited	limit	VERB
dpc-3629	244	16	,	,	PUNCT
dpc-3629	244	17	seen	see	VERB
dpc-3629	244	18	with	with	ADP
dpc-3629	244	19	a	a	DET
dpc-3629	244	20	lower	low	ADJ
dpc-3629	244	21	rate	rate	NOUN
dpc-3629	244	22	.	.	PUNCT
dpc-3629	245	1	there	there	PRON
dpc-3629	245	2	was	be	VERB
dpc-3629	245	3	no	no	DET
dpc-3629	245	4	worsening	worsening	NOUN
dpc-3629	245	5	of	of	ADP
dpc-3629	245	6	erythema	erythema	NOUN
dpc-3629	245	7	during	during	ADP
dpc-3629	245	8	treatment	treatment	NOUN
dpc-3629	245	9	and	and	CCONJ
dpc-3629	245	10	no	no	DET
dpc-3629	245	11	rebound	rebound	NOUN
dpc-3629	245	12	erythema	erythema	NOUN
dpc-3629	245	13	was	be	AUX
dpc-3629	245	14	observed	observe	VERB
dpc-3629	245	15	after	after	ADP
dpc-3629	245	16	treatment	treatment	NOUN
dpc-3629	245	17	in	in	ADP
dpc-3629	245	18	any	any	PRON
dpc-3629	245	19	of	of	ADP
dpc-3629	245	20	our	our	PRON
dpc-3629	245	21	patients	patient	NOUN
dpc-3629	245	22	.	.	PUNCT
dpc-3629	246	1	dapsone	dapsone	NOUN
dpc-3629	246	2	5	5	NUM
dpc-3629	246	3	%	%	NOUN
dpc-3629	246	4	gel	gel	NOUN
dpc-3629	246	5	has	have	AUX
dpc-3629	246	6	only	only	ADV
dpc-3629	246	7	been	be	AUX
dpc-3629	246	8	used	use	VERB
dpc-3629	246	9	in	in	ADP
dpc-3629	246	10	the	the	DET
dpc-3629	246	11	papulopustular	papulopustular	ADJ
dpc-3629	246	12	subtype	subtype	NOUN
dpc-3629	246	13	of	of	ADP
dpc-3629	246	14	rosacea	rosacea	NOUN
dpc-3629	246	15	to	to	ADP
dpc-3629	246	16	date	date	NOUN
dpc-3629	246	17	,	,	PUNCT
dpc-3629	246	18	and	and	CCONJ
dpc-3629	246	19	its	its	PRON
dpc-3629	246	20	efficacy	efficacy	NOUN
dpc-3629	246	21	has	have	AUX
dpc-3629	246	22	been	be	AUX
dpc-3629	246	23	reported	report	VERB
dpc-3629	246	24	to	to	PART
dpc-3629	246	25	be	be	AUX
dpc-3629	246	26	as	as	ADV
dpc-3629	246	27	much	much	ADJ
dpc-3629	246	28	as	as	ADP
dpc-3629	246	29	metronidazole	metronidazole	NOUN
dpc-3629	246	30	0.75	0.75	NUM
dpc-3629	246	31	%	%	NOUN
dpc-3629	246	32	gel	gel	NOUN
dpc-3629	247	1	[	[	X
dpc-3629	247	2	29	29	NUM
dpc-3629	247	3	]	]	PUNCT
dpc-3629	247	4	.	.	PUNCT
dpc-3629	248	1	as	as	ADV
dpc-3629	248	2	far	far	ADV
dpc-3629	248	3	as	as	SCONJ
dpc-3629	248	4	we	we	PRON
dpc-3629	248	5	know	know	VERB
dpc-3629	248	6	,	,	PUNCT
dpc-3629	248	7	this	this	PRON
dpc-3629	248	8	is	be	AUX
dpc-3629	248	9	the	the	DET
dpc-3629	248	10	first	first	ADJ
dpc-3629	248	11	study	study	NOUN
dpc-3629	248	12	in	in	ADP
dpc-3629	248	13	which	which	PRON
dpc-3629	248	14	dapsone	dapsone	NOUN
dpc-3629	248	15	5	5	NUM
dpc-3629	248	16	%	%	NOUN
dpc-3629	248	17	gel	gel	NOUN
dpc-3629	248	18	was	be	AUX
dpc-3629	248	19	used	use	VERB
dpc-3629	248	20	in	in	ADP
dpc-3629	248	21	the	the	DET
dpc-3629	248	22	treatment	treatment	NOUN
dpc-3629	248	23	of	of	ADP
dpc-3629	248	24	etr	etr	PROPN
dpc-3629	248	25	.	.	PUNCT
dpc-3629	249	1	the	the	DET
dpc-3629	249	2	study	study	NOUN
dpc-3629	249	3	has	have	VERB
dpc-3629	249	4	also	also	ADV
dpc-3629	249	5	some	some	DET
dpc-3629	249	6	limitations	limitation	NOUN
dpc-3629	249	7	.	.	PUNCT
dpc-3629	250	1	it	it	PRON
dpc-3629	250	2	was	be	AUX
dpc-3629	250	3	conducted	conduct	VERB
dpc-3629	250	4	in	in	ADP
dpc-3629	250	5	a	a	DET
dpc-3629	250	6	single	single	ADJ
dpc-3629	250	7	center	center	NOUN
dpc-3629	250	8	.	.	PUNCT
dpc-3629	251	1	the	the	DET
dpc-3629	251	2	study	study	NOUN
dpc-3629	251	3	population	population	NOUN
dpc-3629	251	4	was	be	AUX
dpc-3629	251	5	homogenous	homogenous	ADJ
dpc-3629	251	6	,	,	PUNCT
dpc-3629	251	7	limiting	limit	VERB
dpc-3629	251	8	the	the	DET
dpc-3629	251	9	external	external	ADJ
dpc-3629	251	10	validity	validity	NOUN
dpc-3629	251	11	of	of	ADP
dpc-3629	251	12	the	the	DET
dpc-3629	251	13	results	result	NOUN
dpc-3629	251	14	.	.	PUNCT
dpc-3629	252	1	the	the	DET
dpc-3629	252	2	sample	sample	NOUN
dpc-3629	252	3	size	size	NOUN
dpc-3629	252	4	was	be	AUX
dpc-3629	252	5	small	small	ADJ
dpc-3629	252	6	,	,	PUNCT
dpc-3629	252	7	the	the	DET
dpc-3629	252	8	follow	follow	VERB
dpc-3629	252	9	-	-	PUNCT
dpc-3629	252	10	up	up	NOUN
dpc-3629	252	11	period	period	NOUN
dpc-3629	252	12	was	be	AUX
dpc-3629	252	13	relatively	relatively	ADV
dpc-3629	252	14	short	short	ADJ
dpc-3629	252	15	,	,	PUNCT
dpc-3629	252	16	and	and	CCONJ
dpc-3629	252	17	there	there	PRON
dpc-3629	252	18	was	be	VERB
dpc-3629	252	19	no	no	DET
dpc-3629	252	20	control	control	NOUN
dpc-3629	252	21	group	group	NOUN
dpc-3629	252	22	.	.	PUNCT
dpc-3629	253	1	original	original	ADJ
dpc-3629	253	2	article	article	NOUN
dpc-3629	253	3	|	|	ADV
dpc-3629	253	4	dermatol	dermatol	ADJ
dpc-3629	253	5	pract	pract	NOUN
dpc-3629	253	6	concept	concept	NOUN
dpc-3629	253	7	.	.	PUNCT
dpc-3629	254	1	2024;14(1):e2024034	2024;14(1):e2024034	NUM
dpc-3629	254	2	7	7	NUM
dpc-3629	254	3	21	21	NUM
dpc-3629	254	4	.	.	PUNCT
dpc-3629	255	1	sanchez	sanchez	PROPN
dpc-3629	255	2	j	j	PROPN
dpc-3629	255	3	,	,	PUNCT
dpc-3629	255	4	somolinos	somolinos	PROPN
dpc-3629	255	5	al	al	PROPN
dpc-3629	255	6	,	,	PUNCT
dpc-3629	255	7	almodóvar	almodóvar	NOUN
dpc-3629	255	8	pi	pi	NOUN
dpc-3629	255	9	,	,	PUNCT
dpc-3629	255	10	et	et	PROPN
dpc-3629	255	11	al	al	PROPN
dpc-3629	255	12	.	.	PUNCT
dpc-3629	256	1	a	a	DET
dpc-3629	256	2	randomized	randomized	ADJ
dpc-3629	256	3	,	,	PUNCT
dpc-3629	256	4	double	double	ADJ
dpc-3629	256	5	-	-	PUNCT
dpc-3629	256	6	blind	blind	ADJ
dpc-3629	256	7	,	,	PUNCT
dpc-3629	256	8	placebo	placebo	NOUN
dpc-3629	256	9	-	-	PUNCT
dpc-3629	256	10	controlled	control	VERB
dpc-3629	256	11	trial	trial	NOUN
dpc-3629	256	12	of	of	ADP
dpc-3629	256	13	the	the	DET
dpc-3629	256	14	combined	combine	VERB
dpc-3629	256	15	effect	effect	NOUN
dpc-3629	256	16	of	of	ADP
dpc-3629	256	17	doxycycline	doxycycline	NOUN
dpc-3629	256	18	hyclate	hyclate	PROPN
dpc-3629	256	19	20	20	NUM
dpc-3629	256	20	-	-	PUNCT
dpc-3629	256	21	mg	mg	NOUN
dpc-3629	256	22	tablets	tablet	NOUN
dpc-3629	256	23	and	and	CCONJ
dpc-3629	256	24	metronidazole	metronidazole	NOUN
dpc-3629	256	25	0.75	0.75	NUM
dpc-3629	256	26	%	%	NOUN
dpc-3629	256	27	topical	topical	ADJ
dpc-3629	256	28	lotion	lotion	NOUN
dpc-3629	256	29	in	in	ADP
dpc-3629	256	30	the	the	DET
dpc-3629	256	31	treatment	treatment	NOUN
dpc-3629	256	32	of	of	ADP
dpc-3629	256	33	rosacea	rosacea	NOUN
dpc-3629	256	34	.	.	PUNCT
dpc-3629	257	1	j	j	PROPN
dpc-3629	257	2	am	be	AUX
dpc-3629	257	3	acad	acad	ADJ
dpc-3629	257	4	dermatol	dermatol	NOUN
dpc-3629	257	5	.	.	PUNCT
dpc-3629	258	1	2005;53:791–797	2005;53:791–797	PROPN
dpc-3629	258	2	.	.	PUNCT
dpc-3629	259	1	22	22	NUM
dpc-3629	259	2	.	.	PUNCT
dpc-3629	260	1	leyden	leyden	PROPN
dpc-3629	260	2	jj	jj	PROPN
dpc-3629	260	3	.	.	PROPN
dpc-3629	260	4	randomized	randomize	VERB
dpc-3629	260	5	,	,	PUNCT
dpc-3629	260	6	phase	phase	NOUN
dpc-3629	260	7	2	2	NUM
dpc-3629	260	8	,	,	PUNCT
dpc-3629	260	9	dose	dose	NOUN
dpc-3629	260	10	-	-	PUNCT
dpc-3629	260	11	ranging	range	VERB
dpc-3629	260	12	study	study	NOUN
dpc-3629	260	13	in	in	ADP
dpc-3629	260	14	the	the	DET
dpc-3629	260	15	treatment	treatment	NOUN
dpc-3629	260	16	of	of	ADP
dpc-3629	260	17	rosacea	rosacea	NOUN
dpc-3629	260	18	with	with	ADP
dpc-3629	260	19	encapsulated	encapsulate	VERB
dpc-3629	260	20	benzoyl	benzoyl	NOUN
dpc-3629	260	21	peroxide	peroxide	NOUN
dpc-3629	260	22	gel	gel	NOUN
dpc-3629	260	23	.	.	PUNCT
dpc-3629	261	1	j	j	PROPN
dpc-3629	261	2	drugs	drug	NOUN
dpc-3629	261	3	dermatol	dermatol	NOUN
dpc-3629	261	4	.	.	PUNCT
dpc-3629	262	1	2014;13:685–688	2014;13:685–688	NUM
dpc-3629	262	2	.	.	PUNCT
dpc-3629	263	1	23	23	NUM
dpc-3629	263	2	.	.	PUNCT
dpc-3629	264	1	sodha	sodha	NOUN
dpc-3629	264	2	p	p	PROPN
dpc-3629	264	3	,	,	PUNCT
dpc-3629	264	4	suggs	suggs	PROPN
dpc-3629	264	5	a	a	DET
dpc-3629	264	6	,	,	PUNCT
dpc-3629	264	7	munavalli	munavalli	NOUN
dpc-3629	264	8	gs	gs	NOUN
dpc-3629	264	9	,	,	PUNCT
dpc-3629	264	10	friedman	friedman	PROPN
dpc-3629	264	11	pm	pm	PROPN
dpc-3629	264	12	.	.	PUNCT
dpc-3629	265	1	a	a	DET
dpc-3629	265	2	randomized	randomized	ADJ
dpc-3629	265	3	controlled	control	VERB
dpc-3629	265	4	pilot	pilot	NOUN
dpc-3629	265	5	study	study	NOUN
dpc-3629	265	6	:	:	PUNCT
dpc-3629	265	7	combined	combine	VERB
dpc-3629	265	8	595	595	NUM
dpc-3629	265	9	-	-	PUNCT
dpc-3629	265	10	nm	nm	NOUN
dpc-3629	265	11	pulsed	pulse	VERB
dpc-3629	265	12	dye	dye	NOUN
dpc-3629	265	13	laser	laser	NOUN
dpc-3629	265	14	treatment	treatment	NOUN
dpc-3629	265	15	and	and	CCONJ
dpc-3629	265	16	oxymetazoline	oxymetazoline	NOUN
dpc-3629	265	17	hydrochloride	hydrochloride	NOUN
dpc-3629	265	18	topical	topical	ADJ
dpc-3629	265	19	cream	cream	NOUN
dpc-3629	265	20	superior	superior	ADJ
dpc-3629	265	21	to	to	ADP
dpc-3629	265	22	oxymetazoline	oxymetazoline	NOUN
dpc-3629	265	23	hydrochloride	hydrochloride	NOUN
dpc-3629	265	24	cream	cream	NOUN
dpc-3629	265	25	for	for	ADP
dpc-3629	265	26	erythematotelangiectatic	erythematotelangiectatic	ADJ
dpc-3629	265	27	rosacea	rosacea	NOUN
dpc-3629	265	28	.	.	PUNCT
dpc-3629	266	1	lasers	laser	NOUN
dpc-3629	266	2	surg	surg	PROPN
dpc-3629	266	3	med	me	VERB
dpc-3629	266	4	.	.	PUNCT
dpc-3629	267	1	2021;53(10):1307	2021;53(10):1307	NUM
dpc-3629	267	2	-	-	SYM
dpc-3629	267	3	1315	1315	NUM
dpc-3629	267	4	.	.	PUNCT
dpc-3629	268	1	doi	doi	NOUN
dpc-3629	268	2	:	:	PUNCT
dpc-3629	268	3	10.1002	10.1002	NUM
dpc-3629	268	4	/	/	SYM
dpc-3629	268	5	lsm.23439	lsm.23439	NOUN
dpc-3629	268	6	.	.	PUNCT
dpc-3629	269	1	pmid	pmid	NOUN
dpc-3629	269	2	:	:	PUNCT
dpc-3629	269	3	34233378	34233378	NUM
dpc-3629	269	4	.	.	PUNCT
dpc-3629	270	1	pmcid	pmcid	NOUN
dpc-3629	270	2	:	:	PUNCT
dpc-3629	270	3	pmc9290736	pmc9290736	ADJ
dpc-3629	270	4	.	.	PUNCT
dpc-3629	271	1	24	24	NUM
dpc-3629	271	2	.	.	PUNCT
dpc-3629	272	1	wang	wang	PROPN
dpc-3629	272	2	x	x	PROPN
dpc-3629	272	3	,	,	PUNCT
dpc-3629	272	4	wang	wang	PROPN
dpc-3629	272	5	z	z	PROPN
dpc-3629	272	6	,	,	PUNCT
dpc-3629	272	7	sun	sun	PROPN
dpc-3629	272	8	l	l	PROPN
dpc-3629	272	9	,	,	PUNCT
dpc-3629	272	10	liu	liu	PROPN
dpc-3629	272	11	h	h	PROPN
dpc-3629	272	12	,	,	PUNCT
dpc-3629	272	13	zhang	zhang	PROPN
dpc-3629	272	14	f.	f.	PROPN
dpc-3629	272	15	efficacy	efficacy	PROPN
dpc-3629	272	16	and	and	CCONJ
dpc-3629	272	17	safety	safety	NOUN
dpc-3629	272	18	of	of	ADP
dpc-3629	272	19	dapsone	dapsone	NOUN
dpc-3629	272	20	gel	gel	NOUN
dpc-3629	272	21	for	for	ADP
dpc-3629	272	22	acne	acne	NOUN
dpc-3629	272	23	:	:	PUNCT
dpc-3629	272	24	a	a	DET
dpc-3629	272	25	systematic	systematic	ADJ
dpc-3629	272	26	review	review	NOUN
dpc-3629	272	27	and	and	CCONJ
dpc-3629	272	28	meta	meta	ADJ
dpc-3629	272	29	-	-	PUNCT
dpc-3629	272	30	analysis	analysis	NOUN
dpc-3629	272	31	.	.	PUNCT
dpc-3629	273	1	ann	ann	PROPN
dpc-3629	273	2	palliat	palliat	PROPN
dpc-3629	273	3	med	med	PROPN
dpc-3629	273	4	.	.	PUNCT
dpc-3629	274	1	2022;11(2):611	2022;11(2):611	NUM
dpc-3629	274	2	-	-	PUNCT
dpc-3629	274	3	620	620	NUM
dpc-3629	274	4	.	.	PUNCT
dpc-3629	275	1	doi	doi	NOUN
dpc-3629	275	2	:	:	PUNCT
dpc-3629	275	3	10.21037	10.21037	NUM
dpc-3629	275	4	/	/	SYM
dpc-3629	275	5	apm-21	apm-21	NOUN
dpc-3629	275	6	-	-	SYM
dpc-3629	275	7	3935	3935	NUM
dpc-3629	275	8	.	.	PUNCT
dpc-3629	276	1	pmid	pmid	NOUN
dpc-3629	276	2	:	:	PUNCT
dpc-3629	276	3	35249339	35249339	NUM
dpc-3629	276	4	.	.	PUNCT
dpc-3629	277	1	25	25	NUM
dpc-3629	277	2	.	.	PUNCT
dpc-3629	277	3	rainer	rainer	PROPN
dpc-3629	277	4	bm	bm	PROPN
dpc-3629	277	5	,	,	PUNCT
dpc-3629	277	6	kang	kang	PROPN
dpc-3629	277	7	s	s	PROPN
dpc-3629	277	8	,	,	PUNCT
dpc-3629	277	9	chien	chien	PROPN
dpc-3629	277	10	al	al	PROPN
dpc-3629	277	11	.	.	PROPN
dpc-3629	277	12	rosacea	rosacea	PROPN
dpc-3629	277	13	:	:	PUNCT
dpc-3629	277	14	epidemiology	epidemiology	NOUN
dpc-3629	277	15	,	,	PUNCT
dpc-3629	277	16	pathogenesis	pathogenesis	NOUN
dpc-3629	277	17	,	,	PUNCT
dpc-3629	277	18	and	and	CCONJ
dpc-3629	277	19	treatment	treatment	NOUN
dpc-3629	277	20	.	.	PUNCT
dpc-3629	278	1	dermatoendocrinol	dermatoendocrinol	NOUN
dpc-3629	278	2	.	.	PUNCT
dpc-3629	279	1	2017;9(1):e1361574	2017;9(1):e1361574	NOUN
dpc-3629	279	2	.	.	PUNCT
dpc-3629	280	1	doi	doi	NOUN
dpc-3629	280	2	:	:	PUNCT
dpc-3629	280	3	10.1080/19381980.2017.1361574	10.1080/19381980.2017.1361574	NUM
dpc-3629	280	4	.	.	PUNCT
dpc-3629	281	1	pmid	pmid	NOUN
dpc-3629	281	2	:	:	PUNCT
dpc-3629	281	3	29484096	29484096	NUM
dpc-3629	281	4	.	.	PUNCT
dpc-3629	282	1	pmcid	pmcid	NOUN
dpc-3629	282	2	:	:	PUNCT
dpc-3629	282	3	pmc5821167	pmc5821167	ADJ
dpc-3629	282	4	.	.	PUNCT
dpc-3629	283	1	26	26	NUM
dpc-3629	283	2	.	.	PUNCT
dpc-3629	284	1	lowe	lowe	PROPN
dpc-3629	284	2	e	e	PROPN
dpc-3629	284	3	,	,	PUNCT
dpc-3629	284	4	lim	lim	PROPN
dpc-3629	284	5	s.	s.	PROPN
dpc-3629	284	6	paradoxical	paradoxical	PROPN
dpc-3629	284	7	erythema	erythema	ADJ
dpc-3629	284	8	reaction	reaction	NOUN
dpc-3629	284	9	of	of	ADP
dpc-3629	284	10	long	long	ADJ
dpc-3629	284	11	-	-	PUNCT
dpc-3629	284	12	term	term	NOUN
dpc-3629	284	13	topical	topical	ADJ
dpc-3629	284	14	brimonidine	brimonidine	NOUN
dpc-3629	284	15	gel	gel	NOUN
dpc-3629	284	16	for	for	ADP
dpc-3629	284	17	the	the	DET
dpc-3629	284	18	treatment	treatment	NOUN
dpc-3629	284	19	of	of	ADP
dpc-3629	284	20	facial	facial	ADJ
dpc-3629	284	21	erythema	erythema	NOUN
dpc-3629	284	22	of	of	ADP
dpc-3629	284	23	rosacea	rosacea	NOUN
dpc-3629	284	24	.	.	PUNCT
dpc-3629	285	1	j	j	PROPN
dpc-3629	285	2	drugs	drug	NOUN
dpc-3629	285	3	dermatol	dermatol	NOUN
dpc-3629	285	4	.	.	PUNCT
dpc-3629	286	1	2016;15(6):763	2016;15(6):763	NUM
dpc-3629	286	2	-	-	SYM
dpc-3629	286	3	765	765	PROPN
dpc-3629	286	4	.	.	PUNCT
dpc-3629	287	1	pmid	pmid	NOUN
dpc-3629	287	2	:	:	PUNCT
dpc-3629	287	3	27272086	27272086	NUM
dpc-3629	287	4	.	.	PUNCT
dpc-3629	288	1	27	27	NUM
dpc-3629	288	2	.	.	PUNCT
dpc-3629	289	1	cookson	cookson	PROPN
dpc-3629	289	2	h	h	PROPN
dpc-3629	289	3	,	,	PUNCT
dpc-3629	289	4	mcfadden	mcfadden	PROPN
dpc-3629	289	5	j	j	PROPN
dpc-3629	289	6	,	,	PUNCT
dpc-3629	289	7	white	white	PROPN
dpc-3629	289	8	j	j	PROPN
dpc-3629	289	9	,	,	PUNCT
dpc-3629	289	10	white	white	PROPN
dpc-3629	289	11	ir	ir	PROPN
dpc-3629	289	12	.	.	PROPN
dpc-3629	289	13	allergic	allergic	ADJ
dpc-3629	289	14	contact	contact	NOUN
dpc-3629	289	15	dermatitis	dermatitis	NOUN
dpc-3629	289	16	caused	cause	VERB
dpc-3629	289	17	by	by	ADP
dpc-3629	289	18	mirvaso	mirvaso	PROPN
dpc-3629	289	19	®	®	PROPN
dpc-3629	289	20	,	,	PUNCT
dpc-3629	289	21	brimonidine	brimonidine	NOUN
dpc-3629	289	22	tartrate	tartrate	NOUN
dpc-3629	289	23	gel	gel	NOUN
dpc-3629	289	24	0.33	0.33	NUM
dpc-3629	289	25	%	%	NOUN
dpc-3629	289	26	,	,	PUNCT
dpc-3629	289	27	a	a	DET
dpc-3629	289	28	new	new	ADJ
dpc-3629	289	29	topical	topical	ADJ
dpc-3629	289	30	treatment	treatment	NOUN
dpc-3629	289	31	for	for	ADP
dpc-3629	289	32	rosaceal	rosaceal	ADJ
dpc-3629	289	33	erythema	erythema	NOUN
dpc-3629	289	34	.	.	PUNCT
dpc-3629	290	1	contact	contact	NOUN
dpc-3629	290	2	dermatitis	dermatitis	NOUN
dpc-3629	290	3	.	.	PUNCT
dpc-3629	291	1	2015;73(6):366	2015;73(6):366	NUM
dpc-3629	291	2	-	-	PUNCT
dpc-3629	291	3	377	377	NUM
dpc-3629	291	4	.	.	PUNCT
dpc-3629	292	1	doi	doi	NOUN
dpc-3629	292	2	:	:	PUNCT
dpc-3629	292	3	10.1111	10.1111	NUM
dpc-3629	292	4	/	/	SYM
dpc-3629	292	5	cod.12476	cod.12476	NOUN
dpc-3629	292	6	.	.	PUNCT
dpc-3629	293	1	pmid	pmid	NOUN
dpc-3629	293	2	:	:	PUNCT
dpc-3629	293	3	26768997	26768997	NUM
dpc-3629	293	4	.	.	PUNCT
dpc-3629	294	1	28	28	NUM
dpc-3629	294	2	.	.	PUNCT
dpc-3629	295	1	routt	routt	PROPN
dpc-3629	295	2	et	et	PROPN
dpc-3629	295	3	,	,	PUNCT
dpc-3629	295	4	levitt	levitt	PROPN
dpc-3629	295	5	jo	jo	PROPN
dpc-3629	295	6	.	.	PROPN
dpc-3629	296	1	rebound	rebound	VERB
dpc-3629	296	2	erythema	erythema	ADV
dpc-3629	296	3	and	and	CCONJ
dpc-3629	296	4	burning	burn	VERB
dpc-3629	296	5	sensation	sensation	NOUN
dpc-3629	296	6	from	from	ADP
dpc-3629	296	7	a	a	DET
dpc-3629	296	8	new	new	ADJ
dpc-3629	296	9	topical	topical	ADJ
dpc-3629	296	10	brimonidine	brimonidine	NOUN
dpc-3629	296	11	tartrate	tartrate	NOUN
dpc-3629	296	12	gel	gel	NOUN
dpc-3629	296	13	0.33	0.33	NUM
dpc-3629	296	14	%	%	NOUN
dpc-3629	296	15	.	.	PUNCT
dpc-3629	297	1	j	j	NOUN
dpc-3629	297	2	  	  	SPACE
dpc-3629	297	3	am	be	AUX
dpc-3629	297	4	acad	acad	ADJ
dpc-3629	297	5	dermatol	dermatol	NOUN
dpc-3629	297	6	.	.	PUNCT
dpc-3629	298	1	2014;70(2):e37	2014;70(2):e37	X
dpc-3629	298	2	-	-	PUNCT
dpc-3629	298	3	e38	e38	NOUN
dpc-3629	298	4	.	.	PUNCT
dpc-3629	299	1	doi	doi	NOUN
dpc-3629	299	2	:	:	PUNCT
dpc-3629	299	3	10.1016	10.1016	NUM
dpc-3629	299	4	/	/	SYM
dpc-3629	299	5	j	j	PROPN
dpc-3629	299	6	.jaad.2013.10.054	.jaad.2013.10.054	PUNCT
dpc-3629	299	7	.	.	PUNCT
dpc-3629	300	1	pmid	pmid	NOUN
dpc-3629	300	2	:	:	PUNCT
dpc-3629	300	3	24438976	24438976	NUM
dpc-3629	300	4	.	.	PUNCT
dpc-3629	301	1	29	29	NUM
dpc-3629	301	2	.	.	PUNCT
dpc-3629	302	1	faghihi	faghihi	PROPN
dpc-3629	302	2	g	g	PROPN
dpc-3629	302	3	,	,	PUNCT
dpc-3629	302	4	khosravani	khosravani	NOUN
dpc-3629	303	1	p	p	NOUN
dpc-3629	303	2	,	,	PUNCT
dpc-3629	303	3	nilforoushzadeh	nilforoushzadeh	PROPN
dpc-3629	303	4	ma	ma	PROPN
dpc-3629	303	5	,	,	PUNCT
dpc-3629	303	6	et	et	PROPN
dpc-3629	303	7	al	al	PROPN
dpc-3629	303	8	.	.	PUNCT
dpc-3629	304	1	dapsone	dapsone	PROPN
dpc-3629	304	2	gel	gel	NOUN
dpc-3629	304	3	in	in	ADP
dpc-3629	304	4	the	the	DET
dpc-3629	304	5	treatment	treatment	NOUN
dpc-3629	304	6	of	of	ADP
dpc-3629	304	7	papulopustular	papulopustular	ADJ
dpc-3629	304	8	rosacea	rosacea	NOUN
dpc-3629	304	9	:	:	PUNCT
dpc-3629	304	10	a	a	DET
dpc-3629	304	11	double	double	ADJ
dpc-3629	304	12	-	-	PUNCT
dpc-3629	304	13	blind	blind	ADJ
dpc-3629	304	14	randomized	randomize	VERB
dpc-3629	304	15	clinical	clinical	ADJ
dpc-3629	304	16	trial	trial	NOUN
dpc-3629	304	17	.	.	PUNCT
dpc-3629	305	1	j	j	PROPN
dpc-3629	305	2	drugs	drug	NOUN
dpc-3629	305	3	dermatol	dermatol	NOUN
dpc-3629	305	4	.	.	PUNCT
dpc-3629	306	1	2015;14(6):602606	2015;14(6):602606	NUM
dpc-3629	306	2	.	.	PUNCT
dpc-3629	307	1	pmid	pmid	NOUN
dpc-3629	307	2	:	:	PUNCT
dpc-3629	307	3	26091386	26091386	NUM
dpc-3629	307	4	.	.	PUNCT
dpc-3629	308	1	turkderm	turkderm	NOUN
dpc-3629	308	2	-	-	PUNCT
dpc-3629	308	3	turk	turk	NOUN
dpc-3629	308	4	arch	arch	ADJ
dpc-3629	308	5	dermatol	dermatol	NOUN
dpc-3629	308	6	venereology	venereology	NOUN
dpc-3629	308	7	2017;51:46	2017;51:46	NUM
dpc-3629	308	8	-	-	SYM
dpc-3629	308	9	51	51	NUM
dpc-3629	308	10	.	.	PUNCT
dpc-3629	309	1	doi	doi	NOUN
dpc-3629	309	2	:	:	PUNCT
dpc-3629	309	3	10.4274	10.4274	NUM
dpc-3629	309	4	/	/	SYM
dpc-3629	309	5	turkderm.69008	turkderm.69008	NOUN
dpc-3629	309	6	.	.	PROPN
dpc-3629	309	7	13	13	NUM
dpc-3629	309	8	.	.	PUNCT
dpc-3629	309	9	schaller	schaller	PROPN
dpc-3629	309	10	m	m	PROPN
dpc-3629	309	11	,	,	PUNCT
dpc-3629	309	12	dirschka	dirschka	PROPN
dpc-3629	309	13	t	t	PROPN
dpc-3629	309	14	,	,	PUNCT
dpc-3629	309	15	kemény	kemény	PROPN
dpc-3629	309	16	l	l	PROPN
dpc-3629	309	17	,	,	PUNCT
dpc-3629	309	18	briantais	briantais	NOUN
dpc-3629	309	19	p	p	NOUN
dpc-3629	309	20	,	,	PUNCT
dpc-3629	309	21	jacovella	jacovella	PROPN
dpc-3629	309	22	j.	j.	PROPN
dpc-3629	309	23	superior	superior	PROPN
dpc-3629	309	24	efficacy	efficacy	PROPN
dpc-3629	309	25	with	with	ADP
dpc-3629	309	26	ivermectin	ivermectin	NOUN
dpc-3629	309	27	1	1	NUM
dpc-3629	309	28	%	%	NOUN
dpc-3629	309	29	cream	cream	NOUN
dpc-3629	309	30	compared	compare	VERB
dpc-3629	309	31	to	to	ADP
dpc-3629	309	32	metronidazole	metronidazole	NOUN
dpc-3629	309	33	0.75	0.75	NUM
dpc-3629	309	34	%	%	NOUN
dpc-3629	309	35	cream	cream	NOUN
dpc-3629	309	36	contributes	contribute	VERB
dpc-3629	309	37	to	to	ADP
dpc-3629	309	38	a	a	DET
dpc-3629	309	39	better	well	ADJ
dpc-3629	309	40	quality	quality	NOUN
dpc-3629	309	41	of	of	ADP
dpc-3629	309	42	life	life	NOUN
dpc-3629	309	43	in	in	ADP
dpc-3629	309	44	patients	patient	NOUN
dpc-3629	309	45	with	with	ADP
dpc-3629	309	46	severe	severe	ADJ
dpc-3629	309	47	papulopustular	papulopustular	ADJ
dpc-3629	309	48	rosacea	rosacea	NOUN
dpc-3629	309	49	:	:	PUNCT
dpc-3629	309	50	a	a	DET
dpc-3629	309	51	subanalysis	subanalysis	NOUN
dpc-3629	309	52	of	of	ADP
dpc-3629	309	53	the	the	DET
dpc-3629	309	54	randomized	randomized	ADJ
dpc-3629	309	55	,	,	PUNCT
dpc-3629	309	56	investigator	investigator	NOUN
dpc-3629	309	57	-	-	PUNCT
dpc-3629	309	58	blinded	blind	VERB
dpc-3629	309	59	attract	attract	NOUN
dpc-3629	309	60	study	study	NOUN
dpc-3629	309	61	.	.	PUNCT
dpc-3629	310	1	dermatol	dermatol	NOUN
dpc-3629	310	2	ther	ther	ADV
dpc-3629	310	3	(	(	PUNCT
dpc-3629	310	4	heidelb	heidelb	NOUN
dpc-3629	310	5	)	)	PUNCT
dpc-3629	310	6	.	.	PUNCT
dpc-3629	311	1	2016;6(3):427	2016;6(3):427	X
dpc-3629	311	2	-	-	SYM
dpc-3629	311	3	436	436	NUM
dpc-3629	311	4	.	.	PUNCT
dpc-3629	312	1	doi	doi	NOUN
dpc-3629	312	2	:	:	PUNCT
dpc-3629	312	3	10.1007	10.1007	NUM
dpc-3629	312	4	/	/	SYM
dpc-3629	312	5	s13555	s13555	PROPN
dpc-3629	312	6	-016	-016	PROPN
dpc-3629	312	7	-	-	PUNCT
dpc-3629	312	8	0133	0133	NUM
dpc-3629	312	9	-	-	PUNCT
dpc-3629	312	10	6	6	NUM
dpc-3629	312	11	.	.	PUNCT
dpc-3629	313	1	pmid	pmid	NOUN
dpc-3629	313	2	:	:	PUNCT
dpc-3629	313	3	27432169	27432169	NUM
dpc-3629	313	4	.	.	PUNCT
dpc-3629	314	1	pmcid	pmcid	NOUN
dpc-3629	314	2	:	:	PUNCT
dpc-3629	314	3	pmc4972739	pmc4972739	NOUN
dpc-3629	314	4	.	.	PUNCT
dpc-3629	315	1	14	14	NUM
dpc-3629	315	2	.	.	PUNCT
dpc-3629	316	1	abram	abram	PROPN
dpc-3629	316	2	k	k	PROPN
dpc-3629	316	3	,	,	PUNCT
dpc-3629	316	4	silm	silm	PROPN
dpc-3629	316	5	h	h	PROPN
dpc-3629	316	6	,	,	PUNCT
dpc-3629	316	7	maaroos	maaroos	PROPN
dpc-3629	316	8	hi	hi	PROPN
dpc-3629	316	9	,	,	PUNCT
dpc-3629	316	10	oona	oona	PROPN
dpc-3629	316	11	m.	m.	PROPN
dpc-3629	316	12	subjective	subjective	ADJ
dpc-3629	316	13	disease	disease	NOUN
dpc-3629	316	14	perception	perception	NOUN
dpc-3629	316	15	and	and	CCONJ
dpc-3629	316	16	symptoms	symptom	NOUN
dpc-3629	316	17	of	of	ADP
dpc-3629	316	18	depression	depression	NOUN
dpc-3629	316	19	in	in	ADP
dpc-3629	316	20	relation	relation	NOUN
dpc-3629	316	21	to	to	ADP
dpc-3629	316	22	healthcare	healthcare	NOUN
dpc-3629	316	23	-	-	PUNCT
dpc-3629	316	24	seeking	seek	VERB
dpc-3629	316	25	behaviour	behaviour	NOUN
dpc-3629	316	26	in	in	ADP
dpc-3629	316	27	patients	patient	NOUN
dpc-3629	316	28	with	with	ADP
dpc-3629	316	29	rosacea	rosacea	NOUN
dpc-3629	316	30	.	.	PUNCT
dpc-3629	317	1	acta	acta	PROPN
dpc-3629	317	2	derm	derm	PROPN
dpc-3629	317	3	venereol	venereol	NOUN
dpc-3629	317	4	.	.	PUNCT
dpc-3629	318	1	2009;89(5):488	2009;89(5):488	PROPN
dpc-3629	318	2	-	-	PUNCT
dpc-3629	318	3	491	491	NUM
dpc-3629	318	4	.	.	PUNCT
dpc-3629	319	1	doi	doi	NOUN
dpc-3629	319	2	:	:	PUNCT
dpc-3629	319	3	10.2340/000155550716	10.2340/000155550716	NUM
dpc-3629	319	4	.	.	PUNCT
dpc-3629	320	1	pmid	pmid	NOUN
dpc-3629	320	2	:	:	PUNCT
dpc-3629	320	3	19734974	19734974	NUM
dpc-3629	320	4	.	.	PUNCT
dpc-3629	321	1	15	15	NUM
dpc-3629	321	2	.	.	PUNCT
dpc-3629	321	3	dermatology	dermatology	NOUN
dpc-3629	321	4	life	life	NOUN
dpc-3629	321	5	quality	quality	PROPN
dpc-3629	321	6	index	index	NOUN
dpc-3629	321	7	.	.	PUNCT
dpc-3629	322	1	cardiff	cardiff	PROPN
dpc-3629	322	2	university	university	PROPN
dpc-3629	322	3	,	,	PUNCT
dpc-3629	322	4	school	school	NOUN
dpc-3629	322	5	of	of	ADP
dpc-3629	322	6	medicine	medicine	NOUN
dpc-3629	322	7	.	.	PUNCT
dpc-3629	323	1	accessed	access	VERB
dpc-3629	323	2	june	june	PROPN
dpc-3629	323	3	10	10	NUM
dpc-3629	323	4	,	,	PUNCT
dpc-3629	323	5	2023	2023	NUM
dpc-3629	323	6	.	.	PUNCT
dpc-3629	324	1	available	available	ADJ
dpc-3629	324	2	from	from	ADP
dpc-3629	324	3	:	:	PUNCT
dpc-3629	324	4	https://www	https://www	PROPN
dpc-3629	324	5	.cardiff.ac.uk	.cardiff.ac.uk	PUNCT
dpc-3629	324	6	/	/	SYM
dpc-3629	324	7	medicine	medicine	NOUN
dpc-3629	324	8	/	/	SYM
dpc-3629	324	9	resources	resource	NOUN
dpc-3629	324	10	/	/	SYM
dpc-3629	324	11	quality	quality	NOUN
dpc-3629	324	12	-	-	PUNCT
dpc-3629	324	13	of	of	ADP
dpc-3629	324	14	-	-	PUNCT
dpc-3629	324	15	life	life	NOUN
dpc-3629	324	16	-	-	PUNCT
dpc-3629	324	17	questionnaires	questionnaire	NOUN
dpc-3629	324	18	/dermatology	/dermatology	NOUN
dpc-3629	324	19	-	-	PUNCT
dpc-3629	324	20	life	life	NOUN
dpc-3629	324	21	-	-	PUNCT
dpc-3629	324	22	quality	quality	NOUN
dpc-3629	324	23	-	-	PUNCT
dpc-3629	324	24	index	index	NOUN
dpc-3629	324	25	.	.	PUNCT
dpc-3629	325	1	16	16	NUM
dpc-3629	325	2	.	.	PUNCT
dpc-3629	326	1	zhang	zhang	PROPN
dpc-3629	326	2	h	h	PROPN
dpc-3629	326	3	,	,	PUNCT
dpc-3629	326	4	tang	tang	PROPN
dpc-3629	326	5	k	k	PROPN
dpc-3629	326	6	,	,	PUNCT
dpc-3629	326	7	wang	wang	PROPN
dpc-3629	326	8	y	y	PROPN
dpc-3629	326	9	,	,	PUNCT
dpc-3629	326	10	fang	fang	PROPN
dpc-3629	326	11	r	r	PROPN
dpc-3629	326	12	,	,	PUNCT
dpc-3629	326	13	sun	sun	PROPN
dpc-3629	326	14	q.	q.	PROPN
dpc-3629	326	15	rosacea	rosacea	PROPN
dpc-3629	326	16	treatment	treatment	PROPN
dpc-3629	326	17	:	:	PUNCT
dpc-3629	326	18	review	review	NOUN
dpc-3629	326	19	and	and	CCONJ
dpc-3629	326	20	update	update	VERB
dpc-3629	326	21	.	.	PUNCT
dpc-3629	327	1	dermatol	dermatol	NOUN
dpc-3629	327	2	ther	ther	ADV
dpc-3629	327	3	(	(	PUNCT
dpc-3629	327	4	heidelb	heidelb	NOUN
dpc-3629	327	5	)	)	PUNCT
dpc-3629	327	6	.	.	PUNCT
dpc-3629	328	1	2021;11(1):1324	2021;11(1):1324	NUM
dpc-3629	328	2	.	.	PUNCT
dpc-3629	329	1	doi	doi	NOUN
dpc-3629	329	2	:	:	PUNCT
dpc-3629	329	3	10.1007	10.1007	NUM
dpc-3629	329	4	/	/	SYM
dpc-3629	329	5	s13555	s13555	PROPN
dpc-3629	329	6	-	-	PUNCT
dpc-3629	329	7	020	020	NUM
dpc-3629	329	8	-	-	PUNCT
dpc-3629	329	9	00461	00461	NUM
dpc-3629	329	10	-	-	SYM
dpc-3629	329	11	0	0	NUM
dpc-3629	329	12	.	.	PUNCT
dpc-3629	330	1	pmid	pmid	NOUN
dpc-3629	330	2	:	:	PUNCT
dpc-3629	330	3	33170491	33170491	NUM
dpc-3629	330	4	.	.	PUNCT
dpc-3629	331	1	pmcid	pmcid	NOUN
dpc-3629	331	2	:	:	PUNCT
dpc-3629	331	3	pmc7858727	pmc7858727	PROPN
dpc-3629	331	4	.	.	PUNCT
dpc-3629	332	1	17	17	NUM
dpc-3629	332	2	.	.	PUNCT
dpc-3629	333	1	anderson	anderson	PROPN
dpc-3629	333	2	ms	ms	PROPN
dpc-3629	333	3	,	,	PUNCT
dpc-3629	333	4	nadkarni	nadkarni	NOUN
dpc-3629	333	5	a	a	PRON
dpc-3629	333	6	,	,	PUNCT
dpc-3629	333	7	cardwell	cardwell	PROPN
dpc-3629	333	8	la	la	PROPN
dpc-3629	333	9	,	,	PUNCT
dpc-3629	333	10	alinia	alinia	PROPN
dpc-3629	333	11	h	h	PROPN
dpc-3629	333	12	,	,	PUNCT
dpc-3629	333	13	feldman	feldman	PROPN
dpc-3629	333	14	sr	sr	PROPN
dpc-3629	333	15	.	.	PUNCT
dpc-3629	334	1	spotlight	spotlight	PROPN
dpc-3629	334	2	on	on	ADP
dpc-3629	334	3	brimonidine	brimonidine	NOUN
dpc-3629	334	4	topical	topical	ADJ
dpc-3629	334	5	gel	gel	NOUN
dpc-3629	334	6	0.33	0.33	NUM
dpc-3629	334	7	%	%	NOUN
dpc-3629	334	8	for	for	ADP
dpc-3629	334	9	facial	facial	ADJ
dpc-3629	334	10	erythema	erythema	NOUN
dpc-3629	334	11	of	of	ADP
dpc-3629	334	12	rosacea	rosacea	NOUN
dpc-3629	334	13	:	:	PUNCT
dpc-3629	334	14	safety	safety	NOUN
dpc-3629	334	15	,	,	PUNCT
dpc-3629	334	16	efficacy	efficacy	NOUN
dpc-3629	334	17	,	,	PUNCT
dpc-3629	334	18	and	and	CCONJ
dpc-3629	334	19	patient	patient	ADJ
dpc-3629	334	20	acceptability	acceptability	NOUN
dpc-3629	334	21	.	.	PUNCT
dpc-3629	335	1	patient	patient	ADJ
dpc-3629	335	2	prefer	prefer	NOUN
dpc-3629	335	3	adherence	adherence	NOUN
dpc-3629	335	4	.	.	PUNCT
dpc-3629	336	1	2017;11:1143	2017;11:1143	NUM
dpc-3629	336	2	-	-	SYM
dpc-3629	336	3	1150	1150	NUM
dpc-3629	336	4	.	.	PUNCT
dpc-3629	337	1	doi	doi	NOUN
dpc-3629	337	2	:	:	PUNCT
dpc-3629	337	3	10.2147	10.2147	NUM
dpc-3629	337	4	/	/	SYM
dpc-3629	337	5	ppa	ppa	PROPN
dpc-3629	337	6	.	.	PUNCT
dpc-3629	338	1	s115708	s115708	PROPN
dpc-3629	338	2	.	.	PUNCT
dpc-3629	339	1	pmid	pmid	NOUN
dpc-3629	339	2	:	:	PUNCT
dpc-3629	339	3	28740369	28740369	NUM
dpc-3629	339	4	.	.	PUNCT
dpc-3629	340	1	pmcid	pmcid	NOUN
dpc-3629	340	2	:	:	PUNCT
dpc-3629	340	3	pmc5505675	pmc5505675	ADJ
dpc-3629	340	4	.	.	PUNCT
dpc-3629	341	1	18	18	NUM
dpc-3629	341	2	.	.	X
dpc-3629	341	3	oge	oge	PROPN
dpc-3629	341	4	’	'	PUNCT
dpc-3629	341	5	lk	lk	PROPN
dpc-3629	341	6	,	,	PUNCT
dpc-3629	341	7	muncie	muncie	PROPN
dpc-3629	341	8	hl	hl	PROPN
dpc-3629	341	9	,	,	PUNCT
dpc-3629	341	10	phillips	phillips	PROPN
dpc-3629	341	11	-	-	PUNCT
dpc-3629	341	12	savoy	savoy	PROPN
dpc-3629	341	13	ar	ar	PROPN
dpc-3629	341	14	.	.	PROPN
dpc-3629	341	15	rosacea	rosacea	NOUN
dpc-3629	341	16	:	:	PUNCT
dpc-3629	341	17	diagnosis	diagnosis	NOUN
dpc-3629	341	18	and	and	CCONJ
dpc-3629	341	19	treatment	treatment	NOUN
dpc-3629	341	20	.	.	PUNCT
dpc-3629	342	1	am	be	AUX
dpc-3629	342	2	fam	fam	NOUN
dpc-3629	342	3	physician	physician	NOUN
dpc-3629	342	4	.	.	PUNCT
dpc-3629	343	1	2015;92(3):187	2015;92(3):187	NUM
dpc-3629	343	2	-	-	SYM
dpc-3629	343	3	196	196	NUM
dpc-3629	343	4	.	.	PUNCT
dpc-3629	344	1	pmid	pmid	NOUN
dpc-3629	344	2	:	:	PUNCT
dpc-3629	344	3	26280139	26280139	NUM
dpc-3629	344	4	.	.	PUNCT
dpc-3629	345	1	19	19	NUM
dpc-3629	345	2	.	.	PUNCT
dpc-3629	346	1	van	van	PROPN
dpc-3629	346	2	zuuren	zuuren	PROPN
dpc-3629	346	3	ej	ej	PROPN
dpc-3629	346	4	,	,	PUNCT
dpc-3629	346	5	arents	arents	PROPN
dpc-3629	346	6	bwm	bwm	PROPN
dpc-3629	346	7	,	,	PUNCT
dpc-3629	346	8	van	van	PROPN
dpc-3629	346	9	der	der	PROPN
dpc-3629	346	10	linden	linden	PROPN
dpc-3629	346	11	mmd	mmd	PROPN
dpc-3629	346	12	,	,	PUNCT
dpc-3629	346	13	vermeulen	vermeulen	PROPN
dpc-3629	346	14	s	s	PROPN
dpc-3629	346	15	,	,	PUNCT
dpc-3629	346	16	fedorowicz	fedorowicz	PROPN
dpc-3629	346	17	z	z	PROPN
dpc-3629	346	18	,	,	PUNCT
dpc-3629	346	19	tan	tan	PROPN
dpc-3629	346	20	j.	j.	PROPN
dpc-3629	346	21	rosacea	rosacea	PROPN
dpc-3629	346	22	:	:	PUNCT
dpc-3629	346	23	new	new	ADJ
dpc-3629	346	24	concepts	concept	NOUN
dpc-3629	346	25	in	in	ADP
dpc-3629	346	26	classification	classification	NOUN
dpc-3629	346	27	and	and	CCONJ
dpc-3629	346	28	treatment	treatment	NOUN
dpc-3629	346	29	.	.	PUNCT
dpc-3629	346	30	am	be	AUX
dpc-3629	346	31	j	j	PROPN
dpc-3629	346	32	clin	clin	PROPN
dpc-3629	346	33	dermatol	dermatol	NOUN
dpc-3629	346	34	.	.	PUNCT
dpc-3629	347	1	2021;22(4):457	2021;22(4):457	NUM
dpc-3629	347	2	-	-	PUNCT
dpc-3629	347	3	465	465	NUM
dpc-3629	347	4	.	.	PUNCT
dpc-3629	348	1	doi	doi	NOUN
dpc-3629	348	2	:	:	PUNCT
dpc-3629	348	3	10.1007	10.1007	NUM
dpc-3629	348	4	/	/	SYM
dpc-3629	348	5	s40257	s40257	NOUN
dpc-3629	348	6	-	-	PUNCT
dpc-3629	348	7	021	021	NUM
dpc-3629	348	8	-	-	PUNCT
dpc-3629	348	9	00595	00595	NUM
dpc-3629	348	10	-	-	PUNCT
dpc-3629	348	11	7	7	NUM
dpc-3629	348	12	.	.	PUNCT
dpc-3629	349	1	pmid	pmid	NOUN
dpc-3629	349	2	:	:	PUNCT
dpc-3629	349	3	33759078	33759078	NUM
dpc-3629	349	4	.	.	PUNCT
dpc-3629	350	1	pmcid	pmcid	NOUN
dpc-3629	350	2	:	:	PUNCT
dpc-3629	350	3	pmc8200341	pmc8200341	NOUN
dpc-3629	350	4	.	.	PUNCT
dpc-3629	351	1	20	20	NUM
dpc-3629	351	2	.	.	PUNCT
dpc-3629	352	1	fowler	fowler	PROPN
dpc-3629	352	2	jf	jf	PROPN
dpc-3629	352	3	jr	jr	PROPN
dpc-3629	352	4	.	.	PROPN
dpc-3629	352	5	combined	combined	ADJ
dpc-3629	352	6	effect	effect	NOUN
dpc-3629	352	7	of	of	ADP
dpc-3629	352	8	anti	anti	ADJ
dpc-3629	352	9	-	-	ADJ
dpc-3629	352	10	inflammatory	inflammatory	ADJ
dpc-3629	352	11	dose	dose	NOUN
dpc-3629	352	12	doxycycline	doxycycline	NOUN
dpc-3629	352	13	(	(	PUNCT
dpc-3629	352	14	40	40	NUM
dpc-3629	352	15	-	-	PUNCT
dpc-3629	352	16	mg	mg	PROPN
dpc-3629	352	17	doxycycline	doxycycline	NOUN
dpc-3629	352	18	,	,	PUNCT
dpc-3629	352	19	usp	usp	PROPN
dpc-3629	352	20	monohydrate	monohydrate	PROPN
dpc-3629	352	21	controlled	control	VERB
dpc-3629	352	22	-	-	PUNCT
dpc-3629	352	23	release	release	NOUN
dpc-3629	352	24	capsules	capsule	NOUN
dpc-3629	352	25	)	)	PUNCT
dpc-3629	352	26	and	and	CCONJ
dpc-3629	352	27	metronidazole	metronidazole	NOUN
dpc-3629	352	28	topical	topical	ADJ
dpc-3629	352	29	gel	gel	NOUN
dpc-3629	352	30	1	1	NUM
dpc-3629	352	31	%	%	NOUN
dpc-3629	352	32	in	in	ADP
dpc-3629	352	33	the	the	DET
dpc-3629	352	34	treatment	treatment	NOUN
dpc-3629	352	35	of	of	ADP
dpc-3629	352	36	rosacea	rosacea	NOUN
dpc-3629	352	37	.	.	PUNCT
dpc-3629	353	1	j	j	PROPN
dpc-3629	353	2	drugs	drug	NOUN
dpc-3629	353	3	dermatol	dermatol	NOUN
dpc-3629	353	4	.	.	PUNCT
dpc-3629	354	1	2007;6:641–645	2007;6:641–645	NUM
dpc-3629	354	2	.	.	PUNCT